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1. Abstract 
 
In 2013 W. Fenical et al. reported the isolation of a natural product from a marine microorganism of 
streptomyces species, which possessed significant activity against Gram-positive pathogens Bacillus 
anthracis, methicillin-resistant and vancomycin resistant Staphylococcus aureus (MRSA).15 The 
compound responsible for the antibiotic activity was found to be the 14-membered macrolide named 
anthracimycin. The research detailed in this thesis describes the efforts towards the total synthesis of 
this natural product and specifically the formation of the core of anthracimycin in 12-steps. Direct 
palladium catalysed oxidation formed the enone used as a dienophile in a stereo- and regio-selective 
Diels‒Alder/epimerisation sequence, which afforded the trans-decalin. A facial and stereoselective 
Hosomi‒Sakurai 1,4-addition reaction, followed by a selective borylation/dihydroxylation sequence 
on the exocyclic alkene, allowed the formation of the core of anthracimycin (Scheme 1).  
 
Scheme 1. The formation of the decalin core of anthracimcyin. 
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8. Introduction 
 
8.1 Natural product synthesis  
 
The role of total synthesis in the development of new natural product based drugs is of particular 
importance.1 In many cases new synthetic methodology has been developed to allow the synthesis of 
natural products. For example, the development of asymmetric alkylation and aldol methodology by 
Evans, gave access to the complex antibiotic cytovaricin.2 Hydroboration reactions have been used by 
Kishi to develop a new methodology to form propionate fragments for the total synthesis of monensin 
A.3 Plants and natural substances are used in traditional medicine to treat a wide range of illnesses. 
The active compounds, isolated from them, find use in conventional medicine such as taxol in the 
treatment of cancer, acetylsalicyclic acid as an anti-inflammatory drug and pilocarpine in the 
treatment of chronic and acute gluacoma.4, 5 Mother Nature produces molecules which play an 
important role in drug discovery and development processes. These are continuing to expand the 
chemotherapeutic armory and organic chemists are devising new and ingenious strategies to develop 
synthesis of these natural products.4 The pharmaceutical industry seems to have recognised this trend 
and is shifting away from large libraries of simple compounds towards focused libraries of complex, 
natural product-like collections.4 
However, in many cases, supply issues have hindered the development of natural products into drugs. 
This can be because the source organism is not always known, and when it is known the active 
compound is often found in only miniscule quantities. The answer to these supply issues would seem 
to be total chemical synthesis.6  
It is generally accepted that the synthesis of compounds of any complexity can be achieved, given 
enough time and resources.6 However, the vast majority of the reported total synthesis provide only 
milligram quantities of the target compound.7 These amounts are insufficient for significant biological 
studies and therefore have little impact in drug development, especially when the compound can not 
be simplified without the loss of activity. Fortunately, in the last decades several groups have 
12 
 
successfully addressed this issue with an increased focus on scalability of the total synthesis. They 
have succeeded in the production of several highly complex natural products in multigram quantities 
for biological studies.7 
With the excellent potential of natural products as biologically active molecules, and the increased 
focus on the scalability of the synthesis, one can only expect the role of total synthesis in chemistry, 
biology and medicine to increase in the coming years. 
 
8.2 The need for new antibiotics 
 
The Government and the World Health Organisation (WHO) have called for research into new anti-
infective drugs, triggered by the rising threat of the methicillin resistant Staphylococcus aureus 
(MRSA), Clostridium difficile (C. Diff) and Enterobacteriaceae, as well as other resistant pathogens. 8 
These strongly antibiotic resistant bacteria or “superbugs” are untreatable with current antibiotics 
and new research in this area is necessary. Over the years, two parallel and different lines of antibiotic 
discovery and development have been explored: i) the antibacterial activity of natural products (such 
as cephalosporins, quinolones, macrolides and tetracyclines), and, ii) the antibiotic activity of synthetic 
aromatic sulfonamides. After “the golden age of antibiotics research” (1940-1960), different 
generations of the natural antibiotics were developed to overcome bacterial resistance, by 
modification of their chemical scaffolds (Figure 1). 8  
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Antibiotic Class Generation 1  Generation 2  Generation 3 
Cephalosporins 
 
 
 
 
Quinolones 
 
   
Macrolides 
 
 
 
 
Tetracyclines 
 
  
 
 
Figure 1. Generations of different antibiotics.8 
 
Figure 1 shows the different antibiotic classes, in which the lead structure has been modified to create 
different generations to overcome bacteria resistance. 
 
 
 
14 
 
The widespread introduction and the inappropriate use of antibiotics in human and veterinary 
contexts, led to an increase of resistant bacteria and the need of new antibiotic molecules. In 2014, a 
table to compare the year of antibiotics discovery with the year of resistance observed, was published 
showing how quick the clinical resistance has been developed by bacteria (Table 1).8 
 
Antibiotic Year Discovery Clinical resistance 
observed 
Sulfonamides 
 
1930s 1940s 
Penicillin 
 
1943 1946 
Streptomycin 
 
1943 1959 
Chloramphenicol 
 
1947 1959 
Tetracycline 
 
1948 1953 
Erythromycin 
 
1952 1988 
Vancomycin 
 
1956 1988 
Methicillin 
 
1960 1961 
Ampicillin 
 
1961 1973 
Cephalosporins 
 
1960s late 1960s 
Nalidixic acid 
 
1962 1962 
Fluoroquinolones 
 
1980s 1980s 
Linezolid 
 
1999 1999 
Daptomycin 
 
2003 2003 
Retapamulin 
 
2007 2007 
Fidaxomycin 
 
2011 2011 
 
Table 1. Year of resistence observed.8 
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8.2.1 The mechanism of action of antibiotics 
 
Different classes of antibiotic possess different mechanisms of action against bacteria and five major 
antibacterial targets/pathways have been studied: β–lactams and the vancomycin type glycopeptides 
target bacterial peptidoglycan/cell wall biosynthesis (Figure 2). Another target of antibiotics is 
bacterial protein synthesis, with macrolide-based drugs attacking the ribosome. Fluoroquinolones 
targets DNA replication and transcription to RNA.9 Two other targets are the folate biosynthetic 
pathway (sulfamides) 9 and the disruption of bacterial membrane integrity (daptomycin).9 The 
resistance against these antibiotics is different for each class: for example, the substitution of the D-
Ala-D-Ala sequence in the peptidoglycan wall with a D-Ala-D-lactate unit, represents the enterococci-
type bacteria resistance against vancomycin. This causes the loss of one H-bond between the antibiotic 
and the target. Gene mutation in the sequence that encodes for DNA-gyrase enzyme, represents the 
mechanism of resistance against the fluoroquinolone antibiotics class.8 
 
 
 
 
 
 
 
 
 
Figure 2. Mode of action of different antiobitoics.8 
DNA 
RNA 
PABA 
DHF 
THF 
Ribosome
e 
Cell Wall synthesis 
 
Penicillins, 
Cephalosporins, 
Vancomycin, 
Carbapenem 
DNA gyrase 
Quinolones 
  
Disruption of 
cytoplasmatic membrane 
structure 
 
Daptomycin 
Protein synthesis 
 
Macrolides 
Folic acid metabolism 
 
Sulfonamides 
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8.3 Anthracimycin: a new molecule active against MRSA bacteria  
As mentioned in the previous section, the prevalence of methicillin-resistant Staphylococcus aureus 
infections and the slow development of new antibiotics, represents a major clinical challenge.10, 11 The 
availability of novel molecules for treating multi-resistant bacteria, is becoming a problem and new 
structures are needed.12 Natural products, such as secondary metabolites isolated from 
microorganisms, such as fungi and actinomycetes, were found to possess antimicrobial activities and 
this led to new lead structures for drug discovery.13 In some of these specific bioactive secondary 
metabolites such as monacolins, macrolides, pyrrolidine-2-one and 4-hydroxy-2-pyridone alkaloids, a 
common feature in the chemical structure was found to be a “decalin” motif, substituted with variuos 
functional groups.  This peculiar scaffold could be biosynthesised by two different pathways: the 
mevalonate pathway for isoprenoids and the acetate pathway for polyketides.14 In 2013, Fenical and 
his group reported the isolation of a marine microorganism of Streptomyces species from near-shore 
marine sediments near Santa Barbara, CA.15 The culture extracts were found to possess significant 
activity against Bacillus anthracis, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin 
resistant of Staphylococcus aureus. The fractionations of the extract afforded a compound called 
anthracimycin 1, responsible for the antibiotic activity (Figure 3).15 The Bacillus anthracis disease is 
one of the most common infections in farm animals and has also been used as a bioterrorism weapon. 
In 2001, Bacillus anthracis spores were spread by someone sending letters through the US postal 
system, after the World Trade Center attack.15  
Anthracimycin was isolated as a white solid with a molecular formula of C25H32O4 and its structure was 
determined by NMR spectroscopy analysis and X-ray crystallographic data.15 Upon this analysis, the 
structure of this natural compound appeared to be a combination of a 14-, 6- and 6-membered rings 
of polyketide origin.  The 14-membered ring is characterised by the presence of a lactone and an 
enolised β-diketone. The equidistant position of the proton between each oxygen, in the X-ray data, 
confirmed the keto-enol tautomerisation. Anthracimycin is also characterised by the presence of two 
double bonds in the 14-membered ring. One in a Z-configuration and the other as an E-alkene, which 
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was confirmed by the vicinal coupling constants of 10.5 Hz and 15.2 Hz, respectively. This molecule 
possesses a trans-decalin core scaffold, characterised by the presence of two double bonds. 
Anthracimycin also features stereogenic centers at C-2, C-6, C-7, C-12, C-15, C-16 and C-21 and a cis-
orientation of A/B rings, as well as a trans-ring junction of B/C rings.  
This polyketide belongs to the macrolide antibiotic class but is structurally distinct from the typical 
members of this group, by the presence of the tricyclic system characterised by a decalin scaffold and 
the absence of a deoxyhexose motif.16 
 
 
 
Figure 3. The chemical structure of anthracimycin 1.15 
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8.3.1 The biosynthesis of anthracimycin 
In 2015, the biosynthesis of this polyketide was reported and a type I polyketide synthase (PKS) was 
found to be the enzyme responsible for chain assembly.16 Generally, three classes of PKSs have been 
reported: type I, iterative type II and the acyl-carrier protein type III. Type I PKSs contain a β-ketoacyl-
ACP synthase, an acyltransferase and an acyl carrier protein domain, which are responsible for 
choosing and loading the carboxylic acid units for the successive condensation reactions in the chain 
assembly.17 This PKSs catalysed series of Claisen-like condensations, for the formation of metabolite 
intermediates in the chain elongation process (Scheme 2).17  
The biosynthetic pathway of anthracimycin may be initiated by decarboxylation of the malonyl residue 
2, to form the acylated ACP1 metabolite intermediate 3.18, 19 Chain elongation would proceed to 
provide ACP2 4, introducing a β,γ-double bond, which would also be introduced in fragment 5 to form 
a conjugated diene. Module 4 and 5 could be characterised by a chain elongation with the introduction 
of α,β-double bonds to form fragment 6.19 Then, α-methylation and β-keto reduction, followed by the 
introduction of a β,γ-shifted double bond with cis-geometry, would generate intermediate 8.20 Further 
chain elongation would allow the formation of the α,β-unsaturated compound 10, suitable for [4 + 2] 
cycloaddition, to generate the trans-decalin scaffold of the natural product. An endo-transition state 
of 10 could be envisioned for the formation of this trans-decalin core. The last two-step sequence of 
chain elongation, would be characterised by a TE domain to catalyse macrocyclisation and chain 
release (Scheme 2).16 
A small number of natural product biosynthetic pathways, are characterised by the presence of an 
enzyme that is able to catalyse intramolecular [4 + 2] cycloadditions, for the formation of decalin 
scaffolds.21-27 Recently, a FAD-dependent enzyme capable of generating a trans-decalin motif in the 
pyrroindomycin biosynthetic pathway has been identified,28 as well as the LovB PKS enzyme 
responsible for the [4 + 2] cycloaddition involved in the formation of the fungal metabolite 
lovastatin.25, 26, 29 Interestingly, in the case of anthracimycin biosynthesis, it is still unknown if the 
intramolecular Diels‒Alder reaction for the formation of the trans-decalin is catalysed by the enzyme 
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or is spontaneous. In this cycloaddition reaction, fragment 10 is characterised by the presence of a 
dienophile double bond with E geometry and a rigid orientation, due to the presence of the two β,γ-
shifted double bonds. This leads to a diminished degree of freedom, aiding intramolecular 
cycloaddition by steric effects rather than stabilisation by any particular transition state.16 
 
Scheme 2. The biosynthesis of anthracimycin 1.16 
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8.3.2 The biological effect of anthracimycin 
In most macrolides, the mode of action is the inhibition of protein biosynthesis by binding the 50 S 
ribosomial subunit.8 However, macromolecular synthetic studies, suggested that the anthracimycin 
mechanism of action could involve inhibition of DNA and RNA synthesis, in the absence of DNA 
intercalation.30 These assays were performed by measuring the quantitative incorporation of 
radiolabelled precursors of DNA and RNA. Disruption effects of DNA and RNA synthesis occurred at 
the Minimum Inhibitory Concentration (MIC) value on [3H] thymidine and [3H] uridine. It was also 
observed an additional secondary effect of anthracimycin on protein synthesis, at higher 
concentration of the MIC value.31  
These assays also showed potent activity of the natural product against all groups of Staphilococcus 
aureus tested, with a MIC value of < 0.25 mgL-1. Anthracimycin also inhibited vancomycin-resistant 
Enterococcus faecalis, MIC < 0.25 mgL-1, but no relevant Gram-negative activity was found, MIC > 64 
mgL-1 (Table 2).30 
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Strain MIC (mgL-1) 
MRSA  
Sanger 252 (USA200) 0.063 
TCH1516 (USA300) 0.125 
ATCC 33591 0.08 
NRS192 (ST1) 0.16 
Non-S. aureus  
Enterococcus faecalis 0.25 
Enterococcus faecalis isolate 0.125 
Bacillus anthracis 0.03 
Pseudomonas aeruginosa                                         > 64 
Klebsiella pneumoniae > 64 
 
Table 2. MIC values against major classes of bacteria.30 
 
A rapid bactericidal kinetics were also exhibited by this natural compound, with a > 4-log kill of USA 
300 MRSA during a 3 hours period at > 5 x MIC. A minimal post-antibiotic effect, compared with 
vancomycin, and a minimal toxic effect to eukaryotic cells was also observed, having a half maximal 
inhibitory concentration (IC50) = 70 mgL-1, against human carcinoma cells (Figure 4).30  
An effect below the MIC value and sensitisation of the host immune system at sub-MIC anthracimycin 
was also observed.32 The increased effect of human cathelicidin (antimicrobial peptides found in 
macrophages and involved in the innate human defense) on MSRA growth, occurred at 1/4 x MIC of 
anthracimycin. This synergy is without precedent and additional studies will investigate this 
interaction.32 
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Figure 4. Concentration effect of anthracimycin 1.30 J. Antibiot. , 2014 
 
 
Another biological activity of anthracimycin has recently been discovered. In 2017, suppression of cell 
proliferation and motility and induction of apoptosis against hepatocellular carcinoma (HCC), was 
reported.33 This anticancer property of anthracimycin is associated with the mTOR-signalling 
activation.34, 35 The serine/threonine kinase TOR phosphorylates the p70 S6 kinase, which is a protein 
involved in the regulation of cell growth, cell-cycle progression and metabolism.36 Playing such a 
pivotal role in cell metabolism, by activation of protein and lipid synthesis, for example, mTOR-
signalling is induced by many types of cancer.37, 38 The anthracimycin mechanism to deactivate this 
signalling is still unclear, but many biologists suspect that this natural product could inhibit the 
phosphorylation pathway of p70 S6 kinase. This anticancer effect has been observed with an IC50 value 
of 2.5 µg/mL in the HCC cell lines.34 
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8.4 Isolation of an anthracimycin analogue 14 
In 2017, anthracimycin BII-2619 14 was isolated from Nocardiopsis kunsanensis, an actinobacterial 
microorganism (Figure 5).39 This natural product was purified as a white powder and was found to 
have the same molecular formula of anthracimycin 1. Via NMR spectroscopy analysis, the structure 
and relative configuration of 14 was assumed to be the same as anthracimycin, except for the 
presence of the methyl group at C-8 instead of C-2. This analogue of anthracimycin 14 was found to 
have antimicrobial activity against Gram-positive bacteria, but compared to data for anthracimycin 
the MIC values were found to be between 50 and 100-fold lower.  
 
 
Figure 5. The chemical structure of anthracimycin BII-2619 14.39 
 
Target Organism or Cell line 
 
Activity (µg/ml) 
1 
Activity (µg/ml) 
14 
Gram Positive bacteria   
MRSA (ATCC 33591) 0.06 0.125 
MSSA (ATCC 25923) 0.06 1 
Bacillus subtilis (ATCC 6633) 0.5 64 
Enterococcus faecalis  0.125 8 
Gram Negative bacteria   
Escherichia Coli >128 >128 
Pseudomonas aureoginosa >128 >128 
Mammalian cells   
Human lung carcinoma cells ̴32 35 
 
Table 3. Biological activity of anthracimycin BII-2619 14 compared to anthracimycin 1.39 
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8.5 A related polyketide: chlorotonil A 15 
A related tricyclic metabolite with a similar carbon skeleton was found in chlorotonil A 15, isolated 
from the myxobacteria Sorangium cellulosum (Figure 6).40 The pivotal feature of this polyketide is its 
pseudo-enantiomerism with anthracimycin 1. In fact, chlorotonil A 15 exhibits the opposite absolute 
configuration at C-2, C-6, C-7, C-12, C-25, C-21, C-15 and C-6 when compared to anthracimycin 1. 
Additional differences are represented by the presence of the methyl group at C-8 in the C-ring and 
by the presence of a dichloromethylene group at C-4, in the A-ring.40 In Nature, other examples of 
enantiomeric products are reported: a linear precursor geranylgeranyl pyrophosphate is cyclised into 
monoterpenes (+)-limonene and (-)-limonene; (+) notoamide B and (-)-notomamide B are 
enantiomers of the same intermediate precursors.41 In these cases, the enantiomeric products are 
formed by the cyclisation of achiral precursors, instead, in anthracimycin 1 and chlorotonil A 15, a pair 
of enantiomeric precursors generate highly modified related structures.42 These two secondary 
metabolites 1 and 15 share a similar carbon framework and this is a rare case, because anthracimycin 
1 is produced by actinomycetes, whereas, chlorotonil A 15 is produced by myxobacteria. This is also 
the first reported example of pseudo-enantiomers polycyclic secondary metabolites derived from a 
type I PKS.42   
 
 
Figure 6. The chemical structure of chlorotonil A 15.40 
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The molecular formula of chlorotonil A 15 is C26H32Cl2O4, and this polyketide features an unsaturated 
trans-decalin core scaffold between B/C-rings and an unusual gem-dichloro-1,3-dione functionality in 
the A-ring. A cis-relationship between the A/B rings is also observed, as well as the presence of 
stereogenic centers at C-2, C-6, C-7, C-12, C-25, C-21, C15, C-6 and C-8.40  
Compared to anthracimycin 1, chlorotonil A 15 exhibits potent bioactivity against Gram-negative 
bacteria, such as Pseudomonas aeruginosa and also against the malaria protozoan pathogen 
Plasmodium falciparum.43 The ability to penetrate external bacteria membranes, relies upon the 
presence of the gemdichloro-1,3-dione and on the methyl group at C-8, which enhance the 
lipophilicity of this polyketide.  
The biosynthesis of chlorotonil A 15 was studied and biological data showed a PKS pathway 
responsible for the formation of this polyketide in parallel with the biosynthetic route of 
anthracimycin 1 (Scheme 3).13 This similarity, could explain the several homogeneity features in the 
structure of these two secondary metabolites. 
Starting with a malonyl residue-ACP 16, chain elongation takes place via a series of Claisen 
condensation reactions, as reported in the biosynthesis of anthracimycin. Again, the key step in this 
pathway is the intramolecular Diels‒Alder reaction to form the trans-decalin core of the molecule, 
intermediate 24. A hypothesis to explain the inversion of the stereocenters in the trans-decalin 
scaffold compared to anthracimycin, relies on the presence of the methyl group at C-8, which could 
play a role in “pre-organising” the structure of 23, during cycloaddition. 13 After chain elongation, the 
advanced intermediate 27 is released by the PKS domain and an unprecedented double chlorination 
reaction at C-4, between the two carbonyl groups, and a methylation reaction at C-2 take place to 
form chlorotonil A 15 (Scheme 3).13 
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Scheme 3. The biosynthesis of chlorotonil A 15. 13 
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Interestingly, chlorotonil A congeners such as chlorotonil B 29, chlorotonil C 30 and chlorotonil C2 31 
have also been isolated.13 Chlorotonil B 29 and chlorotonil C 30 differ from chlorotonil A by the lack of 
one chlorine atom at C-4, in the A-ring. Chlorotonil B 29 also differs from chlorotonil A by the lack of 
a double bond and the methyl group in the C-ring. In addition, chlorotonil C2 31 differs from 
chlorotonil C 30 by the lack of the methyl group at C-2 and the presence of no chlorine atom. These 
differences in the structure, made the congeners less potent towards bacteria, as highlighted by the 
MIC values (Table 4). This fact indicates that the presence of two chlorine atoms is pivotal for the 
biological acitivty. 13 
 
         
MIC µg/ml             
µM 
µg/ml             
µM 
µg/ml                  
µM 
µg/ml                  
µM 
µg/ml                 
µM 
µg/ml                 
µM 
µg/ml                 
µM 
µg/ml                 
µM 
M.luteus 
DSM-1790 
0.0125 0.025 > 3.2 > 6.4 > 3.2 > 6.4 1.6 3.8 
B.subtilis 
DSM-10 
≤0.003 ≤0.006 > 3.2 > 6.4 > 3.2 > 6.4 1.6 3.8 
S.aureus 
Newman 
0.006 0.012 > 3.2 > 6.4 > 3.2 > 6.4 1.6 3.8 
E.faecalis 
ATCC-29212 
> 3.2 > 6.4 > 3.2 > 6.4 > 3.2 > 6.4 > 3.2 > 6.4 
S.penumoniae 
DSM-20566 
0.0125 0.025 > 3.2 > 6.4 > 3.2 > 6.4 > 3.2 > 6.4 
E.Coli 
 
> 3.2 > 6.4 > 3.2 > 6.4 > 3.2 > 6.4 > 3.2 > 6.4 
 
Table 4. The biological activity of chlorotonil A compared with the congeners.13 
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8.5.1 The total synthesis of chlorotonil A 15 
In 2008, Kalesse et al. reported the total synthesis of chlorotonil A 15, using a biomimetic and 
stereocontrolled strategy (Scheme 4).44 The synthesis started with derivatisation of the Roche ester 
to give the TBS-protected aldehyde 32, which was subjected to a Still-Gennari olefination and DIBAL-
H reduction to afford allyl alcohol 33. Homologation and oxidation formed aldehyde 34, which was 
subjected to a Corey-Fuchs transformation, to generate the dibromoolefin 35.45, 46, 47   
Suzuki coupling between the dibromoolefin 35 and the boronic ester 36 gave intermediate 37,48 which 
after deprotection, oxidation and chain elongation via a Wittig reaction, generated the key 
intermediate 38. A Lewis acid triggered the formation of the trans-decalin 39, with high 
diastereoselectivity due to the presence of the bromine atom (d.r. 13 : 1).49, 50 Lactone opening 
followed by esterification afforded compound 40, which was coupled with the novel allyl phosphonate 
reagent 41, to form 42 Z,E/E,E with a ratio of 3 : 1. Finally, dianion addition of ethyl-2-
methylacetoacetate, followed by macrocyclisation in the presence of a Lewis acid, yielded chlorotonil 
A 15, as a single isomer. To further explain the high selectivity obtained in the Diels‒Alder 
cycloaddition reaction and the key role played by the bromine substituent, the dehalogenated 
intermediate 44 was prepared and subjected to the reaction conditions (Scheme 5). As a result, a 
mixture of the endo-I and endo-II products 45 and 46 were obtained in a 3 : 1 ratio, decreasing the 
selectivity of this cycloaddition reaction. The explanation of this result relied on the conformation of 
transition states 47 and 48, in which the presence of the bromine substituent disfavoured the endo-II 
transition state due to electronic and steric repulsion (Scheme 6).  
29 
 
Scheme 4. The total synthesis of chlorotonil A 15 by Kalesse et al.44 
30 
 
  
Scheme 5. Diels‒Alder reaction without bromine: different ratio of products obtained.44 
 
  
Scheme 6. Transition state of endo-I and endo-II products.44 
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8.6 Computational investigations into IMDA synthesis of 
anthracimycin  
The initial strategy considered towards the total synthesis of anthracimycin 1 was a biomimetic 
approach. The published total synthesis by Kalesse of chlorotonil A 15, utilised a bromine atom to 
direct the intramolecular Diels‒Alder formation of the trans-decalin core in a biomimetic route. 
Computational studies were conducted to decide whether to follow a similar approach or whether a 
new total synthesis would be more appropriate. As highlighted in the biosynthetic pathway of 
anthracimycin 1, whilst the polyketide is still bound to the enzyme, a Diels‒Alder reaction forms the 
trans-decalin scaffold.14 This intramolecular [4 + 2] cycloaddition could generate four possible decalin 
products, yet only one has been isolated.  
Dr. Ian George (postdoctoral researcher in the Clarke group), conducted DFT computational studies to 
better understand the formation of the molecule via a biomimetic synthesis (Figure 7). Interestingly, 
these calculations showed the formation of two compounds 11 and 51 with a considerably lower 
activation barrier (ΔE) than the others. Compound 11 had a structure of the proposed anthracimycin 
intermediate and is both the kinetic and thermodynamic product, based on the activation energy 
value ΔE = 58 KJmol-1 and the energy difference ΔH = -259.9 KJmol-1 between the energy of the starting 
material precursor and the product. The exo-Diels‒Alder product 51, generated from the diene 
approaching the opposite face of the dienophile, also appeared to have a low energy barrier (ΔE = 65 
KJmol-1). The exo-Diels‒Alder compound 49, formed when the diene approached the same face of the 
dienophile, and the endo-Diels‒Alder compound 50, instead, each showed a high activation energy 
value (ΔE = 335.36 KJmol-1 and 268.55 KJmol-1 respectively). The data suggests it would be unlikely for 
these two products 49 and 50 to form. However, as the ΔE of 11 and 51 showed similar values, the 
possibility of forming a mixture of decalin intermediates was potentially very likely and so, the 
biomimetic approach was not pursued any further. 
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Figure 7. Computational calculation to study the biomimetic cycloaddition to form the decalin 
scaffold of anthracimycin, by Dr. Ian George. 
These studies also showed that the stereochemistry of the Diels‒Alder cycloaddition reaction was 
determined by the methyl group, shown in red, presumably due to the steric clash generated in the 
transition state giving a higher barrier to the energy of activation for the disfavoured products 49 and 
50 (Figure 8).   
 
 
 
 
Figure 8. The transition of anthracimycin 11. 
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8.7 Synthesis of functionalised decalin scaffold 
Computational studies showed that formation of a mixture of intramolecular Diels‒Alder products 
was possible, therefore, an alternative strategy was explored for the synthesis of anthracimycin 1. In 
Natural product total synthesis, different strategies for the stereoselective formation of functionalised 
decalins have been reported.51 In general, there are two types of disconnection for the formation of 
these bicyclic systems. In the type I disconnection, functionalisation of the cyclohexane ring (cycle A 
or B) is followed by C-C bond formation, allowing the construction of the AB cycle. In the type II 
disconnection, a single process is involved in the formation of the AB decalin system (Scheme 7).51 
 
 
Scheme 7. The disconnection strategies to form a decalin system.51 
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Type I A disconnection 
Intramolecular allylation reactions are an example of a type I A disconnection, as reported by 
Anderson for the construction of the cis-decalin 55, in the total synthesis of popolohuanone E 56 
(Scheme 8). An intramolecular Hosomi‒Sakurai 1,4-addition, in the presence of TiCl4 and allylsilane 
was used to generate the cis-decalin core of this natural product.52 
 
 
Scheme 8. Allylation reaction as a type I A reaction for the formation of cis-decalin.52 
 
Type I B and I E disconnection 
Radical reactions are well established in the construction of decalin systems, as examples of type I B 
and I E disconnections. In 2013, Carreira et al. reported the total synthesis of ent-crotogoudin 61, in 
which the key step was a radical cyclopropane opening/annulation/elimination reaction promoted by 
SmI2 (type I B) (Scheme 9).53 
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Scheme 9. Radical cyclopropane opening/annulation/elimination for the formation of decalin 60.53 
In 2013, Hong reported a one-pot photocatalytic Michael-aldol sequence (type I E) for the 
enantioselective synthesis of the functionalised decalin system 63 (Scheme 10).54  
 
Scheme 10. Photocatalytic Michael-aldol sequence for the enantioselective synthesis of decalin 63.54 
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Type I C disconnection 
The intermolecular Diels‒Alder cycloaddition reaction is an example of a type I C disconnection. In the 
synthesis of tricyclic ent-kaurenoid natural product 71 reported by Zhang, intermolecular Diels‒Alder 
cycloaddition, followed by intramolecular carbocyclisation was developed to form a common building 
block 70, for the synthesis of this natural product (Scheme 11).55 
 
 
Scheme 11. The Diels‒Alder/carbocyclisation sequence reported by Zhang.55 
 
The asymmetric version of the Robinson annulation reaction was reported by Jung in the total 
synthesis of rhodexin A 78 (Scheme 12).56 In this sequence, acetic acid and (S)-proline catalysed a 
condensation reaction to form compound 75, which was subsequently transformed into cis-decalin 77 
using catalytic hydrogenation conditions.  
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Scheme 12. The total synthesis of rhodexin A 78, by Jung.56 
 
Type I D disconnection 
Pericyclic cyclisation reactions, such as 6π-electrocyclisation, were used by Williams for the formation 
of the cis-hydroxydecalin core of crotonins, as an example of a type I D disconnection.57 A cross-
coupling reaction between 79 and 80 afforded the intermediate 81, which was subjected to a thermal 
electrocyclisation reaction to form 82 in quantitative yield (Scheme 13).   
 
Scheme 13. Pericyclic cyclisations as an example of a type I D disconnection. 57 
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Type II A disconnection 
In 2012, Miyaoka reported the synthesis of (+)-kalihinol A 87, a richly functionalised antimalarial 
diterpenoid.58 The synthetic sequence started with the construction of cis-decalin 86 in 20 steps using 
an intramolecular Diels‒Alder cycloaddition, as an example of type II A disconnection (Scheme 14). 
  
 
Scheme 14. The intramolecular Diels‒Alder (type II A) in the total synthesis of kalihinol A 87. 58 
 
Type II B disconnection 
An example of a type II B disconnection is represented by cationic cyclisation, which has been used by 
Canesi et al., to form the trans-decalin intermediate 90 during the total synthesis of cassaic acid 91.59 
In the presence of PhI(OAc)2 and hexafluoroisopropanol, a phenol was transformed into a highly 
reactive electrophilic species 89 (aromatic ring umpolung). The presence of bromine atoms at the 
ortho-positions, promoted cyclisation at the para-position of the molecule to afford 90 in a 41% yield 
(Scheme 15).  
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Scheme 15. Cationic cyclisation used as an example of type II B disconnection.59 
 
As suggested by the computational studies, the intramolecular Diels‒Alder cycloaddition reaction was 
not a useful strategy to selectively form the trans-decalin core of anthracimycin. Consequently, the 
intermolecular type I disconnections would be explored instead. The intermolecular Diels‒Alder 
cycloaddition and the Robinson annulation (type I C) would be envisioned, as a versatile and common 
strategy to build bicyclic systems with angular substituents stereoselectively. As the trans-decalin core 
of anthracimycin presents two double bonds in the B and C ring, and two side chains in a syn-
relationship, key disconnections of these two envisioned strategies will be proposed and discussed in 
detail in the next chapter. 
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9. Results and discussion 
9.1 The Robinson annulation to form a functionalised trans-decalin  
9.1.1 Retrosynthetic analysis 
The aim of this project was to complete the total synthesis of anthracimycin 1. The proposed 
retrosynthetic strategy (Scheme 16) involved dividing the molecule into three major fragments: the 
Still‒Gennari reagent 92, the β-ketoester 93 and the highly functionalised trans-decalin core 94. The 
desired Z-double bond was envisioned to be formed via Still‒Gennari olefination, and a Weiler-dianion 
addition reaction would connect fragment 92 to the trans-decalin core 94. Finally, a macrocyclisation 
would then generate the 14-membered macrocycle ring and form the desired natural product 1. Key 
disconnections for formation of this highly functionalised trans-decalin core 94 would involve Wittig 
olefination and conjugate addition for the installation of the two side chains. A Robinson annulation 
reaction would be investigated for the synthesis of the decalin system 97. 
 
Scheme 16. The retrosynthetic analysis of anthracimycin 1, using the Robinson annulation strategy. 
ΔE = 268.55 KJMol-1 
ΔH = 232.14  KJMol-1 
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As illustrated in the type I C disconnection, the Robinson annulation reaction is a three-step sequence, 
and due to its ability to form fused systems with angular substituents, it is one of the main reactions 
used for the construction of decalins in natural product synthesis.60 This reaction would be 
investigated for the synthesis of the trans-decalin 97. A conjugate addition reaction followed by 
enolate trapping with Mander’s reagent could be employed to install the methyl ester chain yielding 
100. Further transformations of this compound 100, such as oxidation, Wittig olefination and 
reduction reactions would be explored to form the core of anthracimycin 94 (Scheme 17).  
 
Scheme 17. The Robinson annulation/conjugate addition approach to the synthesis of the decalin 
core 94. 
The annulation of cyclohexanone 101 in the presence of methylvinylketone 99 and KOH as a base was 
attempted,61 and the decalin product 103 was generated in a 3% yield (Scheme 18). The isolation of 
the hydroxyl-decalin intermediate 102 explained the low yield obtained from this cyclisation reaction, 
as a consequence of the incomplete transformation into the decalin final product 103. However, the 
conversion of 102 into the desired decalin 103 was investigated via an elimination reaction using a 
range of acidic and basic conditions. In the presence of strong acid, the desired compound 103 was 
isolated in high yields (Table 5, entry 1 and 2). Basic conditions, however, were not as effective for 
this transformation (Table 5, entry 3 and 4).62 
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Scheme 18. The Robinson annulation of cyclohexanone 101.61  
 
entry condition temperature 
(°C) 
yield 
(%) 
1 glacial AcOH 
H2SO4 
r.t. 90 
2 HCl 4 M r.t. 80 
3 KOH, ethanol r.t. 40 
4 MsCl, Et3N, 
Then DBU CH2Cl2 
0 °C to r.t. 30 
 
Table 5. The elimination conditions for the conversion of 102 into decalin 103.62 
 
The annulation of 4-methyl cyclohexanone 98 in the presence of methylvinylketone 99 and KOH, 
generated decalin 105 in a 2% yield and the hydroxyl-decalin 104 in a 41% yield (Scheme 19). Acidic 
conditions-glacial acetic acid and sulfuric acid-were used to complete the conversion of 104 into the 
desired decalin 105, which was isolated in a 77% yield. 
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Scheme 19. The Robinson annulation of 4-methyl cyclohexanone 98.61  
 
Having achieved the formation of decalins 103 and 105 via a two-step sequence, the conjugate 
addition reaction to functionalise these bicyclic compounds was explored. Treatment of 103 in the 
presence of allyl bromide 108, DMSO and NaH, formed the desired product 106 in a 26% yield. A 
doubly alkylated compound 107 was also generated and the decalin starting material 103 was 
recovered in a 5% yield (Scheme 20).63 A mechanism for this reaction was proposed: (i) the 1,4-
addition of the DMSO ylide to the enone decalin 103 generated the enol-decalin 109, (ii) the alkylation 
of allyl bromide 108 generated intermediate 110, which after, (iii) a final elimination of DMSO formed 
the enone decalin alkylated product 106 (Scheme 20).63  
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Scheme 20. The conjugate addition of 103 and the proposed mechanism of the reaction.63 
 
The conjugated addition of the Mander’s reagent instead of allyl bromide, using these conditions was 
attempted, but formation of the desired product was not observed and the starting material 103 was 
recovered unreacted. Due to the low yields and the formation of side-products during conjugate 
addition, this approach towards the synthesis of the highly functionalised trans-decalin core 94 was 
not pursued further. 
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9.2 Diels‒Alder/epimerisation sequence to the trans-decalin  
9.2.1 Retrosynthetic analysis 
The division of the natural product into three major fragments, the Still‒Gennari reagent 92, the β-
ketoester 93 and the highly-functionalised trans-decalin core 94, remained the proposed 
retrosynthetic strategy (Scheme 21). Key reactions to form the highly functionalised trans-decalin 
system 94 would involve a facially selective and diastereoselective Ireland‒Claisen rearrangement on 
the face that presents the triisopropylsilylmethyloxy chain, and a Diels‒Alder/epimerisation sequence 
starting form enone 115 and diene 116. The conjugated enone 115 would be synthesised via an 
oxidation/reduction sequence of the commercially available keto-ester 117. 
 
Scheme 21. The retrosynthesis analysis of anthracimycin 1. 
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The Diels‒Alder cycloaddition reaction has left a special imprint in natural product total synthesis, due 
to the ability to construct polyfunctional and highly substituted molecules.64 This approach has been 
used as a key step in cascade sequences and has enabled synthetic chemists to obtain numerous 
scaffolds in total synthesis.65 Pericyclic reactions offer an efficient approach to the synthesis of six-
membered rings and bicyclic systems, and have numerous advantages including stereochemical 
control (always a cis addition) and easy predictability of its regiochemistry, with the selectivity of the 
Diels‒Alder cycloaddition rationalised using frontier molecular orbital theory.65 A classical method to 
enhance the rate of the reaction is the use of a Lewis acid-mediated Diels‒Alder cycloaddition reaction 
to decrease the energy gap between the LUMO of the dienophile and the HOMO of the diene.66 As 
reported in the previous section, a range of natural products containing cis- and trans-decalins were 
formed by using this powerful cycloaddition.67, 68 In 2009, Danishefsky and co-workers reported a two-
step “trans-Diels‒Alder reaction” with the use of nitrocycloalkenes to form bicyclic systems.69 This 
pericyclic reaction between diene 118 and dienophile 119 formed the cis-fused decalin adduct 120 in 
a 62% yield. A radical reduction in the presence of AIBN and nBu3SnH, removed the nitro group and 
triggered the conversion from the cis- to the trans-fused system 121 in a 71% yield and in a 5 : 1 ratio 
(Scheme 22).69  
Scheme 22. A two-step “trans-Diels‒Alder reaction”.69 
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In 2010, Danishefsky et al. also described a Lewis acid catalysed Diels‒Alder reaction between α-
bromocyclohexenones 126 and various substituted dienes 127, to provide cis-fused bicyclic systems 
128 (Scheme 23).70, 71 Removal of the bromine atom and the consequent epimerisation from cis- to 
trans-decalin, was performed by radical reduction using AIBN and nBu3SnH. This conversion from α-
halo cis-bicyclic systems to trans-decalins was also studied by Lee in 2015, who performed a new tin-
free photoredox catalysis reaction.72  
 
 
Scheme 23. The epimerisation from cis- to trans-decalin via a radical and a photoredox strategy.70-72 
 
 
With this idea in mind, the Diels‒Alder strategy for the formation of the functionalised trans-decalin 
of anthracimycin was explored. The α-bromo-substituted cyclohexenone 132 was prepared from 
cyclohexanone 131 by treatment with molecular bromine and DMAP, using pyridine and chloroform 
as solvents.73, 74 A Lewis acid (EtAlCl2) catalysed the Diels‒Alder cycloaddition reaction between 132 
and isoprene 133, afforded the cis-decalin 134 in a 62% yield, as a single diastereoisomer (Scheme 
24).72 
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Scheme 24. A Lewis acid-mediated Diels‒Alder reaction to form the cis-decalin 134.70-74  
 
However, using isoprene 133, the position of the methyl group at C-9 in the cis-decalin 134 was 
incorrect for the decalin core of anthracimycin 94. This was not unexpected, due to the largest orbital 
coefficient of the HOMO of the alkene being next to the methyl group. To influence the regiochemistry 
of this cycloaddition and install the methyl group at C-10 as required, the sulfur-substituted diene 116 
was synthesised, in order to exploit the greater electron-donating effect of the thiophenyl group 
compared to the methyl substituent. It is noteworthy that this diene 116 was freshly prepared in a 
quantitative yield before the Diels‒Alder (Scheme 25).74 In this case, EtAlCl2 catalysed the 
cycloaddition between 132 and 116 formed the cis-decalin 136 in a 54% yield as a single 
diastereoisomer (Scheme 26). Due to the instability of the α-bromo cis-decalin 136 to light and air, 
the conversion into the corresponding trans-diastereoisomer 137 was tested under radical conditions, 
but just unreacted starting material was recovered. However, the larger orbital coefficient of the 
HOMO of the alkene next to the thiopenyl group of diene 116, influenced the regiochemistry of this 
cycloaddition reaction and installed the methyl group at C-10 as required for anthracimycin 1. 
 
 
Scheme 25. Palladium catalysed synthesis of the sulfur-substituted diene 116.75 
49 
 
 
Scheme 26. A regioselective Diels‒Alder to form cis-decalin 136.72 
 
Due to the instability of the bromine-containing Diels‒Alder adducts 134 and 136, it was decided to 
investigate the non-halogenated enone 131 as the dienophile in this reaction. The cycloaddition 
reaction of 131 and 133 was performed and generated two decalin products 138 and 139 in a 12 : 1 
crude ratio (cis : trans) (Scheme 27).76 This result showed evidence of an epimerisation from a cis- to 
a trans-decalin under the reaction conditions. Treatment of 138, with further Lewis acid, generated 
the trans-diastereoisomer 139 in a 8 : 92 ratio (cis : trans), which confirmed the conversion via 
epimerisation observed during the cycloaddition (Scheme 28).  
 
 
Scheme 27. The Diels‒Alder cycloaddition between 131 and 133.76  
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Scheme 28. The epimerisation from the cis- to trans-decalin 139. 
 
In order to confirm the stereochemistry of the trans-decalin 139, the carbonyl was reacted with 2,4-
dinitrophenyl hydrazine 140 to form the hydrazone 141 and facilitate the crystallisation of the 
molecule (Scheme 29). The structure of the hydrazone 141, isolated in a 54% yield, was confirmed 
unambiguously by single crystal X-ray diffraction (Figure 9). 
 
Scheme 29. The derivatisation of the trans-decalin 139 into the hydrazone 141. 
 
 
 
 
 
Figure 9. The X-ray diffraction single crystallography of the hydrazone 141 with thermal ellipsoids 
shown at 50%. 
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The X-ray crystal structure in Figure 9 confirmed the trans-ring junction between protons H-7 and H-
12, which was obtained using a Diels‒Alder/epimerisation sequence.   
Armed with this knowledge, formation of the trans-diastereoisomer 139 in one-pot was attempted 
during the Diels‒Alder cycloaddition reaction. Premixing the catalyst with cyclohexenone (131) over a 
period of 30 minutes, formed the two diastereoisomers 138 and 139 in a 0.85 : 1 ratio (cis : trans), 
which were isolated in a 37% and in a 40% yield, respectively. Increasing the amount of catalyst from 
0.2 to 1.2 equivalents, did not significantly improve the formation of the trans-decalin 139. A 0.7 : 1 
ratio (cis : trans) was achieved using stoichiometric amount of EtAlCl2, whereas, a 0.6 : 1 ratio (cis : 
trans) was obtained by re-addition of the catalyst after the consumption of the cyclohexenone 131. 
The epimerisation to the trans-decalin 139 was, therefore, not performed in a one-pot reaction and 
its synthesis was achieved in a Diels‒Alder/epimerisation sequence over two-steps. However, to 
highlight the advantages of this method, different dienophiles and dienes were tested to form trans-
bicyclic systems. The literature reported an AlCl3-catalysed cycloaddition between different ring size 
enones in the presence of diverse dienes, to yield bicyclic adducts in various cis : trans ratio.77, 78  
The Diels‒Alder reaction between cyclohexenone (131)  and 2,3-dimethyl-1,3-butadiene (142) formed 
cis- and trans-decalins 143 and 144 in a 2 : 1 ratio as an inseparable mixture of products. After 
epimerisation, a 1 : 23 ratio (cis : trans) was observed (Scheme 30, Figure 10). The cycloaddition of 
cyclohexenone (131)  in the presence of trans-1,3-pentadiene (145), formed the cis- and trans-decalins 
146 and 147 in a 9.8 : 1 ratio (cis : trans). After epimerisation, the proportion of the trans-decalin 147 
increased, but the diastereomeric ratio remained in favour of the cis-decalin 146, 1.92 : 1 ratio (cis : 
trans) (Scheme 31, Figure 11). The Diels‒Alder reaction between cyclopentenone (148) and isoprene 
(133) formed the cis- and the trans-adducts 149 and 150 in a 1.34 : 1 ratio (cis : trans), which did not 
change under the epimerisation conditions (Scheme 32, Figure 12). In the presence of 2,3-dimethyl-
1,3-butadiene 142, the cis- and the trans-bicyclic systems 151 and 152 were formed in a 4 : 1 ratio (cis 
: trans), which equilibrated to 1.47 : 1 after epimerisation (cis : trans) (Scheme 33, Figure 13). The 
cycloaddition between cycloheptenone (153) and isoprene (133) generated the cis- and trans-
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diastereoisomers 154 and 155 in a 10 : 1 ratio (cis : trans), which were isolated in a 52% and 5% yields, 
respectively (Scheme 34, Figure 14).77, 78 
 
The Diels‒Alder/epimerisation between enone 131 and diene 142, generated cis- and trans-decalins 
143 and 144 in a 1 : 23 ratio (Scheme 30). Due to the presence of many overlapping peaks in the 1H 
NMR spectrum, the diastereomeric ratio of 143 and 144 before and after epimerisation was calculated 
using quantitative 13C NMR analysis. Using around 100 mg of compound and setting a long relaxation 
time (10 seconds) during a 16-hour analysis, it was possible to calculate an accurate diastereomeric 
ratio based on the integration of ketone peaks C-13 of 143 and 144, at 212.5 (cis) and at 212.4 
(trans) ppm respectively (Figure 10).   
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Scheme 30. The Diels‒Alder/epimerisation reaction between 131 and 133. 
 
Figure 10. Ratio of cis- and trans-decalins 143 and 144 calculated on a quantitative 13C NMR 
spectrum based on ketone C-13 integration. 
 
The Diels‒Alder/epimerisation sequence between enone 131 and diene 145 afforded cis- and trans-
decalins 146 and 147 in a 1.92 : 1 ratio (Scheme 31). The literature reported a similar ratio (1.8 : 1 cis 
: trans) using the same substrates in an AlCl3-catalysed Diels‒Alder reaction to form the decalin 
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products 146 and 147.77 As shown in the crude 1H NMR spectrum, the 1.92 : 1 diastereomeric ratio of 
146 and 147 after epimerisation was calculated based on integration of methyl groups peaks; a 
doublet at 1.21  ppm (cis, 146) and a doublet at 0.94 ppm (trans, 147) (Figure 11). These data 
matched the literature assignments: methyl group of the cis-isomer 146 doublet at 1.27 ppm, and 
methyl group of the trans-adduct 147 doublet at 0.94 ppm. 
Scheme 31. The Diels‒Alder/epimerisation sequence between 131 and 145. 
Figure 11. Ratio of cis- and trans-decalins 146 and 147 calculated on a 1H NMR spectrum based on 
methyl integration. 
55 
 
The cycloaddition between 148 and 133 was attempted and a 1.34 : 1 ratio cis : trans was obtained 
before and after epimerisation and the product was isolated as an inseparable mixture (Scheme 32). 
For these substrates, literature reported a 1.7 : 1 ratio cis : trans, calculated on integration of proton 
H-9 at  5.39 ppm (trans, 150) and at 5.36 ppm  (cis, 149).77 As shown in the crude 1H NMR spectrum, 
the 1.34 : 1 diastereomeric ratio of 149 and 150 resulting from the Diels‒Alder/epimerisation 
sequence, was calculated based on integration of H-9 protons, multiplets at 5.46‒5.39 (trans, 150) 
and at 5.36‒5.32 ppm (cis, 149)  (Figure 12). 
Scheme 32. The Diels‒Alder/epimerisation sequence between 148 and 133. 
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Figure 12. Ratio of cis- and trans-decalins 149 and 150 calculated on a 1H NMR spectrum based on 
integration of proton H-9. 
 
The Diels‒Alder/epimerisation reaction between enone 148 and diene 142 afforded an inseparable 
mixture of decalins 151 and 152, isolated in a 1.47 : 1 ratio cis : trans (Scheme 33). Due to the presence 
of many overlapping peaks in the 1H NMR spectrum, the 1.47 : 1 diastereomeric ratio of 151 and 152 
was calculated using a quantitative 13C NMR analysis. Using around 100 mg of compound and setting 
a long relaxation time (10 seconds) in a 16-hour experiment, integration of the ketone C-13 peaks of 
cis- and trans-decalins 151 and 152 of the crude reaction mixture allowed the determination of the 
diastereomeric ratio. The carbonyl peaks (C-13) of the cis- and trans-decalins were found at 219.7 
(cis, 151) and at218.9 (trans, 152) ppm (Figure 13). 
57 
 
Scheme 33. The Diels‒Alder/epimerisation sequence between 148 and 142. 
 
Figure 13. Ratio of cis- and trans-decalins 151 and 152 calculated on a quantitative 13C NMR 
spectrum based on ketone carbonyl integration. 
 
The cycloaddition reaction between enone 153 and diene 133 generated decalins 154 and 155 in a 10 
: 1 ratio cis : trans, isolated in a 52% and 5% yields respectively (Scheme 34). The diastereomeric ratio 
of these two products was calculated based on ketone integration C-13 of the crude reaction mixture 
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using quantitative 13C NMR spectroscopic analysis. The carbonyl peaks (C-13) of the cis- and trans-
decalins were found at 215.7 (cis, 154) and at  217.1 (trans, 155) ppm (Figure 14). The literature 
reported the formation of cis- and trans-diastereosiomers 154 and 155 in a 1 : 45 ratio (cis : trans), 
reporting carbonyl peaks (C-13) of the cis- and trans-decalins at 214.4 (cis, 154) and at 215.9 (trans, 
155).77 
 
Scheme 34. The Diels‒Alder reaction between enone 153 and diene 133. 
 
 
Figure 14. Ratio of cis- and trans-decalins 154 and 155 calculated on a quantitative 13C NMR 
spectrum based on ketone C-13 integration. 
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After this screening, the Diels‒Alder between cyclohexeneone (131) and the sulfur-substituted diene 
116 was attempted, to correct the regioselectivity of the cycloaddition and install the methyl group at 
C-10. The literature reported an EtAlCl2-catalysed cycloaddition between cyclohexenone 131 and the 
sulfur substituted diene 116, to give the cis-decalin 156 in a 35% yield.72 Photoredox conditions then 
triggered the epimerisation from cis- to trans-decalin 137.72 Repeating the EtAlCl2-catalysed Diels‒
Alder conditions, the cis-decalin 156 was generated as a single diastereoisomer in a 37% yield over a 
period of 3 hours at ‒10 °C (Scheme 35 and Table 6, entry 1). It was, however, observed that time and 
temperature had a key role in the formation of impurities, and in the isolation of the desired product 
156 in a high yield. A period of 3 hours at room temperature afforded the cis-decalin 156 in a 51% 
yield (Table 6, entry 2), whereas, a 90% yield of 156 was obtained at room temperature over a period 
of 1.5 hours (Table 6, entry 3). Epimerisation, under the same reaction conditions, formed the trans-
decalin 137 in a 68% yield over a two-step sequence, as observed in the previous studies (Scheme 35). 
 
Scheme 35. The Diels‒Alder/epimerisation sequence to form the trans-decalin 137. 
 
entry catalyst temperature 
(°C) 
time 
(h.) 
yield of 156 
(%) 
1 0.2 eq. EtAlCl2 ‒10 °C 3  37 
2 0.2 eq. EtAlCl2 r.t. 3  51 
3 0.2 eq. EtAlCl2 r.t. 1.5  90 
 
Table 6. The optimization of the Diels‒Alder reaction between cyclohexanone 131 and diene 116. 
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A selective Raney-Nickel reduction was performed in an attempt to remove the thiophenyl group from 
compounds 156 and 137. However, the treatment of the cis-diastereoisomer 156 under these 
conditions generated 157 and 158 in a 23% and 11% yield respectively, where over-reduction to the 
hydroxyl had occurred. In contrast, Raney-Nickel reduction of the trans-diastereoisomer 137 
selectively cleaved the thiophenyl bond, forming exclusively the model trans-decalin 159 that 
possesses the stereochemistry and regiochemistry required for the core of anthracimycin 94 (Scheme 
36).79  
 
Scheme 36. The Raney-Nickel reduction of cis- and trans-decalins 156 and 137.79 
 
To summarise, a Lewis acid catalysed Diels‒Alder/epimerisation sequence allowed the formation of a 
model trans-decalin in a good yield and selectivity as required for anthracimycin, without the need for 
a radical reduction of unstable bromine-containing Diels‒Alder adducts. The scope of this 
cycloaddition was explored using different ring size enones in the presence of diverse dienes, to form 
trans-bicyclic products with a high diastereomeric ratio. The use of the sulfur-substitued diene 116 
permitted us to influence the regiochemistry of the Diels‒Alder cycloaddition reaction, exploiting the 
greater electron-donating effect of the thiophenyl group, and the cis-decalin 156 was obtained in a 
90% yield, optimising the literature reported conditions. Epimerisation to the trans-decalin 137 in 68% 
yield was followed by a selective Raney-Nickel reduction to remove the thiophenyl group, which 
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generated 159 as a model trans-decalin system for that required for the total synthesis. Application 
of these conditions to form the trans-decalin core of anthracimycin will be discussed in the next 
section. 
 
9.3 Formation of the trans-decalin core of anthracimycin 114 
9.3.1 The synthetic plan 
 
Based on the retrosynthetic plan (Scheme 21), the following synthetic route was proposed (Scheme 
37). Starting with a lithium aluminiun hydride reduction of the cheap and commercially available ethyl 
4-oxocyclohexanecarboxylate 117, TIPS-protection of the primary alcohol and oxidation of the 
secondary alcohol would generate ketone 160. Oxidation of 160 to enone 115 would yield the 
dienophile suitable for the Diels‒Alder/epimerisation sequence, optimised in the presence of the 
sulfur substituted diene 116. A selective Raney-Nickel reduction to remove the thiophenyl group 
would afford the required trans-decalin 114. Oxidation of this compound 114 to the enone trans-
decalin 113, would yield a key α,β-unsaturated synthetic intermediate. A stereoselective 1,2-reduction 
of 113 to generate the axial hydroxyl group, followed by treatment with propionyl chloride would 
form the propionate ester of trans-decalin 112. The axial position of the propionate ester would 
ensure a facial and diastereoselective Ireland‒Claisen rearrangement of 112 occurring from the same 
face of the triisopropylsilylmethyloxy chain, to afford the core of anthracimycin 162. Formation of the 
E-enolate of 112 in the presence of LDA should also provide the correct stereochemistry of the methyl 
group in 162. Esterification of 161 would be followed by DIBAL-H reduction to form aldehyde 162, 
setting the required functional group for a Still-Gennari olefination reaction to install fragment 92. 
Protecting group removal (TIPS) from 162, followed by an oxidation/esterification sequence would 
afford the highly functionalised trans-decalin core 94. Compound 94 represents the opposite 
enantiomer of the core of chlorotonil A 40 (except for the absence of the methyl group at C-8), 
reported by Kalesse.41 Following the published total synthesis of this chlorinated polyketide 15,41 
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installation of fragment 92 would be performed by a Still-Gennari olefination reaction with the 
phosphonate reagent 92 and KHMDS at ‒78 °C, to generate the advanced intermediate 163. 
Subsequent, Weiler dianion addition of the commercially available β-ketoester 93 with the use of LDA, 
as base would yield compound 164. Removal of the protecting group (PMB) by treatment with 
BF3·Et2O would also trigger the final macrocyclisation reaction, allowing the conclusion of the total 
synthesis in a total of 19 steps (Scheme 37). 
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Scheme 37. The synthetic plan for anthracimycin 1. 
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Dr. Ian George (postdoctoral researcher in the Clarke group) working on a related trans-decalin natural 
product called streptosetin A, had developed a scalable synthesis of enone 115. Reduction of 
commercially available compound 117, followed by TIPS-protection of the primary hydroxyl group, 
afforded a mixture of alcohols 165 and 166 in a 44% and 14% yield respectively. Swern oxidation, 
scalable to 10 g, was used to convert 165 and 166 into a single ketone 160 in excellent yield (99%). An 
Ito‒Saegusa oxidation was used to transform 160 to enone 115 (Scheme 38). However, the instability 
of the silyl enol-ether intermediate and its unreliable conversion into 115 and the reaction sensitivity 
to scale, forced us to find a more predictable and scalable synthesis of this early intermediate 115.80 
 
 
Scheme 38. The formation of the enone 115 developed by Dr. Ian George. 
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9.4 Direct palladium catalysed oxidation studies 
9.4.1 Direct palladium catalysed oxidation studies: Stahl conditions 
 
A new palladium-catalysed direct oxidation of ketone 160 to enone 115, which obviated the need to 
go via the silyl enol-ether, was developed by Dr. Ian George (postdoctoral researcher in the Clarke 
group) and myself, in collaboration with the Fairlamb group. Inspired by the work of Stahl (Scheme 
39),81 Dr. Ian George investigated conditions to perform the oxidation directly from the starting ketone 
160. In the Stahl proposed oxidation mechanism (Scheme 40),80 the first step would require the 
formation of the α-PdII-ketone intermediate 170, which is in equilibrium with the PdII-enolate species 
171. The β-hydride elimination would then afford the enone product 168.  Oxidation of the Pd0 
complex in the presence of oxygen, would regenerate the PdII-catalyst ready for the catalytic cycle. 
 
 
Scheme 39. Stahl reported condition of direct ketone oxidation.81 
 
 
 
Scheme 40. The proposed mechanism for PdII-catalysed oxidation of cyclic ketone.81 
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Following Stahl’s reported conditions in the presence Pd(OAc)2(DMSO)2 and Pd(TFA)2(DMSO)2 as the 
catalyst, the direct oxidation of ketone 160 to enone 115 was tested. However, after 16 hours at room 
temperature or at 80 °C in AcOH only traces of the enone 115 were formed (Table 7, entry 2-6). Using 
EtOAc, as the solvent, the conversion was not improved (Table 7, entry 7). A conversion of 5% to the 
desired product was observed over a period of 96 hours at room temperature in AcOH (Table 7, entry 
1). As this conversion matched the catalyst loading (5 mol% of Pd(OAc)2(DMSO)2), the catalytic cycle 
was probably arrested and the addition of additives was tested to overcome this problem. 
 
 
 
entry  Solvent Temp 
(°C) 
Time 
    
(h.) 
Conversion 
(%) 
1  AcOH rt 96 5 
2  AcOH 80 16  trace 
3  AcOH rt 16  trace 
4  AcOH 80 16  trace 
5  EtOAc rt 16  trace 
6  AcOH  80 16  trace 
7  EtOAc rt 16  trace 
 
Table 7. Stahl’s conditions on target ketone 160. 
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9.4.2 Direct palladium catalysed oxidation studies: additives effect 
 
The use of additives was explored to improve the conversion. In most cross-coupling reactions, the 
presence of a base (K2CO3, Et3N, NaHCO3) generally helps the β-hydride elimination and improves the 
yield.82 The control experiment in the absence of an additive showed no conversion to the enone 115 
as expected (Table 8, entry 1). The use of 2 equivalents of K2CO3 and Et3N, also showed no 
improvement in the conversion (Table 8, entry 2-3-4).  
 
 
entry Temp 
(°C) 
Additive 
(2 eq.) 
Conversion 
(%) 
1 60 - - 
2 60 K2CO3 - 
3 rt K2CO3 - 
4 60 NEt3 - 
 
Table 8. Additive screening to increase the conversion to the desired enone 115. 
 
 
In 2007, Tsuji reported the direct palladium-catalysed oxidation of cyclic ketones to conjugated 
enones, in chlorobenzene at 120 °C with the use of pyridine and bipyridine ligands as more efficient 
additives for this oxidation (Scheme 41).83 A stabilisation effect of the active palladium species, 
preventing aggregation and extending the catalyst lifetime, could be the role played by these 
bipyridine ligands.82 
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Scheme 41. Tsuji optimised conditions for direct ketone oxidation.83 
 
Inspired by this work,83 the addition of pyridine and bipyridine ligands was tested for the oxidation of 
ketone 160 to the enone 115, using Pd(OAc)2 and Pd(OAc)2(DMSO)2 complex as catalysts, in 
chlorobenzene at 120 °C (Figure 15). Little differences were observed in the conversion between the 
Pd(OAc)2 and the Pd(OAc)2(DMSO)2 complex, using pyridine 174 as a ligand (Table 9, entry 1 and 5). 
The addition of 2,6-lutidine 175 and 1,10-phenathroline 176 did not lead to efficient oxidation by 
either catalyst complex (Table 9, entry 2-3 and 6-7). The use of 2,2ʹ-bipyridyl 177 was found to be a 
highly effective ligand for the Pd(OAc)2 catalyst, increasing the conversion to 58% (Table 9, entry 8). 
In contrast, the addition of this ligand to the Pd(OAc)2(DMSO)2 complex did not improve the level of 
conversion (Table 9, entry 4). A conversion of 76% to the desired enone 115 was finally obtained with 
the use of 4,4ʹ-tBu-2,2ʹ-dipyridyl ligand 178 with Pd(OAc)2 as the catalyst (Table 9, entry 9). 
 
 
 
Figure 15. Pyridine and bipyridine ligands used. 
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entry Catalyst Ligand 
(mol%) 
Conversion  
(%) 
 
1 Pd(OAc)2(DMSO)2  174 (10) 19 
2 Pd(OAc)2(DMSO)2 175 (10) - 
3 Pd(OAc)2(DMSO)2  176 (5) - 
4 Pd(OAc)2(DMSO)2  177 (5) 17 
5 Pd(OAc)2 174 (10) 18 
6 Pd(OAc)2  175 (10) - 
7 Pd(OAc)2  176 (5) - 
8 Pd(OAc)2  177 (5) 58 
9 Pd(OAc)2  178 (5) 76 
 
Table 9. Pyridyl and bipyridyl ligand screening to improve the conversion of ketone 160 into enone 
115. 
 
Having identified the oxidation conditions, the conversion of ketone 160 into the enone 115 was 
monitored over time. The rate of this transformation followed an exponential growth, slowing at 
approximately 35% conversion. To improve conversion, additional catalyst was added which restored 
the reaction rate. A 92% conversion to the desired enone 115 was achieved after two subsequent 
additions of catalyst and ligand: 15 mol% Pd(OAc)2 and 15 mol% ligand total (Figure 16). 
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Figure 16. The re-addition of the catalyst restored the conversion rate of the oxidation. 
 
 
9.4.3 Direct palladium catalysed oxidation studies: the nitrate effect 
 
In the proposed reaction mechanism reported by Stahl (Scheme 40), the Pd0-species was oxidised by 
oxygen to PdII to re-start the catalytic cycle. However, during the reoxidation of palladium, aggregation 
and deactivation of the catalyst could take place arresting the cycle.82 The need of two subsequent 
additions of Pd(OAc)2 and ligand to reach a 92% conversion to the enone 115, suggested that 
deactivation of the catalyst was occurring during the oxidation reaction. The Fairlamb group have 
previously reported the nitrate effect in a range of oxidative palladium mediated processes, 
highlighting the role of the NO3‒ anion as a co-catalyst of the palladium complex.84, 85 To progress the 
conversion without the need of subsequent additions of Pd(OAc)2, the role of the nitrate was tested. 
In the presence of 19 mol% of KNO3, a rate enhancement was indeed observed: over a period of 80 
hours, a 60% conversion was seen (Figure 17). A conversion of 80% over the same period was observed 
with the use of 50 mol% of KNO3, whereas, in the presence of stoichiometric KNO3 a slower conversion 
was detected compared to the 50 mol% KNO3 experiment. A possible poison effect of stoichiometric 
quantities of the NO3‒ anion to the Pd(OAc)2 catalyst may explain this result (Figure 17).84, 85 
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Figure 17. The effect of KNO3 concentration on the oxidation rate of the formation of the enone 115. 
 
 
 
The optimised reaction conditions, 5 mol% of Pd(OAc)2, 5 mol% of 4,4ʹ-tBu-2,2ʹ-dipyridyl as a ligand 
and 50 mol% of KNO3 as a co-catalyst, were performed on a 10 g scale oxidation of ketone 160 to the 
enone 115, which was isolated in an 85% yield (9.0 g).  
In conclusion, a scalable and robust synthesis of the enone 115 was performed to afford the dienophile 
required for the Diels‒Alder cycloaddition, for the formation of the trans-decalin core of 
anthracimycin. The reported Stahl and Tsuji direct palladium-catalysed oxidation conditions were 
tested with no success, and a new catalytic system was developed. The use of the nitrate anion as a 
co-catalyst was found to be pivotal for the rate of conversion of ketone 160 into the enone 115. 
However, more studies need to be performed to investigate the appropriate mechanism of this 
reaction, which is still unknown, and to obtain the same level of conversion and yield in a shorter 
period of time. 
 
 
 
 19 mol% of KNO3 
 50 mol% of KNO3 
  1 equiv. of KNO3 
                No KNO3   
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9.4.4 Direct palladium catalysed oxidation studies: substrate scope 
To investigate if the optimised oxidation conditions were applicable to the formation of other enone 
systems, various ketone substrates were tested. A 50% conversion of the model trans-decalin 139 into 
the model enone trans-decalin 179, was achieved after 5 days. However, compound 179 was isolated 
in a 23% yield and unreacted ketone 139 was recovered in a 42% yield (Scheme 42). Purification issues 
explained the poor yield of 179, as enone 179 may remain coordinated to the Pd0 species. 
 
 
Scheme 42. The optimised oxidation conditions to form the model enone trans-decalin 179. 
 
The oxidation of cholesterone 180 generated enone 181 in 18% yield; compound 182 was also isolated 
in a 24% yield due to an unexpected addition of nucleophilic oxygen to the γ-alkene, and the 
consequent α,β migration of the double bond (Scheme 43).  
 
Scheme 43. Palladium catalysed direct oxidation of cholesterone 180. 
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The allyl-substituted enone 184 was isolated in a 37% yield as a consequence of the direct oxidation 
of 183, occurring exclusively on the less hindered side of the molecule (Scheme 44). This selectivity 
was hypothesised to be due to the steric repulsion between the palladium complex and the allyl 
substituent, which directed the oxidation to the less hindered position, α to the carbonyl group of 184. 
However, the starting material 183 was recovered in a 31% yield. 
 
Scheme 44. Palladium catalysed direct oxidation of allyl-substituted cyclohexanone 183. 
 
The oxidation of ketones 185, 186, 187 and 189 did not yield any enone products. Ketones 185 and 
186 exclusively formed polymerised material, whereas, the volatility of cyclopentanone 187 and 
heptanone 189 was responsible of the failure of these reactions (Scheme 45).  
 
 
 Scheme 45. Substrate scope using the optimised oxidation conditions. 
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In conclusion, the optimised palladium-catalysed direct oxidation conditions were not always 
applicable for the dehydrogenation of diverse substrates. Enones 179, 181 and 184 were formed in 
poor yields compared to the 85% isolated yield of enone 115. The reason is still unclear and more 
work is required to optimise and apply these conditions to the oxidation of various ketone substrates 
to enones in high yields. 
9.5 Enone 115 in the Diels-Alder reaction 
The power of this oxidation reaction allowed the synthesis of the enone 115 to be performed on a 
multi-gram scale and this compound was used as a dienophile in the Diels‒Alder/epimerisation 
sequence. In the presence of isoprene 133 as a diene, cis- and trans-decalins 191 and 192 were formed 
in a 0.83 : 1 ratio (cis : trans) (Scheme 46). Determination of the stereochemistry at C-6 was required. 
To this end, the trans-diastereoisomer 191 was converted into the hydrazone 193 by treatment with 
2,4-dinitrophenyhydrazine 140, in dry methanol and catalytic acetic acid. However, good quality single 
crystal X-ray diffraction could not be obtained. 
 
Scheme 46. The Diels‒Alder/epimerisation sequence between enone 115 and isoprene 133. 
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Following these results, the Diels‒Alder cycloaddition between enone 115 and the sulfur-substituted 
diene 116 was attempted. After 10 minutes, diene 116 was consumed completely and the desired 
product 194 was isolated in a 10% yield. Under the standard conditions, the rate of decomposition of 
diene 116 was faster than the rate of product formation and this explained the poor yield. To solve 
this problem, a large excess of diene 116 (10 equivalents) was used and compound 194 was isolated 
in an 85% yield, as a single cis-diastereoisomer (Scheme 47). Determination of the stereochemistry of 
the ring junction protons C-12 and C-7 and between C-7 and C-6, was the key information needed to 
progress in the total synthesis (Figure 18). The nOe 1H NMR analysis showed a prominent through-
space interaction between H-7 and H-12 (nOe = 2.66%), as well as a strong correlation between H-5 
and both ring junctions protons (nOe = 2.22% and 2.14%, H-12 and H-7 respectively) (Figure 18). No 
through-space interaction was observed between H-6 and the ring junction proton H-12 (Figure 19). 
According to these nOe data, the structure of 194 was deduced to be a cis-decalin with an anti-
relationship between protons H-6 and H-7. This stereochemical assignment was later confirmed by 
single crystal X-ray diffraction of derivative 196. 
 
 
Scheme 47. The Diels-Alder cycloaddition between enone 115 and the sulfur substituted diene 116. 
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Figure 18. The 1H NMR spectrum of cis-decalin 194 and the nOe analysis of H-12. 
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 Figure 19. The nOe analysis of H-7 and H-6. 
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Figure 18 shows the 1H NMR expansion between 4.3 and 0.7 ppm to highlight the key protons (H-5, 
H-12, H-7 and H-6) involved in the determination of the stereochemistry of the cis-decalin 194. The 
expansion between 4.3 and 0.7 ppm of the nOe spectrum of proton H-12 showed the through-space 
interaction with H-7 (nOe = 2.66%) and H-5 (nOe = 2.22%). Figure 19 shows the expansion between 
4.3 and 0.7 ppm of the nOe of H-7, in which a correlation of 2.14% with H-5 and 2.18% with H-12 
was observed, whereas, the nOe of H-6 showed no through-space interaction with H-12 (nOe = 0%) 
and a correlation with H-7 of 1.37%. 
Consequently, EtAlCl2-catalysed epimerisation of the cis-cycloadduct 194 gave the trans-
diastereoisomer 195, after 3 days at room temperature in an 84% yield. The thiophenyl group was 
removed using selective Raney-Nickel reduction and the desired trans-decalin 114 was obtained in 
77% yield (Scheme 48). To confirm the stereochemistry determined by nOe 1H NMR analysis, trans-
decalin 114 was converted into the hydrazone 196 using 2,4-dinitrophenylhydrazine 140 in dry 
methanol and catalytic glacial acetic acid. Compound 196 was isolated in 70% yield as an orange solid 
and crystallised in a hexane/EtOAc, antisolvent-solvent system. Gratifyingly, single crystal X-ray 
diffraction confirmed the stereochemistry determined by nOe 1H NMR studies. An anti-relationship 
between the protons H-6 and H-7 and a trans-stereochemistry of the ring junction protons, H-12 and 
H-7, were observed (Figure 20). The 1H NMR spectroscopic analysis of the trans-decalins 114 and 192 
were identical and it was concluded that both compounds had the same anti-relationship between 
protons H-6 and H-7 and a trans-stereochemistry of the ring junction protons, H-7 and H-12.  
 
79 
 
 
Scheme 48. The formation of the trans-decalin core 114.  
 
 
 
 
 
 
Figure 20. Single crystal X-ray diffraction of hydrazone 196 with thermal ellipsoids shown at 50%. 
  
Figure 20 shows the structure of the hydrazone trans-decalin 196. A trans-relationship at the ring 
junction protons H-7 and H-12 and an anti-relationship between protons H-7 and H-6 is evident, as 
required for the trans-decalin core of anthracimycin. 
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9.6 Oxidation of trans-decalin 114 to enone trans-decalin 113 
9.6.1 The Ito‒Saegusa oxidation 
To progress the synthesis, the conversion of the trans-decalin 114 into the enone trans-decalin 113 
was required, but this transformation was very challenging and so various oxidation methods were 
explored. Firstly, this oxidation was attempted using the optimised conditions of the direct palladium-
mediated oxidation. However, this transformation was particularly slow and the catalyst and the 
ligand had to be re-added every 24 hours. After 5 days, 87% conversion to the desired enone 113 was 
seen by 1H NMR analysis, but enone 113 was isolated in only 20% yield (Scheme 49). Purification issues 
could explain the poor yield of 113, becuase the enone trans-decalin 113 could have remained 
coordinated to the Pd0 species formed during the reoxidation process of the catalyst. The presence of 
two double bonds in the product may be responsible for this coordination, because under the same 
oxidation conditions the model enone trans-decalin 179 was also isolated in poor yield (50% 
conversion, 23% yield).  
 
 
Scheme 49. The conversion of the trans-decalin 114 to the enone trans-decalin 113 applying the 
optimised palladium oxidation conditions. 
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The Ito‒Saegusa oxidation reaction was attempted in order to improve the yield of enone 113. In 
1999, Dirk Trauner et al. reported the crystallisation and isolation of the Pd0-tetrolefin complex 199 
to highlight the mechanism of this reaction.86 Ketone 197 was converted into the silyl enol ether 198 
using KHMDS and TMSCl, and subsequently oxidised in the presence of stoichiometric Pd(OAc)2 in 
CH3CN (Scheme 50). 
 
 
Scheme 50. The Ito‒Saegusa oxidation conditions reported by Dirk Trauner.86 
 
Inspired by these conditions,86 the model trans-decalin 139 was converted into the TMS-enol ether 
intermediate 201 in the presence of LDA at ‒78 °C and TMSCl. Due to the propensity for hydrolysis of 
201 to the ketone starting material 139 in water, air and any non-anhydrous solvent suitable for the 
work-up of the reaction, it was not possible to isolate this compound. However, the formation of this 
TMS-enol ether was detected by TLC and was subsequently oxidised in the presence of Pd(OAc)2 to 
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form the model enone trans-decalin 179. Catalytic quantities of Pd(OAc)2 did not produce the desired 
product, but in the presence of 1.5 equivalents of Pd(OAc)2 the model enone trans-decalin 179 was 
generated in a 30% yield (Scheme 51). Hydrolysis of the TMS-enol ether 201 to the ketone starting 
material 139 occurred over time and this decomposition competed with the formation of the product 
179. To avoid this hydrolysis, the use of a large excess (3.5 equivalents) of Pd(OAc)2 was tested. A 
conversion of 82% to the model enone trans-decalin 179 was seen by 1H NMR analysis, but the desired 
product was isolated in just 25% yield (Scheme 51). Again, purification issues may explain the poor 
yield; elevated quantities of the catalyst may lead to high levels of Pd0 species in the reoxidation 
process, causing coordination of 179 and reduction of the yield. 
 
 
Scheme 51. The Ito‒Saegusa oxidation to form the enone 179. 
 
In 2011, Nishida et al. reported the Ito‒Saegusa oxidation of various TES-enol ether substrates, 
highlighting the high stability of these silyl enol ethers for this transformation.87 Inspired by this report, 
the model TES-enol ether trans-decalin 202 was formed and isolated in 78% yield. The ease of isolation 
was a consequence of the stability of the silyl enol ether in water and on silica chromatography. 
Treatment of 202 with stoichiometric Pd(OAc)2 in CH3CN formed the desired product 179, but only in 
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20% isolated yield (Scheme 52). The low yield was thought to be due to purification issues caused by 
the presence of the Pd0 species, and so this transformation was attempted using catalytic Pd(OAc)2 
loading. However, the desired product 179 was not obtained after five days, and the starting TES-enol 
ether 202 was recovered unreacted. The use of DMSO as a solvent resulted in formation and isolation 
of the desired product 179 in variable yields, of between 40% and 50%, when 60 mol% of Pd(OAc)2 
was used (Scheme 52).88 
 
 
Scheme 52. The Ito‒Saegusa oxidation of the model TES-enol ether trans-decalin 202.87, 88 
 
Following these encouraging results, the conversion of the trans-decalin 114 to the enone trans-
decalin 113 was attempted (Scheme 53). Formation of the TES-enol ether 203 in a 79% yield, was 
followed by the Ito‒Saegusa oxidation, which had a similar outcome; enone 113 was isolated in 
variable yields (30%-50%) in the presence of 60 mol% of Pd(OAc)2 in DMSO (Table 10, entry 1). The 
use of CH3CN as solvent did not increase the yield (Table 10, entry 2 and 3). The use of additives to 
increase the catalyst efficiency during the reoxidation process of the Pd0 species was tested. However, 
the presence of benzoquinone and Oxone® had a negative effect on this transformation; enone 113 
was isolated in 20% and 10% yield respectively (Table 10, entry 4 and 5).89, 90  
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Scheme 53. The Ito‒Saegusa oxidation to form enone 113.89, 90 
 
entry additives 
      
solvent temperature 
(°C) 
yield 
(%) 
1 - DMSO 40 30-50  
2 - CH3CN 23 20  
3 - CH3CN 40  20  
4 benzoquinone CH3CN 23 20  
5 Oxone® CH3CN 23 10  
 
Table 10. The attempted Ito‒Saegusa oxidation conditions.89, 90 
 
9.6.2 The selenoxide elimination  
Low yields had been obtained, and so the model trans-decalin 139 was used to scope other oxidation 
methods suitable for this transformation. Treatment of trans-decalin 139 in the presence of LDA at ‒
78 °C and phenylselenium chloride formed the selenide intermediate 204, which was oxidised with an 
excess of 30% H2O2 in water. The model enone trans-decalin 179 was generated in yields of 10% and 
33%, using CH2Cl2 and THF as solvents respectively (Scheme 54). 
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Scheme 54. The selenoxide chemistry used for the oxidation of 139. 
 
This oxidation method formed the model enone trans-decalin 179 in low yields due to the formation 
of many impurities, (confirmed by 1H NMR analysis), and so the conversion of the trans-decalin 114 
into the enone trans-decalin 113 under these conditions was not attempted. 
 
9.6.3 The α-bromination/elimination sequence 
An oxidation method to progress in the total synthesis had to be identified and so, model studies were 
used to test other conditions. In 2002, Baran and his group reported a robust and high yielding method 
to form dienone 206, as a key intermediate in their concise synthesis of (‒)-thapsigargin.91 The use of 
TMSOTf and Et3N converted ketone 205 into the TMS-enol ether, which was subsequently α-
brominated in the presence of NBS. Treatment of this intermediated with DBU formed the desired 
dienone product 206 in an 85% yield (Scheme 55).  
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Scheme 55. The oxidation conditions reported by Baran and his group.91 
 
Following the described method,91 the model trans-decalin 139 was converted to the model TMS-enol 
ether 201 by treatment with LDA at ‒78 °C and TMSCl. After formation of TMS-enol ether 201 had 
been established by TLC analysis, the α-bromination/elimination sequence in the presence of NBS and 
DBU generated tetralone 207 in a 13% yield (Scheme 56). The starting trans-decalin 139 was recovered 
in 40% yield, likely due to the hydrolysis of the TMS-enol ether 201. A possible explanation for the 
formation of tetralone 207, is equilibration of the kinetic to the thermodynamic enol ether, which 
occurred when the reaction was warmed to 0 °C in the α-bromination step.  
 
Scheme 56. Oxidation of ketone 139 in the presence of NBS and DBU, as reported by Baran et al.91 
 
9.6.4 The Rubottom oxidation 
The α-functionalisation of ketone 139 with a leaving group suitable for elimination, and the 
subsequent formation of the enone 179 was investigated using the Rubottom oxidation reaction.92 
Literature reported this mild method to synthesise α-hydroxy ketones, via formation of silyl enol ether 
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intermediates followed by oxidation in the presence of m-CPBA (Scheme 57). This approach would 
allow the formation of the α-hydroxy trans-decalin 214, which could be subjected to a 
mesylation/elimination sequence to yield the desired model enone 179.  
 
 
Scheme 57. Literature examples of Rubottom oxidation.92 
 
Treatment of the model trans-decalin 139 in the presence of LDA at ‒78 °C and TMSCl generated the 
TMS-enol ether 201. However, hydrolysis of the silyl enol ether 201 to the starting ketone trans-
decalin 139 occurred in the oxidation step (Scheme 58). This oxidation method was therefore not 
pursued further. 
 
Scheme 58. The Rubottom oxidation method to form the model enone trans-decalin.92 
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9.6.5 The oxidation in the presence of IBX 
Model studies to discover a robust and reliable oxidation method continued to be explored to progress 
the total synthesis. In 2002 Nicolaou et al.,93 reported the direct oxidation of various ketone substrates 
to generate enones by treatment with 2-iodoxy benzoic acid (IBX) at elevated temperatures. Inspired 
by this work, the model trans-decalin 139 was treated with 1.5 equivalents of IBX at 95 °C, but after 
16 hours only tetralone 207 was formed in a 23% yield (Scheme 59). Presumably, generation of 
tetralone 207 was a consequence of the thermodynamic enol formation followed by 
oxidation/aromatisation, occurring at elevated temperature. 
 
 
Scheme 59. Oxidation of the model trans-decalin 139 using the reported literature conditions.93 
 
To avoid the formation of the thermodynamic enol, the synthesis of the TES-enol ether trans-decalin 
202 at a lower temperature was proposed. Treatment of the model trans-decalin 139 with LDA and 
TESCl at ‒78 °C formed TES-enol ether 202 in a 78% yield, which was then subjected to the IBX 
oxidation at 40 °C, the minimum temperature needed to dissolve IBX (Scheme 60). Interestingly, it 
was observed that the stoichiometry of IBX played an important role in the formation of the desired 
product in good yield. The use of 1.5 equivalents of IBX formed the model enone trans-decalin 179 
and the ketone trans-decalin 139 in a 1 : 1 ratio (Table 11, entry 1). Increasing the stoichiometry of 
IBX to 2.5 equivalents formed 179 and 139 in a 1 : 0.37 ratio with the isolation of 179 in a 62% yield 
(Table 11, entry 2). The use of a large excess of IBX (5 and 10 equivalents) did not improve the 
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conversion from 63%, as 179 and 139 were isolated in a 1 : 0.46 and 1 : 0.47 ratios respectively (Table 
11, entry 3 and 4).  
 
Scheme 60. The IBX oxidation of the model TES-enol trans-decalin 202. 
 
entry equivalents of 
IBX 
crude ratio 
179 : 139 
combined yield 
of 179 and 139 
(%) 
1 1.5             1 : 1 78 (a) 
2 2.5       1 : 0.37 62 (b) 
3 5       1 : 0.46 80 (a) 
4 10        1 : 0.47 75 (a)  
(a) crude yield, (b) isolated yield of enone trans-decalin 179 
Table 11. The IBX oxidation of the model TES-enol intermediate 202. 
 
The formation of the model enone trans-decalin 179 in a good yield under IBX oxidation, prompted 
the application of these conditions to convert the trans-decalin 114 to the enone trans-decalin 113. 
After formation of the TES-enol ether intermediate 203 in a 79% yield, oxidation of TES-enol ether 203 
in the presence of 2.5 equivalents of IBX formed the desired enone 113 in a 65% conversion and a 63% 
yield (Scheme 61, Table 12, entry 2). The amount of IBX played an important role in the formation of 
enone 113 in a good ratio and yield. The use of 1.5 equivalents of IBX formed 113 and 114 in a 1 : 1 
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ratio (Table 12, entry 1), whereas, a large excess of IBX (5 equivalents) did not improve the conversion 
and yield from 65% and 63% respectively (Table 12, entry 3). 
 
 
Scheme 61. The IBX oxidation to form the enone trans-decalin 113. 
 
entry equivalents of  
IBX 
crude ratio 
113 : 114 
yield 
(%) 
1 1.5 1 : 1 45 
2 2.5      1 : 0.35 63 
3 5      1 : 0.42 62 
 
Table 12. The IBX oxidation of the model TES-enol intermediate 203. 
 
In conclusion, the formation of the enone trans-decalin 113 was found to be very challenging and 
several oxidation methods were studied to afford 113 in a good yield to progress the total synthesis. 
The model trans-decalin 139 was therefore used to scope an appropriate strategy. The direct 
palladium-oxidation method developed by Dr. Ian George and the Ito‒Saegusa reaction, formed the 
desired enone products in a good conversion. Nevertheless, purification issues explained the low 
91 
 
yields of 113 and 179. Model studies involving selenoxide chemistry were not successful and afforded 
the desired product in low yields with many impurities.  
The strategies used by Baran and Rubottom to α-functionalise the model trans-decalin 139 with a 
suitable leaving group prone to elimination were found to be unreliable. The Nicolaou IBX oxidation 
protocol, generated tetralone 207 due to the formation of the thermodynamic enol followed by an 
oxidation/aromatisation reaction. In contrast, the formation of the model TES-enol ether intermediate 
202 allowed the IBX-mediated formation of the model enone trans-decalin 179 to be accomplished in 
a good yield. The identification of this reliable, consistent and robust oxidation method permitted the 
isolation of the desired enone trans-decalin 113 in a good yield, allowing progression of the total 
synthesis.  
Stereoselective 1,2 reduction of this key intermediate 113 followed by treatment with propionyl 
chloride to form the propionate ester trans-decalin 112, suitable for the facial and diasteroselective 
Ireland‒Claisen rearrangement will be discussed in the next section. 
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9.7 Strategies to the core of anthracimycin 162 
9.7.1 The Ireland‒Claisen rearrangement 
The use of an Ireland‒Claisen rearrangement was the reaction envisioned for functionalisation to give 
the core of anthracimycin 162. This approach would start with a stereoselective Luche reduction of 
113,95 followed by treatment with propionyl chloride to provide 112, an allylic ester suitable for the 
rearrangement reaction (Scheme 62).  
 
 
Scheme 62. Formation of the propionate ester trans-decalin 112. 
 
The axial position of the propionate ester would ensure the rearrangement occurring from the same 
face of the triisopropylsilylmethyloxy side chain, to install the double bond and the side chain in the 
correct positions. Rearrangement of the E-enolate would proceed via chair-like or boat-like transition 
states I and II. A chair-like transition state I would form 161a with the stereochemistry of the methyl 
group opposite to anthracimycin, whereas, a boat-like transition state II would install the methyl group 
with the required stereochemistry for the natural product (Scheme 63). In his synthesis of Monensin, 
Ireland amply demonstrated the formation of substituted cyclohexenyl fragments by using the 
Ireland-Claisen rearrangement, which proceeded via a boat-like transition state (Scheme 64).96, 97, 98, 
99, 100, 101, 102 
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Scheme 63. Proposal for stereocontrol in the Ireland‒Claisen rearrangement. 
 
 
Scheme 64. Boat-like transition state in a Ireland‒Claisen rearrangement, applied to the total 
synthesis of Monensin. 96, 97, 98, 99, 100, 101, 102 
 
Methods to control the formation of the E-enolates were investigated for the synthesis of the core of 
anthracimycin 162. In 1991, Ireland and his group reported kinetically controlled enolate formation 
for the stereoselective formation of both Z- and E-silyl ketene acetals in THF and THF/dipolar solvent 
system with the use of LDA.103 According to their studies, various ratios of Z- and E-enolates 220 and 
221 were formed depending on the solvent effect. A 6 : 94 ratio (Z- : E-)  was produced in THF, whereas 
in the presence of additives, such as  DMPU (30% in THF) and HMPA (23% in THF) ratios of 98 : 2 and 
a 85 : 15 (Z- : E-) respectively were observed (Scheme 65). 
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Scheme 65. The Z- and E-enolate formation.103 
 
The 6-membered ring transition states IV and V were rationalised to explain the stereochemical 
control during enolate formation (Scheme 66). The transition state IV permitted a close interaction 
between the lithium cation, carbonyl oxygen and the base; in the presence of HMPA as an additive, 
transition state V was preferred. The transition state V is characterised by a 1,3-diaxial interaction 
between the N-isopropyl group and the R enolate group. However, this strain was reduced in the 
presence of DMPU or HMPA due to the greater degree of solvation of the lithium cation. As a result, 
in transition state V the association between ester and base diminished minimising the 1,3-diaxial 
interaction, whereas, the transition state IV is still destabilised by the 1,3-diaxial strain.103 
 
Scheme 66. The two transition states in kinetic enolisation of esters.103 
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Stereoselective 1,2-reduction was investigated with the use of the model enone trans-decalin 179 as 
the substrate. Luche conditions were tested in the presence of equimolar amounts of CeCl3·7H2O and 
NaBH4 in MeOH, in order to favour 1,2-reduction over possible 1,4-reduction. This reaction produced 
the allylic alcohol 224 in a 62% yield as a single diastereoisomer (Scheme 67).95  
The nOe 1H NMR analysis was used to assign the stereochemistry of 224 at H-13. However, the only 
prominent through-space interaction (nOe = 0.16%) was found between protons H-13 and H-12 and 
one of the two H-11 (Scheme 67, Figure 21). Due to this ambiguous nOe result and the absence of 
other clear evidence, the stereochemistry of 224 was tentatively assigned based on the known 
mechanism of the sodium borohydride reduction. Wigfield amply demonstrated that hydrides 
preferentially attack from a pseudo-axial trajectory in unhindered cyclohexanones, to give the 
hydroxyl group in the equatorial position.104 As the model enone trans-decalin 179 was considered an 
unhindered cyclohexanone, the hydroxyl was tentatively assigned as having an equatorial positon, as 
a result of pseudo-axial attack of the hydride on the carbonyl group. 
 
 
Scheme 67. The Luche reduction of the model enone trans-decalin 179.95, 104 
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Figure 21. The 1H NMR spectrum of alcohol 224 in d6 benzene. 
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The expansion of the 1H NMR spectrum between 4.44-1.32 ppm showed the key peaks H-13 and H-
12 needed to be irradiated to determine the stereochemistry of 224. The expansion between 4.31-
1.32 ppm of the nOe analysis of H-13 showed the through-space interaction with H-12 (nOe = 0.16%), 
which was in a multiplet with H-11. Due to the overlap of these two protons (H-12 and H-11) it was 
not possible to determine the stereochemistry of 224 at H-13 unambiguously (Figure 21). 
The allylic alcohol 224 was derivatised to produce the propionate and acetate esters 226 and 227, in 
order to clarify the stereochemistry of H-13 by nOe 1H NMR analysis (Scheme 68). However, the 
formation of these two esters did not help to establish the configuration of 224, due to the overlap of 
key peaks in the 1H NMR spectrum. In the acetate ester 226, H-12 was overlapping with H-6 between 
1.80-1.75 ppm, whereas, in the propionate ester 227 H-12 was in a multiplet with H-11, H-7 and H-
8 between 1.93-1.84 ppm.  
 
 
 
 
 
 
 
 
 
 
Scheme 68. The esterification of 224 to understand the stereochemistry of H-13. 
 
Pseudo axial attack of the hydride onto the model enone trans-decalin 179 with consequent formation 
of the equatorial hydroxyl-substituted trans-decalin 224 was expected, so various reducing agents 
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were tested to explore their influence on the selectivity of this reduction reaction. In 2000, De Groot 
reported the stereoselective 1,2-reduction of ketone 229 to give alcohol 230 by the use of DIBAL-H.105 
The presence of the methyl group at the ring junction of the trans-decalin system 229 ensured the 
high selectivity of this reduction reaction. In this case, attack of hydride from the equatorial face of 
the ketone, ensured formation of the axial hydroxyl group in 230 (Scheme 69).105 
 
 
Scheme 69. The stereoselective reduction of ketone 229.105 
 
The use of DIBAL-H as the reducing agent produced the alcohol 224 as the major product, but in the 
1H NMR spectrum of 224, other related decalin peaks were seen (Figure 22). A possible explanation 
for the presence of these peaks was formation of the axial alcohol 231, because the bulkier reducing 
agent influenced the selectivity of the 1,2-reduction, directing pseudo-equatorial hydride attack. 
However, it was not possible to unambiguously determine this because the two possible 
diastereoisomers, 224 and 231, were isolated as an inseparable mixture.  
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Figure 22. The 1H NMR spectrum of the possible formation of the axial hydroxyl 231. 
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Figure 22 shows the 1H NMR spectrum of alcohol 224 formed as a single compound under the Luche 
conditions, and the 1H NMR spectrum of alcohol 224 under DIBAL-H reduction, in which the presence 
of extra-olefin peaks between 6.00-5.31 ppm suggested formation of the axial alcohol 231 as the 
minor diastereoisomer. 
Nevertheless, DIBAL-H 1,2-reduction of the model enone 179 generated the equatorial and axial 
alcohols 224 and 231 as an inseparable mixture, in an 8 : 2 ratio in toluene and in a 9 : 1 ratio in THF 
(Table 13, entry 2 and 3). The use of a bulkier reducing agent such as Red-Al® also formed the alcohol 
224, as the major diastereoisomer in an 8 : 2 ratio (Table 13, entry 4). Interestingly, Al(iOPr)3 and IPA 
formed alcohol 224 exclusively, whereas, with L-selectride only the model ketone 139 was isolated, as 
a consequence of a 1,4-reduction (Table 13, entry 1 and 5).105 These results showed that the substrate 
controlled 1,2-reduction of 179, biases hydride to attack from the axial face of 179.  
 
entry reagent temperature 
(°C) 
solvent time 
(minutes) 
selectivity 
224 : 231  
yield 
(%) 
1 L-selectride ‒78  THF 30 139 70 
2 DIBAL-H ‒78  Toluene 30 8 : 2 74 
3 DIBAL-H ‒78  THF 30 9 : 1 76 
4 Red-Al® ‒78  THF 30 8 : 2 56 
5 Al(iOPr)3 50  IPA/Toluene 5 days 224 20 
 
Table 13. The 1,2-reduction of the enone trans-decalin 179.106 
 
101 
 
In conclusion, the Luche reduction of ketone 179 generated the alcohol trans-decalin 224 in which the 
stereochemistry of H-13 was assigned tentatively based on the mechanism of sodium borohydride 
reduction of unhindered cyclic ketones, and the nOe 1H NMR analysis. Inversion of the selectivity, 
forcing the hydride attack from the equatorial face of ketone 179, was attempted with the use of a 
bulkier reducing agents such as DIBAL-H, Red-Al, L-selectride and Al(iOPr)3 in IPA. Under these 
conditions, alcohol 224 was formed as the major product and in the 1H NMR spectrum new key olefin 
decalin peaks were indeed observed, suggesting the possible formation of the axial alcohol 231. 
However, it was not possible to prove this outcome unambiguously because alcohols 224 and 231 
were isolated as an inseparable mixture of products. 
As the literature reported the 1,2-reduction of a related decalin system similar to the enone 228 by 
the use of DIBAL-H,105 treatment of this compound under these conditions was attempted with the 
hope of achieving the correct stereoselectivity. However, the 1,2-reduction of ketone 113 in the 
presence DIBAL-H generated the diastereoisomeric alcohols 232 and 215 in a 5 : 1 ratio in toluene, 
and in a 3 : 1 ratio in THF (Scheme 70). 
 
 
Scheme 70. The 1,2-reduction of the enone trans-decalin 113.105 
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The stereochemistry of the alcohols 232 and 215 was determined by nOe 1H NMR analysis. In the 
major diastereoisomer 232, a significant through-space interaction (nOe = 0.74%) between H-13 and 
axial H-7 was detected, whereas, no interaction (nOe = 0%) between protons H-13 and H-6 was 
observed (Figure 23). In the minor diastereoisomer 215 a significant through-space interaction (nOe 
= 1.03%) between H-13 and H-6 was detected, as well as between protons H-13 and H-12 (nOe = 
1.32%). This nOe analysis allowed tentative assignment of the stereochemistry of the major and minor 
alcohols 232 and 215 (Figure 23). 
 
Figure 23. The nOe correlation of compounds 232 and 215. 
 
These reduction conditions were found to be non-selective for formation of the desired axial alcohol 
215, which was isolated as the minor diastereoisomer. As shown in the model studies, the use of Red-
Al, L-selectride and Al(iOPr)3 in IPA did not improve the selectivity, and favoured formation of the 
equatorial hydroxyl group, and so other conditions were not tested.  
After separation and isolation of the alcohols trans-decalins 232 and 215, the minor diastereoisomer 
215 was converted into the propionate ester 112 to test the Ireland‒Claisen rearrangement reaction 
(Scheme 71). However, in the presence of LDA and TMSCl, compound 112 did not rearrange to form 
the expected compound 161.103  
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Scheme 71. The attempted Ireland‒Claisen rearrangement.103 
 
In conclusion, due to the low selectivity of the 1,2-reduction reaction to give the alcohol 215 and the 
difficulties encountered when attempting to form compound 161 via the Ireland‒Claisen 
rearrangement, this approach to the synthesis of the core of anthracimycin was not taken further.  
 
9.7.2 The Tsuji‒Trost transformation 
In 1993, Tsuji reported a stereocontrolled method to generate cis-ring junctions in decalins, in which 
compound 233 was converted into the cis-bicyclic product 236 in a 79% yield by use of a Tsuji‒Trost 
reaction. This approach to the synthesis of the core of the natural product was explored (Scheme 
72).107 
 
Scheme 72. The stereocontrolled formation of cis-ring junction decalin by Tsuji.107 
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A second strategy was therefore envisioned to generate the core of anthracimycin 162. The major 
diastereoisomeric alcohol 232 was derivatised to give the acetate 238, and used as a substrate for the 
Tsuji‒Trost transformation (Scheme 73).  
 
 
Scheme 73. The proposal Tsuji‒Trost reaction to the core of anthracimycin 162.  
 
Following this strategy, the model allylic alcohol 224 was converted into the corresponding acetate 
224 in a 72% yield. In the presence of Pd(OAc)2, PPh3 and dimethylmethylmalonate, as a soft 
nucleophile, unreacted model acetate 224 was recovered in 80% yield (Scheme 74). Acetylation of the 
allylic alcohol 232 formed the acetate ester 238, which under the Tsuji‒Trost conditions generated 
the enone 113 and the alcohol 232 in yields of 40% and 30% respectively (Scheme 74).108, 109, 110, 111, 112 
The presence of water, in the solvent and/or in the atmosphere of the reaction, may explain the 
formation of these products. Once the Pd(II) π-decalin system had formed, water could have added as 
a nucleophile to generate the alcohol trans-decalin 232, which could then oxidised to the enone 113 
under the reaction conditions. 
 
105 
 
 
Scheme 74. The Tsuji‒Trost transformation of esters 226 and 238, as substrates.108, 109, 110, 111, 112 
 
In conclusion, the 1,2-reduction of the enone 113 afforded the desired alcohol 215 as the minor 
diastereoisomer. This compound 215 was converted to the ester 112, which did not rearrange to form 
the core of anthracimycin 162, using the Ireland‒Claisen transformation. The major alcohol 
diastereoisomer 232 was converted to the acetate 238 and subjected to the Tsuji‒Trost conditions. 
However, this strategy also failed to deliver the core of anthracimycin 162 and, hence, a new approach 
to functionalise the enone 113 was required. 
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9.7.3 The Mukaiyama‒Michael strategy 
The Mukaiyama‒Michael approach to synthesise the core of anthracimycin 162 was next explored. To 
this end, E-ethyl-propanoate silyl ketene acetal 240 was synthesised and used as a nucleophile to 
accomplish 1,4-addition to the enone 113.113 When TiCl4 was employed as a Lewis acid, compound 241 
was isolated as a single diastereoisomer in a 45% yield (Scheme 75). When Yb(OTf)3 was used to 
promote the addition  reaction, compound 242 was obtained in quantitative crude yield and was 
converted into 241 under acidic conditions (Scheme 75). The instability of 241 on silica explained the 
poor yield.114, 115, 116 
 
 
Scheme 75. The Mukaiyama‒Michael 1,4-addition. 114, 115, 116 
 
Determination of the stereochemistry of 241 was required and the conversion of this compound into 
the tricyclic system 247 was proposed (Scheme 77), in order to determine its configuration via nOe 1H 
NMR analysis. To this end, the ketone of Mukaiyama‒Michael adduct 241 needed to be converted 
into an alkene by use a triflation-enol formation/palladium reduction sequence reported by 
Ishibashi.116 In the first instance, these conditions were studied using the model trans-decalin 139 as 
the substrate. Treatment of ketone 139 in the presence of LDA and N-phenyl-bis-
trifluoromethanesulfonimide 243 formed the triflate enol trans-decalin 244 in a 36% yield.   
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Palladium-mediated reduction in the presence of Pd(OAc)2(PPh3)2, Bu3N and formic acid completed 
this transformation to form the alkene between C-13 and C-14, to generate the diene 245 (Scheme 
76).117 
 
 
Scheme 76. The model studies of the conversion of a ketone into an alkene.117 
 
Following these studies, the triflation of the Mukaiyama‒Michael adduct 241 in the presence of LDA 
and N-phenyl-bis-trifluoromethanesulfonimide 243, was followed by TIPS-removal using TBAF to 
generate the tricyclic system 246, which was isolated in 67% yield over two-steps (Scheme 77). 
Palladium reduction conditions converted enol triflate 246 into alkene 247 in a 51% yield (Scheme 77, 
Figure 24). The single crystal X-ray diffraction of the tricyclic lactone 247, showed that the addition of 
the E-ethyl-propanoate silyl ketene acetal 240 had occurred selectively opposite to the face of the 
bicyclic system 113 presenting the triisopropylsilylmethyloxy group. The methyl group at C-25 had the 
required stereochemistry for the core of the natural product (Figure 24) 
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Scheme 77. The transformation of 239 to the tricyclic system 245.117  
 
 
 
 
Figure 24. The single crystal X-ray diffraction of 247 with thermal ellipsoids shown at 50%. 
 
Figure 24 shows the anti-relationship between protons H-15 and H-6, and shows that addition of the 
E-ethyl-propanoate silyl ketene acetal 240 occurred from the face opposite to that presenting the 
triisopropylsilylmethyloxy chain. The stereochemistry of the methyl group at C-25 was instead correct 
for the core of the natural product. 
In conclusion, the Mukaiyama‒Michael strategy formed the “epi-core of anthracimycin 247”, upon 
selective 1,4-addition to 113 from the face of the decalin opposite to that presenting the 
H-15 
 
H-6 C-25 
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triisopropylsilylmethyloxy chain. However, contemporaneous studies towards the decalin-core of 
streptosetin A 260 performed by Dr. Ian George, showed an Hosomi‒Sakurai approach might be the 
answer to the problem of selectivity in this 1,4-addition reaction and might allow continuation of the 
total synthesis.  
 
9.7.4 The Hosomi‒Sakurai strategy 
The Hosomi‒Sakurai transformation was explored to synthesise the core of anthracimycin 162. As 
reported in the literature, this 1,4-addition process involves a Lewis acid-promoted allylation of 
various electrophiles such as aldehydes, ketones and enones in the presence of allyltrimethylsilane 
250.118 This strategy is recognised as a mild method for C-C bond formation, and has the possibility to 
generate new stereogenic centres. Generally, the reaction proceeds by the addition of the alkene of 
the allyltrimethylsilane 250 to the carbon electrophile 249, leading to the formation of a carbocation 
intermediate 251 stabilised by the presence of the β-silicon atom. Stabilisation arises from the orbital 
overlap between the empty orbital on the carbocation and the co-planar C–Si σ-bond (Scheme 78).119 
 
Scheme 78. The mechanism of the Hosomi‒Sakurai 1,4-addition.119 
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9.7.5 The Hosomi‒Sakurai to the core of streptosetin A 
This 1,4-addition reaction was studied by the group, during the synthesis of the core of streptosetin A 
260 (Dr. Ian George). The decalin core of this natural product was synthesised using the Hosomi‒
Sakurai transformation between allyltrimethylsilane 250 and the enone 115, followed by an aldol 
addition reaction in the presence of aldehyde 255. The reaction sequence generated a mixture of 256 
and 257 in a 3 : 1 ratio (Scheme 79). An alkene metathesis reaction of 255 and 257 formed decalins 
258 and 259, which were crystallised to confirm the stereochemistry of the two diastereoisomers. The 
single crystal X-ray diffraction of 258 and 259, showed a syn-selective addition of allyltrimethylsilane 
250 to enone 115, as highlighted by the syn-relationship of protons H-7 and H-6 in both compounds 
(Figure 25). The aldol addition reaction, instead, generated the two diastereoisomers 256 and 257 at 
C-11 in a 3 : 1 crude ratio (Scheme 79).  
 
 
Scheme 79. The Hosomi‒Sakurai approach to streptosetin A 260. 
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In compounds 258 and 259, a syn-relationship of protons H-7 and H-6 was observed, whereas, the 
diastereoselectivity at C-11, is a consequence of the aldol addition reaction (Figure 25).  
A possible hypothesis based on the transition state conformation of the titanium-complex 261 was 
used to rationalise these results. The addition of allyltrimethylsilane 250 from the same face of the 
triisopropylsilylmethyloxy chain of 261, led to a favoured “chair” intermediate 261a, forming the syn-
adduct. If the addition of 250, instead, occurred from the opposite face of the 
triisopropylsilylmethyloxy chain, a disfavoured “twist boat” intermediate 261b was formed, leading to 
the anti-adduct 262 (Scheme 80). 
 
 
Scheme 80. A possible explanation for the formation of the major syn-adduct. 
 
9.7.6 The Hosomi‒Sakurai approach towards anthracimycin core 162 
Inspired by this work, model studies of the Hosomi‒Sakurai 1,4-addition between enone 115 and 
allyltrimethylsilane 250 were performed, and compound 183 was generated as a single product in a 
60% yield. The determination of the stereochemistry of 183 was achieved following a 
deprotection/iodoetherification sequence.120 Removal of the TIPS-group of the allyl-substituted 
cyclohexanone 183 under HF/pyridine conditions generated alcohol 263, which was subjected to 
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cyclisation by an iodoetherification reaction upon treatment with I2 and NaHCO3. This formed two 
bicyclic products 264 and 265 in a 2.7 : 1 crude ratio (Scheme 81). The major diastereoisomer 264 was 
crystallised and the single crystal X-ray diffraction showed a syn-relationship between protons H-6 and 
H-15, as required for anthracimycin (Figure 26).  
 
 
Scheme 81. Formation of 183 and the use of a deprotection/iodocyclisation sequence to determine 
its stereochemistry.120 
 
 
 
 
Figure 25. The single crystal X-ray diffraction of 264 with thermal ellipsoids shown at 50%. 
 
Figure 25. Structure of 264 established by single crystal X-ray diffraction showing the syn-
relationship between protons H-6 and H-15. 
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Following these studies, the 1,4-addition reaction between allyltrimethylsilane 250 and the enone 
trans-decalin 113 was tested and two diastereoisomeric products 266 and 267 were generated in a 
61% and 7% yield, respectively (Scheme 82). Derivatisation of the major diastereoisomer 266 to give 
the hydrazone 268 by treatment with 2,4-dinitrophenylhydrazine 140 and acetic acid, allowed the 
determination of the stereochemistry of the addition reaction (Scheme 82). The single crystal X-ray 
diffraction of 268 showed a syn-relationship between protons H-15 and H-6, which confirmed the 
outcome of the Hosomi‒Sakurai 1,4-addition of allyltrimethylsilane 250 (Figure 27).  
 
 
Scheme 82. The Hosomi‒Sakurai addition between 113 and 250, and formation of hydrazone 268 
from the major diastereoisomer 266.  
 
 
 
 
 
114 
 
H-6
 
 
 
 
 
  
 
 
Figure 26. The single crystal X-ray diffraction of compound 268 with thermal ellipsoids shown at 
50%. 
 
Figure 26. Single crystal X-ray diffraction of hydrazone 268 produced from the product of the Hosomi‒
Sakurai 1,4 addition reaction. 
  
Following determination of the stereochemistry of the major diastereoisomer 266, the biological 
activity of compound 269 was tested by the biologist collaborators in this project: Dr. Gavin Thomas 
and Dr. Emmanuele Severi. To this end, TIPS-removal of the major diastereoisomer allyl trans-decalin 
266 was performed under HF/pyridine conditions and compound 269 was isolated in a 98% yield 
(Scheme 83). However, this advanced intermediate in the synthesis of the core of anthracimycin did 
not possess antimicrobial activity.  
 
 
Scheme 83. The TIPS-removal of 266 to test the antimicrobial activity. 
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To install the methyl group at C-25 via this strategy, the use of the E-crotyltrimethylsilane 272, as a 
nucleophile, was envisioned, but the synthesis of this compound was found to be challenging. The 
literature reported a number of different approaches to synthesise the E-crotyltrimethylsilane 272: 
121, 122 in one of them, the treatment of propargyl trimethylsilane 270 with methyl lithium and 
iodomethane formed compound 271 in a 48% yield.121 Conversion of 271 into E-crotyltrimethylsilane 
272 was achieved by treatment with Ni(OAc)2·4H2O and NaBH4 under H2 atmosphere (Scheme 84).121 
 
 
Scheme 84. An approach to the synthesis of E-crotyltrimethylsilane 272.121 
 
Inspired by this work, the formation of the E-crotyltrimethylsilane 272 was explored. Commercially 
available methyl propargyl bromide 274 was converted into methyl propargyl trimethylsilane 271, 
following the conditions reported by Xiao et al. by treatment with stoichiometric quantities of Mg and 
TMSCl, and a catalytic amount of HgCl.123 However, 271 was isolated in just 10% yield due to the 
volatility of this compound (Scheme 85). Conversion of 271 into 272 was attempted by treatment with 
Ni(OAc)2·4H2O and NaBH4,121 but crude 1H NMR analysis, showed that the desired compound 272 was 
not formed and only polymerisation was detected (Scheme 85). 
 
 
Scheme 85. The attempted synthesis of E-crotyltrimethylsilane 272.121, 123 
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In order to synthesise E-crotyltrimethylsilane 272, another strategy involving a two-step sequence was 
explored.122 In the first step, the trans-crotylchloride 274 was converted into intermediate 275 by 
reaction with Et3N, CuCl and Cl3SiH. This was followed by the methylation of 275 using MeMgI to form 
the desired E-crotyltrimethylsilane 272 in a 59% yield.122 Following these conditions, the E-
crotyltrimethylsilane 272 was isolated in only 30% yield when working on a large scale and under 
rigorously inert atmospheric conditions (N2). The low yield was attributed to the instability in air of 
276 and the volatility of the desired product 272 (Scheme 86). 
 
 
Scheme 86. The synthesis of the E-crotyltrimethylsilane 272.122 
 
With compound 272 in hand, the 1,4-addition between the enone trans-decalin 113 and the E-
crotyltrimethylsilane 272 was investigated. When this reaction was performed at ‒78 °C, the product 
was not formed and the starting material 113 was recovered unreacted. When the temperature was 
increased to ‒40 °C, an inseparable mixture of two diastereoisomers 276 and 277 was generated in a 
2 : 1 ratio (43% yield) (Scheme 87). The instability of 276 and 277 on silica explained the poor yield, as 
all of the enone 113 was consumed to form the products.  
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Scheme 87.  The Hosomi‒Sakurai addition between the enone trans-decalin 113 and E-
crotyltrimethylsilane 272. 
 
This 1,4-addition reaction generated an inseparable mixture of two diastereoisomeric products, and 
two new stereogenic centres at C-15 and C-16 were created. Determination of the stereochemistry of 
the major and the minor diastereoisomers 276 and 277 was needed to progress in the total synthesis. 
To this end, a deprotection/iodocyclisation sequence was envisioned to separate and derivatise these 
two diastereoisomers to form two tricyclic systems, facilitating the determination of the 
stereochemistry by nOe 1H NMR analysis.120 It was hoped that the TIPS-removal of 276 and 277 would 
allow the separation of the major and the minor diastereoisomers, and so this inseparable mixture of 
compounds was treated with HF/pyridine (Scheme 88). The reaction, however, produced multiple 
products. The major diastereoisomer 276 was fully deprotected and generated an inseparable mixture 
of two diastereoisomer alcohols 278 and 279 in a 1 : 1 ratio, as a consequence of an epimerisation 
from a trans- to a cis-decalin (Scheme 88). Partial deprotection of the minor diastereoisomer 277 was 
accomplished, and alcohol 280 was isolated in just 13% yield after a 16-hour reaction (Scheme 88). 
Unreacted minor diastereoisomer 277 was recovered in 41% yield. Treatment of 277 over an extended 
period of time (2 days) under HF/pyridine conditions, allowed the isolation of alcohol 280 in a 78% 
yield (Scheme 88).  
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Scheme 88. The TIPS-removal of the inseparable mixture of the major and the minor 
diastereoisomers 276 and 277. 
 
After TIPS-removal and the separation of the major and minor diastereoisomers 276 and 277, an 
iodoetherification cyclisation reaction was used to derivatise these compounds.120 Treatment of the 
inseparable mixture of alcohol products 278 and 279, isolated from the deprotection of the major 
diastereoisomer 276,  in the presence of I2 and NaCHO3, generated two tricyclic systems 281 and 282 
in a 27% and 29% yields respectively (Scheme 89).120 Both products 281 and 282 were isolated as solids 
and the presence of iodine facilitated the crystallisation of these molecules. The X-ray diffraction single 
crystallography of 281 and 282 allowed the determination of the stereochemistry of the major 
diastereoisomer 276 (Scheme 89, Figure 28). As shown in the crystal structures of 281 and 282, the 
major diastereoisomer 276 had the required syn-relationship between protons H-15 and H-6, as well 
as the correct stereochemistry at the methyl-bearing stereocentre C-25 needed for anthracimycin. 
However, in compound 282 a cis-decalin ring junction was observed, indicating that epimerisation 
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from a trans- to a cis-decalin had occurred during the deprotection of the major diastereoisomer 276 
under HF/pyridine conditions. 
 
 
Scheme 89. The iodocyclisation reaction used to establish the stereochemistry of the major 
diastereoisomer 276.120 
 
 
 
 
 
 
 
 
Figure 27. The X-ray diffraction single crystallography of 281 and 282 with thermal ellipsoids shown 
at 50%. 
Figure 27 shows the stereochemistry of the derivatives of the major diastereoisomer 281 and 282 of 
the Hosomi‒Sakurai reaction, which was what was required for the synthesis of anthracimycin. A syn-
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relationship between protons at H-15 and H-6 was observed, as well as the correct stereochemistry 
of the methyl group at C-25 required for the core of anthracimycin 162. 
 
The epimerisation from a trans- to a cis-decalin was also studied using the model trans-decalin 139, 
as the substrate. Treatment of trans-decalin 139 with 40 equivalents of 70% HF in pyridine, triggered 
the epimerisation from the trans-decalin 139 to the cis-cycloadduct 138 in an 8 : 2 ratio, over the same 
period of time as the deprotection reaction (16-hour) (Scheme 90).  
 
 
Scheme 90. The epimerisation of the model trans-decalin 139 to the cis-decalin 138. 
 
Having established the stereochemistry of the major diastereoisomer 276, the deprotected minor 
diastereoisomer 280 was treated under the iodoetherification conditions to determine its 
configuration. However, no iodocyclisation occurred and compound 280 was recovered unreacted, 
which meant that it was impossible to determine the stereochemistry of the minor diastereoisomer 
277 using this approach. 
 
 
 
121 
 
To summarise, the Hosomi‒Sakurai 1,4-addition reaction between the enone 113 and the E-
crotyltrimethylsilane 272 generated an inseparable mixture of products 276 and 277 in a 2 : 1 ratio 
(Scheme 88). A deprotection/iodoetherification sequence allowed the determination of the 
stereochemistry of the major diastereoisomer 276, which confirmed that the stereochemistry at both 
stereogenic centres C-15 and C-25 had been established correctly for the core of anthracimycin.  
 
 
Scheme 87.  The Hosomi‒Sakurai addition between the enone trans-decalin 113 and E-
crotyltrimethylsilane 272. 
 
As highlighted in Figure 28, 276 and 277 were isolated as an inseparable mixture of diastereoisomers 
in a 2 : 1 ratio. Due to the presence of many overlapping peaks in the 1H NMR spectrum, the 
diastereomeric ratio was calculated based on the integration of resolved resonances for proton H-5. 
The expansion between 4.01 and 3.70 ppm shows a major 276 doublet-doublet at 3.77 and a 
doublet-doublet at 3.74 ppm, as well as a minor 277 multiplet at 3.95‒3.89 ppm.  The methyl 
groups at C-25 were also resolved peaks: a major 276 doublet at 0.99 ppm, and a minor 277 doublet 
at 0.94 ppm.  
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Figure 28. The 1H NMR data of the inseparable mixture of the two diastereoisomers of the Hosomi‒
Sakurai addition between 276 and 277.  
 
The 1H NMR spectrum of the inseparable mixture (1 : 1 ratio) of 278 and 279, generated during the 
TIPS-removal of the major diastereoisomer 276 under HF/pyridine conditions was obtained (Figure 
29).  Due to the 1 : 1 ratio and the presence of many overlapping peaks in the 1H NMR spectrum, 
analysis of the 1H-H COSY was too challenging to determine which resolved proton peaks belonged to 
which isomer. 
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Figure 29. The 1H NMR data of the inseparable mixture of the deprotected trans- and cis-decalins 
278 and 279 (1 : 1 ratio).  
 
Figure 29 shows the 1H NMR spectrum of the trans- and cis-decalins 278 and 279, isolated as 
inseparable mixture of deprotected products. The 1 : 1 ratio of these two diastereoisomers was 
calculated based on the integration of resolved resonances for proton H-17, doublet-doublet-doublet 
at  5.79 and at 5.68 ppm; protons H-9 multiplets at  5.38‒5.33 and at 5.33‒5.28 ppm; protons 
H-5 doublet-doublet at  4.05, at 3.93, at 3.75 and at 3.66 ppm; methyl groups of H-25 doublet 
at  1.01 and at 0.98 ppm. 
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9.7.7 Functionalisation of the exocyclic double bond 
Now that the stereochemistry of the major diastereoisomer 276 had been established, selective 
functionalisation of the exocyclic alkene became the new challenge. Epoxidation and dihydroxylation 
reactions were attempted, with the hope that the less sterically demanding exocyclic double bond 
would react preferentially. In the presence of catalytic OsO4 (5 mol%) and 1 equivalent of NMO, diols 
283 and 284 were formed exclusively by reaction of the endocyclic alkene (Scheme 91). Determination 
of the reactivity was established by the 1H NMR analysis of the crude reaction mixture, in which the 
absence of the olefin peak of proton H-9 was seen. The exocyclic peaks of H-17 and H-18 remained 
unchanged.  Treatment of the inseparable mixture of diastereoisomers 276 and 277 with m-CPBA, also 
formed epoxide at the endocyclic alkene as a consequence of the higher reactivity of this alkene 
(Scheme 91). Determination of the selectivity of this epoxidation reaction was again established by 1H 
NMR analysis of the crude reaction mixture, in which the absence of proton H-9 was seen. 
 
Scheme 91. Epoxidation and dihydroxylation functionalised the endocyclic alkene preferentially. 
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Under these conditions, electronic effects predominated over steric hindrance and epoxide and diols 
were formed selectively at the endocyclic double bond, as a consequence of the higher reactivity of 
this alkene. Other conditions were therefore explored to selectively functionalise the exocyclic double 
bond. In the last few years, Morken and his group have focused their chemistry research on the 
enantioselective diborylation and hydroboration of alkenes, forming enantioriched diols.124, 125, 126 The 
selective functionalisation of the exocyclic alkene was attempted by use of this 
borylation/dihydroxylation sequence in the presence of a boronic ester reagent, trans-
cyclohexanediol and Cs2CO3, followed by the addition of 3 M NaOH and 30% H2O2 aqueous solutions. 
123, 124, 125 Under these conditions, selective functionalisation of the exocyclic alkene was possible and 
diols 288 and 289 were generated (Scheme 92). The formation of these products was determined by 
1H NMR analysis of the crude mixture; the NMR spectrum showed an absence of the olefin peaks 
(protons H-17 and H-18), whereas, the endocyclic alkene (proton H-9) remained unchanged. The use 
of 1 equivalent of B2pin2 and methanol formed diols 288 and 289 in a 56% conversion and in a 40% 
yield, along with the recovery of the starting material 276 and 277 in a 37% yield (Table 14, entry 1). 
In the presence of 1 equivalent of B2pin2 and 0.3 equivalents of trans-cyclohexanediol 287, the diols 
288 and 289 were instead formed with 53% conversion, whereas, with the use of 1 equivalent of trans-
cyclohexanediol 287 90% conversion into the desired products 288 and 289 was achieved (Table 14, 
entry 2 and 3). The use of a catalyst such as Pt2(dba)3 was also tested to increase the level of conversion 
and the yield. A conversion of 80% was obtained, but diols 288 and 289 were isolated in just 39% yield 
(Table 14, entry 4). 124, 125, 126 
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Scheme 92. A selective dihydroxylation reaction of the exocyclic alkene. 124, 125, 126 
 
entry conditions time 
(d.) 
conversion 
(%) 
yield 
(%) 
1 B2pin2, 5 eq. 
MeOH, 0.15 eq. 
Cs2CO3 
5  56 40 
2 B2pin2, 0.3 eq. 
diol, 0.15 eq. 
Cs2CO3 
5  53 40 
3 B2pin2, 1 eq. 
diol, 0.15 eq. 
Cs2CO3 
5  90 41 
4 B2pin2, 2.5 
mol.% Pt2(dba)3, 
0.15 eq. Cs2CO3 
2  80 39 
 
Table 14. The reaction conditions tested for the borylation of 276 and 277. 124, 125, 126 
 
Morken’s conditions allowed the selective functionalisation of the less sterically demanding and less 
electronically reactive exocyclic alkene of the molecule. The use of 1 equivalent of B2pin2 and trans-
cyclohexanediol 287 allowed the formation of diols 288 and 289 with 90% conversion, but a 41% yield 
was obtained upon isolation of the products (Table 14, entry 3). The instability on silica of 288 and 
289, was responsible for the low yield and these dihydroxylated intermediates were carried into the 
next step without silica chromatography purification. A periodate cleavage reaction was used to 
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convert the diol into an aldehyde, the functionality required for the subsequent Still‒Gennari 
olefination. Treatment of the crude reaction mixture of diols 288 and 289 with NaIO4 in CH2Cl2 : H2O 
(1 : 1), delivered the aldehydes 290 and 291 in 30% and 16% yield respectively (Scheme 93). Instability 
on silica chromatography again explained the low yields.  
Scheme 93. The periodate cleavage to the advanced precursor 290 and 291. 
 
The presence of the ketone at C-13 made 290 and 291 unstable to silica chromatography and could 
give rise to selectivity issues in the Still‒Gennari olefination with the phosphonate reagent 92, 
competing with the aldehyde functionality. To this end, the previously studied conditions that had 
been used to convert the carbonyl group into an alkene, were used to avoid these problems. The 
inseparable mixture of diastereoisomers 276 and 277 produced by the Hosomi‒Sakurai 1,4-addition 
reaction was treated with LDA and N-phenyl-bis-trifluoromethanesulfonimide 243. This reaction 
yielded the enol triflates 292 and 293 with quantitative conversion, as evident by 13C NMR analysis of 
the crude reaction mixture.116 Palladium-mediated reduction of the enol triflates with 
Pd(OAc)2(PPh3)2, Bu3N and formic acid completed the transformation to form the alkene, between C-
13 and C-14, and generated the trans-decalins 294 and 295 in a 56% yield as an inseparable mixture 
of isomers in a 2 : 1 ratio (Scheme 94, Figure 30).117 
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Scheme 94. Conversion of the carbonyl functionality into an alkene to form 294 and 295.117 
 
The 56% yield of 294 and 295 was the highest yield obtained in the enol triflate formation/palladium 
reduction sequence. As the second step always gave full conversion into the desired products 294 and 
295, the triflation of 276 and 277 was identified as the problematic-step. The purity of the N-phenyl-
bis-trifluoromethanesulfonimide (243), a small scale reaction in which it was difficult to prevent 
moisture and water destroying freshly prepared LDA solution, and the purity of 276 and 277 isolated 
as a crude mixture due to the instability on silica, are factors that could have led to decrease in the 
yield. To solve these problems, Comin’s reagent was used instead of N-phenyl-bis-
trifluoromethanesulfonimide (243), and the crude mixture of 276 and 277 was concentrated in vacuo 
with benzene to azeotrope any residual water. However, the yield could not be increased from 56%. 
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Figure 30. The 1H NMR spectrum of 294 and 295 after the triflation/palladium reduction sequence. 
 
Figure 30 shows the 1H NMR spectrum of 294 and 295 after the triflation/palladium reduction 
sequence. The region between 4.00 and 3.59 ppm contained the only resolved resonances for 
proton H-5 of the major and the minor diastereoisomers 294 and 295. Based on the integration of 
these peaks it was possible to measure an unchanged 2 : 1 ratio of 294 and 295 after the two-step 
sequence. 
 
Following conversion of the carbonyl functionality into an alkene, as the B-ring of anthracimycin 
required, selective functionalisation of the exocyclic double bond was performed using the 
borylation/dihydroxylation sequence.  Reaction of trienes 294 and 295 with 1 equivalent of B2pin2 and 
trans-cyclohexanediol 287 and 0.15 equivalents of Cs2CO3 as a base, followed by the addition of 
aqueous solutions of NaOH and H2O2, resulted in selective dihydroxylation of the exocyclic alkene. 124, 
125, 126 These conditions allowed the selective functionalisation of the less reactive double bond based 
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on steric hindrance. The formation of diols 296 and 297 at the exocyclic alkene was confirmed by 1H 
NMR analysis, which showed the absence of the olefin peak of protons H-17 and H-18.  Cleavage of 
diols 296 and 297 to afford the aldehyde functionality was attempted by reaction with NaIO4. These 
conditions formed the aldehyde 162 corresponding to the core of anthracimycin 162, which was 
isolated as an inseparable mixture with 298 (2 : 1 ratio) in a 60% isolated yield b.r.s.m. (Scheme 95). 
 
Scheme 95. The formation of the core of anthracimycin 162. 
 
In conclusion, the Hosomi‒Sakurai 1,4-addition reaction between the E-crotyltrimethylsilane 272 and 
the enone 113, allowed the formation of all the C-C bonds with the required stereochemistry for the 
core of anthracimycin 162. Subsequent selective borylation/dihydroxylation of the exocyclic alkene 
and periodate cleavage of diols 296 and 297 delivered the desired core of the molecule. The aldehyde 
162 was isolated as an inseparable mixture with 298 in a 2 : 1 ratio in a 45% yield (60% yield b.r.s.m.). 
Overall, the aldehyde 162 was obtained in 12-steps. 
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9.7.8 The synthesis of the Still‒Gennari reagent 92 
To progress the total synthesis, the formation of the side chain 92 was prepared following Kalesse’s 
procedure.44 To this end, PMB protection of the enantiopure D-(+)-lactate methyl ester (299) afforded 
the ester 301, which was converted into the aldehyde 302 by DIBAL-H reduction. This was followed by 
Wittig methylenation and an alkene metathesis reaction between 303 and 304 using Grubbs-II 
catalyst, which generated side chain 92 in a 34% yield (Scheme 96).44 
 
Scheme 96. The synthesis of the Still‒Gennari reagent 92.44 
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To summarise, different strategies were explored for the synthesis of the core of anthracimycin 162. 
The 1,2-reduction of key intermediate 113 was found to be non-selective and two diastereoisomeric 
alcohols 232 and 215 were isolated and used to scope the Ireland‒Claisen rearrangement reaction 
and the Tsuji‒Trost reaction. However, these two approaches did not yield the core of anthracimycin 
162. 
The Mukaiyama‒Michael addition afforded the lactone 247 corresponding to the C-15 epimer of the 
core of the natural product, suitable for the synthesis of analogues.  
Inspired by previous work in the group towards the synthesis of the core of streptosetin A, the 
Hosomi‒Sakurai 1,4-addition reaction was explored to yield the desired core of anthracimycin 162. 
This approach introduced the allyl side chain with a high syn-selectivity forming compound 266, but 
the synthesis of the E-crotyltrimethylsilane 272 was needed. In the presence of this nucleophile, the 
Hosomi‒Sakurai 1,4-addition reaction gave products 276 and 277 as an inseparable mixture in a 2 : 1 
ratio, with the major diastereoisomer 276 having the stereochemistry necessary for the core of 
anthracimycin. Selective functionalisation of the exocyclic alkene was performed using Morken’s 
diborylation/hydroxylation conditions, which allowed the selective functionalisation of the exocyclic 
double bond. This strategy permitted the formation of the core of anthracimycin 162, which was 
isolated with 298, as an inseparable mixture of products in a 2 : 1 ratio. 
Having achieved the synthesis of 162, the phosphonate reagent 92 was formed following the synthetic 
route reported by Kalesse. However, the Still‒Gennari olefination could not be explored due to the 
difficulty in the separation of 162 and 298.  
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The core of anthracimycin was formed as an inseparable mixture of diastereoisomers, which hindered 
the progression of the total synthesis. 
Removal of the TIPS-group of compounds 294 and 295 was performed in order to convert the major 
diastereoisomer 294 into the core of anthracimycin 162 and test the Still‒Gennari olefination reaction. 
However, deprotection followed by Dess-Martin oxidation yielded a mixture of products, which was 
impossible to interpret by 1H NMR and 13C NMR analysis or to separate by silica chromatography 
(Scheme 97, Figure 31). Identification of the major diastereoisomer was not possible. The 1H NMR and 
13C NMR analysis of the products obtained from the Dess-Martin oxidation reaction showed the 
presence of multiple unexpected aldehyde peaks, in the region between 10.0 and 9.48 ppm in the 
1H NMR spectrum, as well as in the region between 207.5 and 203.5 ppm in the 13C NMR spectrum 
(Figure 32). 
 
 
Scheme 97. The attempted isolation of the major diastereoisomer 294. 
 
134 
 
 
Figure 31. The 1H NMR and 13C NMR spectrum of the deprotection reaction. 
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Figure 32. The 1H NMR and 13C NMR spectrum of the Dess-Martin oxidation.  
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10. Conclusions 
The formation of the core of anthracimycin 162 was achieved in a 12-step sequence. The development 
of the direct palladium oxidation conditions in the presence of Pd(OAc)2, 4,4ʹ-tBu-2,2ʹ-dipyridyl and 
KNO3, allowed the formation of enone 115, suitable for the Diels‒Alder cycloaddition to generate the 
cis-decalin 194 in an 85% yield. This was followed by epimerisation and Raney-Nickel reduction to 
afford the trans-decalin 114, which was oxidised to 113 in the presence of IBX. The planned Luche 
reduction/ Ireland‒Claisen rearrangement sequence failed to deliver the core of the natural product. 
However, the Hosomi‒Sakurai 1,4-addition between the enone 113 and the E-crotyltrimethylsilane 
272, allowed the installation of the crotyl chain and delivered 276 and 277 as an inseparable mixture 
of diastereoisomers in a 2 : 1 ratio. The major diastereoisomer 276 had the stereochemistry required 
for the core of anthracimycin, which was determined by a deprotection/iodoetherification sequence. 
Conversion of the ketone carbonyl group of 276 and 277 into an alkene was performed via a 
triflation/palladium reduction sequence, which afforded 294 and 295 in a 56% yield.  Morken’s 
conditions allowed the selective dihydroxylation of the exocyclic double bond in the presence of two 
potentially reactive endocyclic alkenes, using B2pin2, trans-cyclohexanediol and Cs2CO3. This was 
followed by diol cleavage with the use of NaIO4, which formed the core of anthracimycin 162 in an 
inseparable mixture with 298 in a 2 : 1 ratio in a 45% yield (60% yield b.r.s.m.). (Scheme 98). 
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Scheme 98. The formation of the core of anthracimycin 162. 
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11. Future work 
The inability to separate the major and the minor diastereoisomers 294 and 295 and the difficulties in 
interpretation of the NMR spectrum of the deprotection and Dess-Martin oxidation products 305 and 
306, represented a real challenge of this strategy. This has forced the redesign of the Hosomi‒Sakurai 
1,4-addition approach to give the core of the natural product as a single compound. The new route 
will involve a Hosomi‒Sakurai reaction between allyltrimethylsilane 250 and the enone 113, to 
generate compound 266 as the major diastereoisomer. This compound could be derivatised to give 
the core of the natural product, by converting the carbonyl group into an alkene 307, via enol-triflation 
formation and palladium reduction. Selective dihydroxylation of the exocyclic alkene followed by 
periodate cleavage could form aldehyde 309, which would then be converted into the methyl ester 
310. Removal of the TIPS-group, would yield the tricyclic system 311. Installation of the methyl group 
as required for the core of the natural product, could be achieved with the use of LDA and methyl 
iodide (Scheme 99). The concave shape of the A/B-ring, as a cis-decalin, should ensure installation of 
the methyl group with the required stereochemistry, forming the core of anthracimycin as a single 
diastereoisomer 312. 
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Scheme 99. The new strategy envisioned for the core of anthracimycin 162. 
 
Compound 312 would then be used to complete the synthesis. Subsequent functionalisation would 
involve DIBAL-H reduction, Still‒Gennari olefination and a Weiler dianion addition reaction after 
oxidation of the hydroxyl methylene to an ester. Macrocyclisation would then allow the completion 
of anthracimycin 1. 
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12. Experimental  
12.1 General experimental 
Melting points were determined using a Stuart SMP3 apparatus. Optical rotations were carried out 
using a JASCO-DIP370 polarimeter and [α]D values are given in 10-1deg.cm2.g-1. Infra-red spectra were 
acquired on a ThermoNicolet Avatar 370 FT-IR spectrometer. Nuclear magnetic resonance spectra 
were recorded on a Jeol ECX-400, a Jeol ECS-400, Bruker DRX 500 at ambient temperature; chemical 
shifts are quoted in parts per million (ppm) and were referenced as follows: CDCl3 7.27 ppm, C6D6 
7.16 ppm for 1H NMR; CDCl3 77.0 ppm, central line of triplet, C6D6 128.4 ppm, central line of triplet 
for 13C NMR.13C NMR spectra were assigned using DEPT experiments. Coupling constants (J) are 
quoted in Hertz. Mass spectrometry was performed by the University of York mass spectrometry 
service using electron spray ionisation (ESI), electron ionization (EI) and atmospheric pressure 
chemical ionization (APCI) techniques. All the Mass-spectra data were in a 5 ppm error. Thin layer 
chromatography was performed on glass-backed plates coated with Merck Silica gel 60 F254. The 
plates were developed using ultraviolet light, acidic aqueous ceric ammonium molybdate, basic 
aqueous potassium permanganate. Liquid chromatography was performed using forced flow (flash 
column) with the solvent systems indicated. The stationary phase was silica gel 60 (220–240 mesh) 
supplied by Fluorochem or silica gel Merck TLC grade 11695 supplied by Sigma-Aldrich. Hexane, CH2Cl2, 
toluene, THF and Et2O were all purified using Innovative Technology Solvent Purification System; 
diisopropylamine was distilled from calcium hydride. All other solvents and reagents were used as 
received from commercial suppliers. All numbering on the structures below is for the benefit of 
characterisation and does not necessarily conform to IUPAC rules. Compounds numbers are reported 
in relation to anthracimycin numbers.15 
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12.2 Methods and Characterisation of Compounds 
 
7-Hydroxyoctahydronaphthalen-15(1H)-one, 102 
 
 
To a solution of cyclohexanone 101 (5.28 mL, 50.9 mmol) in dry THF (63.3 mL) at 0 °C, a solution of 
KOH/MeOH (0.74 M, 7.79 mmol, 1.04 mL) and a solution of methylvinyl ketone 99 (2.07 mL, 25.5 
mmol) in dry THF (63.3 mL) were added slowly over 30 minutes.  The reaction was stirred at room 
temperature for 2 days.  After this time, the solvent was removed in vacuo and the residue was 
dissolved with EtOAc (60 mL) and the organic phase was washed with water (10 mL) and brine (10 
mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product was triturated with 
hexane (30 mL), filtered and the desired product 102 was isolated, without further purification, as a 
white solid (1.41 g, 34% yield).61 Melting point = 142‒144 °C. Rf = 0.11 (EtOAc : hexane 10% : 90%). IR 
(ATR): νmax 3353 (C-OH), 2952, 2854, 1706 (C=O), 1451, 1346, 1296, 958, 656 cm-1. 1H NMR (400 MHz, 
CDCl3):  2.47‒2.27 (4H, m), 1.89‒1.62 (5H, m), 1.53‒1.47 (4H, m), 1.39‒1.24 (2H, m) ppm. 13C NMR 
(400 MHz, CDCl3):  210.6 (C=O), 73.9 (C-OH), 55.3 (CH2), 42.6 (CH), 41.4 (CH2), 39.6 (CH2), 28.6 (CH2), 
27.7 (CH2), 25.7 (CH2), 20.8 (CH2) ppm. MS (ESI): m/z 191 (M+Na+); HRMS: found: (M+Na+) 191.1042. 
C10H16NaO2 requires (M+Na+) 191.1043. 
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13,12,11,10,9,8-Hexahydronaphthalen-15(3H)-one, 10361 
 
 
To a solution of hydroxyl decalin 102 (720 mg, 4.23 mmol) in glacial acetic acid (11.5 mL), was added 
H2SO4 98% solution in water (1.0 mL) and the reaction was stirred at 50 °C for 30 minutes. After this 
time, the reaction was quenched with cold water (10 mL) and saturated aqueous solution of NaHCO3 
(20 mL). The aqueous phase was extracted with CH2Cl2 (3 × 10 mL) and the combined organic layers 
were washed with brine (10 mL), dried with Na2SO4, filtered and concentrated in vacuo. The desired 
product 103 was obtained without further purification as an orange oil (570 mg, 90% yield).62 Rf = 0.23 
(EtOAc : hexane 10% : 90%).  IR (ATR): νmax 2926, 2855, 1667 (C=O), 1205, 858 cm-1. 1H NMR (400 MHz, 
CDCl3):  5.82 (1H, s), 2.48‒2.40 (1H, m), 2.40‒2.36 (1H, m), 2.35‒2.25 (2H, m), 2.25‒2.15 (1H, m), 2.09 
(1H, dddd, J = 13.3, 4.9, 4.9, 4.9 Hz), 2.00‒1.79 (3H, m), 1.63 (1H, dddd, J = 13.3, 13.3, 9.0, 4.9 Hz),  
1.55‒1.33 (2H, m), 1.28‒1.4 (1H, m) ppm. 13C NMR (400 MHz, CDCl3):  200.1 (C=O), 167.4 (C=C), 124.3 
(CH), 37.6 (CH), 36.6 (CH2), 35.4 (CH2), 34.4 (CH2), 29.3 (CH2), 26.8 (CH2), 25.5 (CH2) ppm. MS (ESI): m/z 
173 (M+Na+); HRMS: found: (M+Na+) 173.0937. C10H14NaO requires (M+Na+) 173.0937. m/z 151 
(M+H+); HRMS: found: (M+H+) 151.1113. C10H15O requires (M+H+) 151.1117. Characterisation of this 
compound matched the compound reported in the literature.61 
 
7-Hydroxy-10-methyloctahydronaphthalen-15(1H)-one, 104 
 
 
To a solution of 4-methyl-cyclohexanone 98 (5.40 mL, 44.6 mmol) in dry THF (65.5 mL) at 0 °C, a 
solution of KOH/MeOH (0.74 M, 8.22 mmol, 1.20 mL) and a solution of methylvinyl ketone 99 (1.86 
mL, 22.4 mmol) in dry THF (65.5 mL) were added slowly over 30 minutes.  The reaction was stirred at 
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room temperature for 2 days.  After this time, the solvent was removed in vacuo and the residue was 
dissolved with EtOAc (60 mL) and the organic phase was washed with water (10 mL) and brine (10 
mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product was triturated with 
hexane (30 mL), filtered and the desired product 104 was isolated, without further purification, as a 
white solid (1.67 g, 41% yield).61 Melting point = 137‒139 °C. Rf = 0.11 (EtOAc : hexane 10% : 90 %). 
IR (ATR): νmax 3358 (C-OH), 2925, 2856, 1709 (C=O), 1458, 1402, 1268, 1252, 960, 640 cm-1. 1H NMR 
(400 MHz, CDCl3):  2.49‒2.28 (3H, m), 2.13‒2.08 (1H, m), 1.96‒1.56 (4H, m), 1.55‒1.53 (5H, m), 1.48‒
1.40 (1H, m), 1.30 (3H, d, J = 7.8 Hz) ppm. 13C NMR (400 MHz, CDCl3):  210.8 (C=O), 74.1 (C-OH), 55.3 
(CH2), 41.5 (CH2), 36.5 (CH), 33.9 (CH2), 33.2 (CH2), 28.6 (CH2), 26.8 (CH), 25.8 (CH2), 17.5 (CH3) ppm. 
MS (ESI): m/z 205 (M+Na+); HRMS: found: (M+Na+) 205.1201. C11H18NaO2 requires (M+Na+) 205.1199. 
 
10-Methyl-13,12,11,10,9,8-hexahydronaphthalen-15(3H)one, 105 
 
 
To a solution of hydroxyl decalin 104 (100 mg, 0.560 mmol) in glacial acetic acid (1.50 mL), was added 
H2SO4 98% solution in water (0.50 mL). The reaction was stirred at 50 °C for 30 minutes. After this 
time, the reaction was quenched with cold water (10 mL) and saturated aqueous solution of NaHCO3 
(20 mL). The aqueous phase was extracted with CH2Cl2 (3 × 10 mL) and the combined organic layers 
were washed with brine (10 mL), dried with Na2SO4, filtered and concentrated in vacuo. The desired 
product 105 was obtained without further purification as an orange oil (71.0 mg, 77% yield).62 Rf = 
0.21 (EtOAc : hexane 10% : 90%).  IR (ATR): νmax 2922, 2856, 1664 (C=O), 1503, 1455, 1329, 1256, 1243, 
894, 848 cm-1. 1H NMR (400 MHz, CDCl3):  5.83 (1H, s), 2.49‒2.40 (2H, m), 2.40‒2.25 (3H, m), 2.09 
(1H, ddd, J = 13.3, 9.6, 5.0 Hz), 1.95‒1.82 (2H, m), 1.73‒1.56 (3H, m), 1.17‒1.03 (1H, m), 0.95 (3H, d, J 
= 6.4 Hz) ppm. 13C NMR (400 MHz, CDCl3):  200.2 (C=O), 166.9 (C=C), 124.3 (CH), 42.8 (CH2), 37.5 (CH), 
36.7 (CH2), 35.3 (CH2), 35.0 (CH2), 31.9 (CH), 29.2 (CH2), 21.9 (CH3) ppm. MS (ESI): m/z 187 (M+Na+); 
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HRMS: found: (M+Na+) 187.1095. C11H16NaO requires (M+Na+) 187.1093. m/z 165 (M+H+); HRMS: 
found: (M+H+) 165.1268. C11H17O requires (M+H+) 165.1274. 
 
6-Allyl-13,12,11,10,9,8-hexahydronaphthalen-15(3H)-one, 106 
 
14-Diallyl-13,12,11,10,9,8-hexahydronaphthalen-15(3H)-one, 107 
 
  
Anhydrous DMSO (1.50 mL) was added to a NaH (60% dispersion in mineral oil, 28.0 mg, 0.72 mmol) 
and the mixture was stirred at 50 °C for 1 hour. After this time, it was cooled to room temperature 
and dry THF (1.50 mL) was added and then the reaction was cooled to 0 °C. A solution of decalin 103 
(100 mg, 0.610 mmol) in dry THF (1.50 mL) was added dropwise (5 minutes) and stirred at 0 °C for 2 
hours. Allyl bromide (0.060 mL, 0.72 mmol) was added and the reaction was warmed to room 
temperature and stirred for 16 hours. The reaction was quenched with saturated aqueous solution of 
NH4Cl (10 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with 
brine (10 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified 
by silica gel flash column chromatography (5% to 10% EtOAc in hexanes) to yield 106 as a pale yellow 
oil (30.0 mg, 26% yield) and 107 as a pale yellow oil (20.0 mg, 15% yield).63 6-Allyl-13,12,11,10,9,8-
hexahydronaphthalen-15(3H)-one, 106; Rf = 0.62 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 2925, 
2855, 1667 (C=O), 1450, 1363, 1194, 910 cm-1. 1H NMR (400 MHz, CDCl3):  5.85‒5.70 (1H, m), 4.96‒
4.89 (2H, m), 3.13‒3.06 (1H, m), 2.88‒2.77 (1H, m), 2.52‒2.39 (2H, m), 2.37‒2.27 (2H, m), 2.07 (1H, 
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dddd, J = 13.7, 5.4, 5.4, 5.4 Hz), 2.01‒1.77 (3H, m), 1.70‒1.54 (2H, m), 1.49 (1H, dddd, J = 13.7, 13.7, 
3.2, 3.2 Hz), 1.42‒1.20 (2H, m) ppm.13C NMR (400 MHz, CDCl3):  198.8 (C=O), 161.6 (C=C), 136.3 (CH), 
130.5 (C=C), 114.4 (CH2), 38.9 (CH), 36.4 (CH2), 35.0 (CH2), 31.4 (CH2), 28.8 (CH2), 28.7 (CH2), 26.9 (CH2), 
25.5 (CH2) ppm. MS (ESI): m/z 213 (M+Na+); HRMS: found: (M+Na+) 213.1249. C13H18NaO requires 
(M+Na+) 213.1250. m/z 191 (M+H+); HRMS: found: (M+H+) 191.1421. C13H19O requires (M+H+) 
191.1430. 14-Diallyl-13,12,11,10,9,8-hexahydronaphthalen-15(3H)-one, 107; Rf = 0.57 (EtOAc : 
hexane 10% : 90%). IR (ATR): νmax 2923, 2857, 1705 (C=O), 1443, 1325, 1212, 1169, 994, 911 cm-1. 1H 
NMR (400 MHz, CDCl3):  5.71‒5.54 (2H, m), 5.06‒4.99 (4H, m), 4.97 (1H, s), 2.60 (1H, dddd, J = 14.5, 
7.2, 1.3, 1.3 Hz), 2.48 (1H, dddd, J = 13.5, 6.9, 1.4, 1.4 Hz), 2.44‒2.39 (2H, m), 2.39‒2.27 (1H, m), 2.23 
(1H, dddd, J = 13.5, 7.6, 1.4, 1.4 Hz), 2.12‒2.06 (2H, m), 1.94‒1.83 (2H, m), 1.77‒1.66 (1H, m), 1.54‒
1.40 (2H, m), 1.36‒1.24 (2H, m) ppm. 13C NMR (400 MHz, CDCl3):  213.8 (C=O), 139.5 (C=C), 135.1 
(CH), 133.5 (CH), 123.7 (CH), 117.9 (CH2), 117.1 (CH2), 58.0 (C-C), 44.5 (CH2), 39.5 (CH2), 39.2 (CH), 34.8 
(CH2), 30.7 (CH2), 29.9 (CH2), 25.6 (CH2), 21.1 (CH2) ppm. MS (ESI): m/z 253 (M+Na+); HRMS: found: 
(M+Na+) 253.1559. C16H22NaO requires (M+Na+) 253.1563. 
 
(10-Methylbuta-11,7-dien-9-yl)(phenyl)sulfane, 11675 
 
 
In a pressure vessel were placed Pd(OAC)2 (134 mg, 0.600 mmol), dry THF (15.2 mL), 2-methyl-1-buten-
3-yne 135 (2.88 mL, 30.2 mmol) and thiophenol (3.10 mL, 30.2 mmol) were added. The reaction was 
stirred at 60 °C for 16 hours. After this period, the mixture was filtrated through celite with EtOAc (50 
mL) and the solvent was concentrated in vacuo. The crude product was purified by silica gel flash 
column chromatography (100% hexane) to yield 116 as a pale yellow liquid (5.32 g, quantitative 
yield).75 Rf = 0.66 (100% hexane). IR (ATR): νmax 2978, 2952, 1617, 1574, 1478, 1458, 1440, 1375, 1119, 
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1025 cm-1. 1H NMR (400 MHz, CDCl3):  7.34‒7.16 (5H, m, Ar-H), 5.55 (1H, s, H-11), 5.51 (1H, s, H-11), 
5.22 (1H, d, J = 1.4 Hz, H-7), 5.05 (1H, d, J = 1.4 Hz, H-7), 1.96 (3H, s, H-24) ppm. 13C NMR (400 MHz, 
CDCl3):  143.8 (C-9), 140.4 (C-10), 134.4 (Ar), 130.9 (Ar-H), 128.7 (Ar-H), 126.7 (Ar-H), 117.1 (C-11), 
116.4 (C-7), 20.9 (C-24) ppm. MS (APCI): m/z 177 (M+H+); HRMS: found: (M+H+) 177.0736. C11H13S 
requires (M+H+) 177.0732. Characterisation of this compound matched the compound reported in the 
literature.75  
 
12-Bromocyclohex-13-enone, 13274 
 
 
To a solution of cyclohexenone 131 (0.500 mL, 5.21 mmol) in pyridine : CHCl3 (1 : 1, 4.0 mL) at 0 °C, 
were added DMAP (127 mg, 1.04 mmol) and a solution of bromine (0.500 mL, 10.4 mmol) in pyridine 
: CHCl3 (1 : 1, 4.0 mL) and the reaction was stirred at room temperature for 16 hours. After this time, 
the reaction was diluted with EtOAc (100 mL), washed with aqueous solution of 2 M HCl (20 mL), water 
(10 mL) and brine (10 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product 
was purified by silica gel flash column chromatography (5% to 10% EtOAc in hexanes) to yield 132 as 
a white solid (360 mg, 40% yield).74.Melting point = 75‒76 °C. Rf = 0.24 (EtOAc : hexane 10% : 90%). 
IR (ATR): νmax 2942, 2872, 1678 (C=O), 1461, 1424, 1315, 1124, 971, 813 cm-1. 1H NMR (400 MHz, 
CDCl3):  7.44 (1H, dd, J = 4.6, 4.6 Hz, H-7), 2.65 (2H, ddd, J = 6.4, 3.2, 3.2 Hz, H-14), 2.45‒2.43 (2H, m, 
H-6), 2.14 (2H, ddd, J = 6.4, 6.4, 4.6 Hz, H-15) ppm. 13C NMR (400 MHz, CDCl3):  191.3 (C-13), 151.1 
(C-7), 123.9 (C-12), 38.3 (C-14), 28.4 (C-15), 22.7 (C-6) ppm. MS (ESI): m/z 196 (M+Na+), 198 (M+Na+); 
HRMS: found: (M+Na+) 196.9568. C6H779BrNaO requires (M+Na+) 196.9572. Characterisation of this 
compound matched the compound reported in the literature74 
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(12S*, 7S*)-12-Bromo-9-methyl-15,6,7,6,11,12-hexahydronaphthalen-13(2H)-one, 13470 
 
 
 
To a solution of 2-bromocyclohexenone 132 (173 mg, 1.00 mmol) in dry CH2Cl2 (5.0 mL) at ‒10 °C, were 
sequentially added a 1.0 M solution of EtAlCl2 in hexane (0.20 mL, 0.20 mmol) and isoprene 133 (1.00 
mL, 10.0 mmol) and the reaction was stirred at ‒10 °C for 2 hours. After this time, Rochelle’s salt 10% 
aqueous solution (20 mL) was added and the mixture was stirred vigorously for 1 hour. The mixture 
was then diluted with water (10 mL) and the organic phase was extracted with CH2Cl2 (3 × 10 mL). The 
combined organic layers were washed with water (5 mL) and brine (5 mL), dried with Na2SO4, filtered 
and concentrated in vacuo. The crude product was purified by silica gel flash column chromatography 
(5% to 10% EtOAc in hexanes) to yield 134 as pale yellow oil (150 mg, 62% yield).70 Rf = 0.44 (EtOAc : 
hexane 5% : 95%). IR (ATR): νmax 2912, 1714 (C=O), 1447, 1424, 1310, 1168, 1071, 783 cm-1. 1H NMR 
(400 MHz, CDCl3):  5.28‒5.23 (1H, m, H-10), 3.20 (1H, ddd, J = 15.1, 10.5, 7.3 Hz, H-14), 3.18‒3.10 
(1H, m, H-11), 2.71‒2.58 (2H, m, H-14 + H-7), 2.45‒2.34 (2H, m, H-15 + H-11), 2.15 (1H, dd, J = 17.4, 
6.9 Hz, H-8), 2.08‒1.58 (4H, m, H-8 + H-15 + H-6), 1.63 (3H, s, H-24) ppm. 13C NMR (400 MHz, CDCl3): 
 204.0 (C-13), 131.7 (C-9), 118.2 (C-10), 70.6 (C-12), 43.5 (C-7), 36.3 (C-14), 36.3 (C-11), 33.0 (C-8), 
26.7 (C-15), 23.0 (C-24), 22.5 (C-6) ppm. MS (ESI): m/z 265 (M+Na+), 267 (M+Na+); HRMS: found: 
(M+Na+) 265.0197. C11H1579BrNaO requires (M+Na+) 265.0198. Characterisation of this compound 
matched the compound reported in the literature.70  
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(12S*, 8S*)-12-Bromo-10-methyl-9-(phenylthio)-15,6,7,8,11,12-hexahydronaphthalen-13(2H)-one, 
13672 
  
 
To a solution of 2-bromocyclohexenone 132 (36.0 mg, 0.210 mmol) in dry CH2Cl2 (0.50 mL) at ‒10 °C, 
was added a 1.0 M solution of EtAlCl2 in hexane (0.04 mL, 0.04 mmol) and stirred for 10 minutes. A 
solution of sulfur substituted diene 116 (150 mg, 0.850 mmol) in dry CH2Cl2 (0.55 mL) was then added 
and the reaction was stirred at ‒10 °C for 2 hours. After this time, Rochelle’s salt 10% aqueous solution 
(20 mL) was added and the mixture stirred vigorously for 1 hour. The mixture was diluted with water 
(10 mL) and the organic phase was extracted with CH2Cl2 (3 × 10 mL). The combined organic layers 
were washed with water (5 mL) and brine (5 mL), dried with Na2SO4, filtered and concentrated in 
vacuo. The crude product was purified by silica gel flash column chromatography (3% to 5% EtOAc in 
hexanes) to yield 136 as a pale yellow oil (40.0 mg, 54% yield).72 Rf = 0.56 (EtOAc : hexane 5% : 95%). 
IR (ATR): νmax 2931, 1716 (C=O), 1477, 15852, 1477, 1233, 1024, 741, 760 cm-1. 1H NMR (400 MHz, 
CDCl3):  7.22‒7.13 (2H, m, Ar-H), 7.09‒7.00 (3H, m, Ar-H), 3.24 (1H, d, J = 17.9 Hz, H-11), 3.16 (1H, 
ddd, J = 15.1, 9.2, 9.2 Hz, H-14), 2.74 (1H, d, J = 17.9, Hz, H-11), 2.64‒2.57 (1H, m, H-7), 2.37‒2.23 (3H, 
m, H-14 + H-15 + H-6), 2.22‒2.11 (1H, m, H-6), 1.90 (3H, s, H-24), 1.81‒1.75 (2H, m, H-8), 1.53‒1.45 
(1H, m, H-15) ppm. 13C NMR (400 MHz, CDCl3):  203.7 (C-13), 139.5 (C-9), 135.8 (Ar), 129.0 (Ar-H), 
128.0 (Ar-H), 125.6 (Ar-H), 120.7 (C-10), 68.8 (C-12), 44.5 (C-7), 43.0 (C-11), 36.0 (C-14), 34.1 (C-6), 
26.1 (C-15), 22.2 (C-8), 20.9 (C-24) ppm. MS (ESI): m/z 373 (M+Na+), 375 (M+Na+); HRMS: found: 
(M+Na+) 373.0229. C17H1979BrNaOS requires (M+Na+) 373.0232. Characterisation of this compound 
matched the compound reported in the literature.72  
 
 
 
149 
 
(12S*, 7S*)-10-Methyl-9-(phenylthio)-15,6,7,8,11,12-hexahydronaphthalen-13(2H)-one, 13772 
 
 
To a solution of thiophenyl cis-declalin 156 (100 mg, 0.370 mmol) in dry CH2Cl2 (2.0 mL), was added a 
1.0 M solution of EtAlCl2 in hexane (0.07 mL, 0.07 mmol) and the reaction was stirred at room 
temperature for 16 hours. After this time, Rochelle’s salt 10% aqueous solution (20 mL) was added 
and stirred vigorously for 16 hours. The mixture was then diluted with water (10 mL) and the organic 
phase was extracted with CH2Cl2 (3 × 10 mL). The reunited organic layers were washed with water (10 
mL) and brine (10 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product was 
purified by silica gel flash column chromatography (5% to 10% EtOAc in hexanes) to yield 137 as a 
white solid (68.0 mg, 68% yield). Melting point = 76‒79 °C. Rf = 0.45 (EtOAc : hexane 10% : 90%). IR 
(ATR): νmax 2923, 1709 (C=O), 1581, 1476, 1438, 1370, 1085, 740, 691 cm–1. 1H NMR (500 MHz, CDCl3): 
 7.29‒7.25 (2H, m, Ar-H), 7.21‒7.13 (3H, m, Ar-H), 2.52‒2.39 (1H, m, H-11), 2.42 (1H, dddd, J = 13.8, 
4.4, 2.5, 1.9 Hz, H-14), 2.41‒2.29 (4H, m, H-14 + H-12 + H-8 + H-11), 2.21‒2.13 (1H, m, H-8), 2.11‒2.05 
(1H, m, H-15), 2.01 (3H, s, H-24), 1.83 (1H, dddd, J = 13.3, 6.6, 3.4, 1.6 Hz, H-6),  1.78‒1.72 (1H, m, H-
7), 1.68‒1.59 (1H, m, H-15), 1.42 (1H, dddd, J = 13.3, 13.3, 11.7, 3.7 Hz, H-6) ppm. 13C NMR (500 MHz, 
CDCl3):  211.3 (C-13), 140.5 (C-9), 136.0 (Ar), 128.7 (Ar-H), 127.9 (Ar-H), 125.2 (Ar-H), 121.2 (C-10), 
50.7 (C-12), 42.1 (C-14), 41.9 (C-7), 39.9 (C-8), 32.3 (C-6), 32.1 (C-11), 26.3 (C-15), 21.8 (C-24) ppm. MS 
(ESI): m/z 295 (M+Na+); HRMS: found: (M+Na+) 295.1119. C17H20NaOS requires (M+Na+) 295.1127. 
Characterisation of this compound matched the compound reported in the literature72 
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(12R*, 7S*)-9-Methyl-15,6,7,8,11,12-hexahydronaphthalen-13(2H)-one, 13876 
 
(12S*, 7S*)-9-Methyl-15,6,7,8,11,12-hexahydronaphthalen-13(2H)-one, 13970 
 
 
To a solution of cyclohexeneone 131 (0.50 mL, 5.0 mmol) in dry CH2Cl2 (25.0 mL), was added a 1.0 M 
solution of EtAlCl2 in hexane (1.0 mL, 1.0 mmol) and stirred at room temperature for 30 minutes. 
Isoprene 133 (5.0 mL, 50 mmol) was then added, and the reaction was stirred at 30 °C for 8 hours. 
After this time, Rochelle’s salt 10% aqueous solution (20 mL) was added and the mixture stirred 
vigorously for 1 hour. The mixture was diluted with water (10 mL) and extracted with CH2Cl2 (3 × 10 
mL). The combined organic layers were washed with water (5 mL) and brine (5 mL), dried with Na2SO4, 
filtered and concentrated in vacuo. The crude product was purified by silica gel flash column 
chromatography (2% to 5% EtOAc in hexanes) to yield 138 as a pale yellow oil (305 mg, 37% yield) and 
139 as a pale yellow oil (371 mg, 40% yield). (12R*, 7S*)-9-Methyl-15,6,7,8,11,12-
hexahydronaphthalen-13(2H)-one, 138; Rf = 0.42 (EtOAc : hexane 5% : 95%). IR (ATR): νmax 2922, 2866, 
1708 (C=O), 1444, 1377, 1310, 1234, 1179, 919, 889 cm–1. 1H NMR (500 MHz, CDCl3):  5.31‒5.27 (1H, 
m, H-10), 2.63 (1H, ddd, J = 10.9, 4.5, 2.0 Hz, H-12), 2.47‒2.45 (1H, m, H-11), 2.43‒2.31 (2H, m, H-14 + 
H-7), 2.24 (1H, dddd, J = 15.1, 9.2, 5.7, 1.3 Hz, H-14), 2.02‒1.90 (2H, m, H-8 + H-11), 1.89‒1.66 (4H, m, 
H-8 + H-6 + H-15), 1.74‒1.67 (1H, m, H-6), 1.59 (3H, s, H-24) ppm.13C NMR (500 MHz, CDCl3):  213.1 
(C-13), 131.9 (C-9), 118.2 (C-10), 48.0 (C-12), 40.0 (C-14), 36.3 (C-7), 32.2 (C-15), 28.5 (C-6), 24.2 (C-8), 
24.1 (C-11), 23.8 (C-24) ppm. MS (ESI): m/z 187 (M+Na+); HRMS: found: (M+Na+) 187.1090. C11H16NaO 
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requires (M+Na+) 187.1093. m/z 165 (M+H+); HRMS: found: (M+H+) 165.1273. C11H17O requires (M+H+) 
165.1274. Characterisation of this cis-decalin 138 matched the compound reported in the literature76  
 (12S*, 7S*)-9-Methyl-15,6,7,8,11,12-hexahydronaphthalen-13(2H)-one, 139; Rf = 0.48 (EtOAc : 
hexane 5% : 95%). IR (ATR): νmax 2921, 1705 (C=O), 1439, 1378, 1340, 1310, 1149, 1060, 824 cm–1. 1H 
NMR (500 MHz, CDCl3):  5.39‒5.34 (1H, m, H-10), 2.04 (1H, dddd, J = 13.7, 4.5, 2.8, 1.7 Hz, H-14), 2.34 
(1H, dddd, J = 13.7, 13.7, 5.7, 0.7 Hz, H-14),  2.40‒2.11 (3H, m, H-12 + H-11), 2.10‒2.01 (2H, m, H-8 + 
H-15), 1.93‒1.84 (2H, m, H-8 + H-6), 1.76‒1.66 (2H, m, H-7 + H-15), 1.64 (3H, s, H-24), 1.45 (1H, dddd, 
J = 13.2, 13.2, 11.7, 3.4 Hz, H-6) ppm. 13C NMR (500 MHz, CDCl3):  212.1 (C-13), 132.1 (C-9), 118.7 (C-
10), 50.0 (C-12), 41.8 (C-14), 40.2 (C-7), 38.1 (C-8), 32.4 (C-6), 25.9 (C-15), 24.4 (C-11), 22.9 (C-24) ppm. 
MS (ESI): m/z 187 (M+Na+); HRMS: found: (M+Na+) 187.1091. C11H16NaO requires (M+Na+) 187.1093. 
m/z 165 (M+H+); HRMS: found: (M+H+) 165.1221. C11H17O requires (M+H+) 165.1274. Characterisation 
of this trans-decalin 139 matched the compound reported in the literature70  
Epimerisation Method 
To a solution of cis-decalin 138 (326 mg, 1.99 mmol), in dry CH2Cl2 (10.0 mL), was added a 1.0 M 
solution of EtAlCl2in hexane (0.40 mL, 0.40 mmol) and stirred for 16 hours. After this time, Rochelle’s 
salt 10% aqueous solution (20 mL) was added and the reaction was stirred vigorously for 1 hour. The 
mixture was diluted with water (10 mL) and the organic phase was extracted with CH2Cl2 (3 × 10 mL). 
The combined organic layers were washed with water (5 mL) and brine (5 mL), dried with Na2SO4, 
filtered and concentrated in vacuo. The crude product was purified by silica gel flash column 
chromatography (2% to 5% EtOAc in hexanes) to yield 139 as a pale yellow oil (245 mg, 75% yield). 
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13-(2,4-Dinitrophenyl)-14-((12S*, 7S*)-9-methyl-15,6,7,8,11,12-hexahydronaphthalen- 
13(2H)-ylidene)hydrazine, 141 
 
 
To a solution of trans-decalin 139 (40.0 mg, 0.270 mmol) in methanol (1.0 mL), were added 2,4-
dinitrophenyl hydrazine 140 (120 mg, 0.540 mmol), glacial acetic acid (0.50 mL) and H2SO4 98% 
solution in water (0.10 mL). The reaction was stirred at 50 °C for 2 hours and after this period the 
reaction was cooled to room temperature and then quenched with cold water (10 mL) and saturated 
aqueous solution of NaHCO3 (20 mL). The mixture was extracted with CH2Cl2 (4 × 10 mL) and the 
combined organic layers were washed with brine (10 mL), dried with Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by silica gel flash column chromatography (2% 
to 5% EtOAc in hexanes) to yield 141 as an orange solid (50.0 mg, 54% yield). Crystallized using 
solvent/antisolvent system: EtOAc/hexane. Melting point = 192‒194 °C. Rf = 0.55 (EtOAc :  hexane 
10% : 90%). IR (ATR): νmax 3328, 2927, 1615 (C=N), 1587, 1514, 1500, 1264, 1296, 741 cm–1. 1H NMR 
(500 MHz, CDCl3):  11.29 (1H, s, NH), 9.14 (1H, d, J = 2.5 Hz, Ar-H), 8.31 (1H, dd, J = 9.6, 2.5 Hz, Ar-H), 
7.98 (1H, d, J = 9.6 Hz, Ar-H), 5.51‒5.47 (1H, m, H-10), 2.95‒2.92 (1H, m, H-14), 2.41‒2.32 (2H, m, H-
11), 2.19 (1H, ddd, J = 11.4, 7.8, 6.5 Hz, H-12), 2.14‒2.04 (3H, m, H-14 + H-8 + H-15), 1.95‒1.91 (1H, m, 
H-6), 1.92‒1.84 (1H, m, H-8), 1.69 (3H, s, H-24), 1.64‒1.60 (1H, m, H-7), 1.55‒1.51 (1H, m, H-15), 1.33 
(1H, dddd, J = 13.1, 13.1, 11.2, 3.1 Hz, H-6) ppm. 13C NMR (500 MHz, CDCl3):  162.1 (C=N), 145.7 (C-
9), 137.5 (Ar), 132.5 (Ar), 128.9 (Ar-H), 128.4 (Ar), 123.7 (Ar-H), 120.2 (C-10), 116.5 (Ar-H), 44.9 (C-12), 
40.1 (C-7), 38.6 (C-8), 33.0 (C-6), 27.5 (C-14), 26.8 (C-11), 25.3 (C-15), 23.4 (C-24) ppm. MS (ESI): m/z 
367 (M+Na+); HRMS: found: (M+Na+) 367.1375. C17H20N4NaO4 requires (M+Na+) 367.1377. 
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(12R*, 7S*)-9,10-Dimethyl,15,6,7,8,11,12-hexahydronaphthalen-13-(2H)-one, 14377 
 
(12S*, 7S*)-9,10-Dimethyl,15,6,7,8,11,12-hexahydronaphthalen-13-(2H)-one, 14477 
 
To a solution of cyclohexanone 131 (0.10 mL, 1.0 mmol) in dry CH2Cl2 (5.0 mL), was added a 1.0 M 
solution of EtAlCl2 in hexane (0.20 mL, 0.20 mmol) and the reaction was stirred at room temperature 
for 30 minutes. 2,3-Dimethyl-1,3-butadiene 142 (1.20 mL, 10.0 mmol) was added and the reaction was 
stirred at room temperature for 24 hours. After this time, Rochelle’s salt 10% aqueous solution (20 
mL) was added and the mixture was stirred vigorously for 1 hour. The mixture was then diluted with 
water (10 mL) and the organic phase was extracted with CH2Cl2 (3 × 10 mL). The combined organic 
layers were washed with water (5 mL) and brine (5 mL), dried with Na2SO4, filtered and concentrated 
in vacuo. The crude product was purified by silica gel flash column chromatography (10% EtOAc in 
hexanes) to yield as an inseparable mixture 143 and 144 in a 2 : 1 ratio as pale yellow oil (178 mg, 99% 
yield).  
Epimerisation 
To a solution of the inseparable mixture of cis-decalin 143 and trans-decalin 144 2: 1 ratio (178 mg, 
1.00 mmol) in dry CH2Cl2 (5.0 mL), was added a 1.0 M solution of EtAlCl2 in hexane (0.20 mL, 0.20 
mmol) and the reaction was stirred at room temperature for 24 hours. After this time, Rochelle’s salt 
10% aqueous solution (20 mL) was added and stirred vigorously for 1 hour. The mixture was then 
diluted with water (10 mL) and the organic phase was extracted with CH2Cl2 (3 × 10 mL). The combined 
organic layers were washed with water (5 mL) and brine (5 mL), dried with Na2SO4, filtered and 
154 
 
concentrated in vacuo. The crude product was purified by silica gel flash column chromatography (10% 
EtOAc in hexanes) to yield 144 as a pale yellow oil in a 23 : 1 ratio (166 mg, 93% yield). Data reported 
for the trans-diasteroisomer 144 only, after epimerization. Rf = 0.52 (EtOAc : hexane 10% : 90%). IR 
(ATR): νmax 2911, 1708 (C=O), 1445, 1380, 1237, 1180, 1131, 515 cm–1. 1H NMR (400 MHz, CDCl3):  
2.40 (1H, dddd, J = 13.7, 4.3, 2.6, 1.6 Hz, H-14), 2.33 (1H, dddd, J = 13.7, 13.7, 5.6, 0.9 Hz,  H-14), 2.21‒
2.13 (2H, m, H-11 + H-12), 2.10‒1.98 (3H, m, H-15 + H-7), 1.97‒1.86 (2H, m, H-11 + H-6), 1.72‒1.63 
(2H, m, H-8), 1.61 (3H, s, H-24), 1.57 (3H, s, H-25), 1.41 (1H, dddd, J = 13.0, 13.0, 11.9, 3.7 Hz, H-6) 
ppm. 13C NMR (400 MHz, CDCl3):  212.5 (C-13), 124.5 (C-9), 123.9 (C-10), 51.0 (C-12), 41.8 (C-14), 40.9 
(C-7), 40.2 (C-8), 32.3 (C-6), 30.7 (C-11), 26.1 (C-15), 18.8 (C-24), 18.6 (C-25) ppm. MS (ESI): m/z 179 
(M+H+); HRMS: found: (M+H+) 179.1441. C12H19O requires (M+H+) 179.1430. 
 
(12S*, 7S*)-10-Methyl,15,6,7,8,11,12-hexahydronaphthalen-13-(2H)-one, 14677 
 
To a solution of cyclohexanone 131 (0.10 mL, 1.0 mmol) in dry CH2Cl2 (5.0 mL), was added a 1.0 M 
solution of EtAlCl2 in hexane (0.20 mL, 0.20 mmol) and the reaction was stirred at room temperature 
for 30 minutes. trans-1,3-Pentadiene 145 (1.00 mL, 10.0 mmol) was added and the reaction was 
stirred at room temperature for 24 hours. After this time, Rochelle’s salt 10% aqueous solution (20 
mL) was added and stirred vigorously for 1 hour. The mixture was then diluted with water (10 mL) and 
the organic phase was extracted with CH2Cl2 (3 × 10 mL). The combined organic layers were washed 
with water (5 mL) and brine (5 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude 
product was purified by silica gel flash column chromatography (10% EtOAc in hexanes) to yield 146 
as a pale yellow oil (164 mg, 99% yield). Rf = 0.54 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 2899, 
1710 (C=O), 1444, 1367, 1212, 1139, 1063, 803 cm–1. 1H NMR (400 MHz, CDCl3):  5.57‒5.53 (2H, m, 
H-10 + H-9), 2.83 (1H, dd, J = 4.6, 4.6 Hz, H-12), 2.60‒2.52 (1H, m, H-7), 2.44‒2.31 (2H, m, H-14 + H-
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11), 2.29‒2.21 (1H, m, H-14), 2.05‒1.88 (5H, m, H-15 + H-6 + H-8), 1.76‒1.68 (1H, m, H-8), 1.21 (3H, d, 
J = 7.3 Hz, H-24) ppm. 13C NMR (400 MHz, CDCl3): 211.3 (C-13), 131.2 (C-10), 123.8 (C-9), 53.8 (C-12), 
43.3 (C-14), 39.6 (C-7), 32.7 (C-11), 30.0 (C-15), 26.2 (C-8), 24.9 (C-6), 17.9 (C-24) ppm. MS (APCI): m/z 
165 (M+H+); HRMS: found: (M+H+) 165.1277. C11H17O requires (M+H+) 165.1274. Characterisation of 
this compound matched the compound reported in the literature.77  
 
(12R*, 7S*)-10-Methyl,15,6,7,8,11,12-hexahydronaphthalen-13-(2H)-one, 14777 
 
To a solution of cis-decalin 146 (164 mg, 1.00 mmol) in dry CH2Cl2 (5.0 mL), was added a 1.0 M solution 
of EtAlCl2 in hexane (0.20 mL, 0.20 mmol) and the reaction was stirred at room temperature for 24 
hours. After this time, Rochelle’s salt 10% aqueous solution (20 mL) was added stirred vigorously for 
1 hour. The mixture was then diluted with water (10 mL) and the organic phase was extracted with 
CH2Cl2 (3 × 10 mL). The reunited organic layers were washed with water (5 mL) and brine (5 mL), dried 
with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by silica gel flash 
column chromatography (2% to 5% EtOAc in hexanes) to yield 147 as a pale yellow oil (38.0 mg, 23% 
yield). Rf = 0.56 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 2924, 2870, 1707 (C=O), 1447, 1363, 1278, 
1109, 895 cm–1. 1H NMR (400 MHz, CDCl3):  5.57 (1H, dddd, J = 10.0, 5.0, 2.7, 2.3 Hz, H-9), 5.55‒5.45 
(1H, m, H-10), 2.59 (1H, dqdd, J = 9.1, 6.9, 4.5, 2.7 Hz, H-11), 2.44‒2.37 (2H, m, H-14), 2.20‒2.06 (2H, 
m, H-8 + H-6), 2.00‒1.85 (3H, m, H-12 + H-15 + H-8), 1.80‒1.63 (2H, m, H-15 + H-7), 1.47 (1H, dddd, J 
= 13.0, 13.0, 11.9, 3.7 Hz, H-6), 0.98 (3H, d, J = 6.9 Hz, H-24) ppm. 13C NMR (400 MHz, CDCl3):  212.2 
(C-13), 133.0 (C-10), 123.5 (C-9), 58.2 (C-12), 43.0 (C-14), 41.0 (C-7), 33.1 (C-6), 33.0 (C-8), 29.1 (C-11), 
27.2 (C-15), 21.1 (C-24) ppm. MS (APCI): m/z 165 (M+H+); HRMS: found: (M+H+) 165.1278. C11H17O 
requires (M+H+) 165.1274. Characterisation of this compound matched the compound reported in the 
literature.77  
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(12R*, 7S*)-9-Methyl-14-15-7,8,11,12-hexahydro-inden-13-one, 14977 
 
(12S*, 7S*)-9-Methyl-14-15-7,8,11,12-hexahydro-inden-13-one, 15077 
 
To a solution of cyclopenteone 148 (0.10 mL, 1.2 mmol) in dry CH2Cl2 (6.0 mL), was added a 1.0 M 
solution of EtAlCl2 in hexane (0.24 mL, 0.24 mmol) and stirred at room temperature for 30 minutes. 
Isoprene 133 (1.20 mL, 12.0 mmol) was added and the reaction was stirred at room temperature for 
3 days. After this time, Rochelle’s salt 10% aqueous solution (20 mL) was added and the mixture stirred 
vigorously for 1 hour. The mixture was then diluted with water (10 mL) and the organic phase was 
extracted with CH2Cl2 (3 × 10 mL). The combined organic layers were washed with water (5 mL) and 
brine (5 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified 
by silica gel flash column chromatography (10% EtOAc in hexanes) to yield as an inseparable mixture 
149 and 150 in a 1.34 : 1 ratio as a pale yellow oil (41.0 mg, 23% yield). Rf = 0.51 (EtOAc : hexane 10% 
: 90%). On a mixture IR (ATR): νmax 2923, 1738 (C=O), 1438, 1377, 1172, 1125, 886, 783 cm–1. 
Integration of the 1H NMR are reported as a 1 : 1 mixture due to the presence of overlapping peaks. 
1H NMR (400 MHz, CDCl3):  5.46‒5.39 (1H, m, 150), 5.36‒5.32 (1H, m, 149), 2.57‒2.48 (1H, m, 149), 
2.47‒2.39 (1H, m, 149), 2.38‒2.29 (3H, m, 2H x 149 + 1H x 150), 2.28‒2.23 (3H, m, 1H x 149 + 2H x 
150), 2.23‒2.12 (4H, m, 1H x 149 + 3H x 150), 2.11‒1.93 (5H, m, 3H x 149 + 2H x 150), 1.85‒1.76 (3H, 
m, 1H x 149 + 2H x 150), 1.71 (3H, s, 150), 1.63 (3H, s, 149) ppm. 13C NMR (400 MHz, CDCl3):  219.8 
(C=O), 218.5 (C=O), 134.3 (C=C), 132.3 (C=C), 120.3 (CH), 118.7 (CH), 51.2 (CH2), 46.6 (CH), 39.4 (CH), 
37.7 (CH), 37.3 (CH2), 34.2 (CH2), 32.8 (CH), 30.8 (CH2), 27.8 (CH2), 26.5 (CH2), 24.8 (CH2), 23.9 (CH3), 
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23.6 (CH3), 21.7 (CH2) ppm. On a mixture MS (ESI): m/z 173 (M+Na+); HRMS: found: (M+Na+) 173.0938. 
C10H14NaO requires (M+Na+) 173.0937. Characterisation of this compound matched the compound 
reported in the literature77  
Epimerisation 
To a solution of the inseparable mixture of  cis-decalin 149 and trans-decalin 150 1.34 : 1 (41.0 mg, 
0.270 mmol) in dry CH2Cl2 (2.0 mL), was added a 1.0 M solution of EtAlCl2 in hexane (0.05 mL, 0.05 
mmol) and the reaction was stirred at room temperature for 24 hours. After this time, Rochelle’s salt 
10% aqueous solution (10 mL) was added and the mixture stirred vigorously for 1 hour. The mixture 
was then diluted with water (10 mL) and the organic phase was extracted with CH2Cl2 (3 × 10 mL). The 
combined organic layers were washed with water (5 mL) and brine (5 mL), dried with Na2SO4, filtered 
and concentrated in vacuo. The crude product was purified by silica gel flash column chromatography 
(10% EtOAc in hexanes) to yield as an inseparable mixture 149 and 150 in an unchanged 1.34 : 1 ratio 
as a pale yellow oil (39.0 mg, 99% yield). 
 
(12R*, 7S*)-9,10-Dimethyl,14,15,7,8,11,12-hexahydro-1H-inden-13-one, 151 
 
(12S*, 7S*)-9,10-Dimethyl,14,15,7,8,11,12-hexahydro-1H-inden-13-one, 152 
 
To a solution of cyclopenteone 148 (0.10 mL, 1.2 mmol) in dry CH2Cl2 (6.0 mL), was added a 1.0 M 
solution of EtAlCl2 in hexane (0.24 mL, 0.24 mmol) and the reaction was stirred at room temperature 
for 30 minutes. 2,3-Dimethyl-1,3-butadiene 142 (1.40 mL, 12.0 mmol) was added and the reaction was 
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stirred at room temperature for 3 days. After this time, Rochelle’s salt 10% aqueous solution (20 mL) 
was added and the mixture was stirred vigorously for 1 hour. The mixture was then diluted with water 
(10 mL) and the organic phase was extracted with CH2Cl2 (3 × 10 mL). The combined organic layers 
were washed with water (5 mL) and brine (5 mL), dried with Na2SO4, filtered and concentrated in 
vacuo. The crude product was purified by silica gel flash column chromatography (10% EtOAc in 
hexanes) to yield as an inseparable mixture 151 and 152 in a 4 : 1 ratio as a pale yellow oil (149 mg, 
76% yield).  
Epimerisation 
To a solution of the inseparable mixture of  cis-decalin 151 and trans-decalin 152 4 : 1 (149 mg, 0.910 
mmol) in dry CH2Cl2 (4.50 mL), was added a 1.0 M solution of EtAlCl2 in hexane (0.18 mL, 0.18 mmol) 
and the reaction was stirred at room temperature for 24 hours. After this time, Rochelle’s salt 10% 
aqueous solution (10 mL) was added and stirred vigorously for 1 hour. The mixture was then diluted 
with water (10 mL) and the organic phase was extracted with CH2Cl2 (3 × 10 mL). The combined organic 
layers were washed with water (5 mL) and brine (5 mL), dried with Na2SO4, filtered and concentrated 
in vacuo. The crude product was purified by silica gel flash column chromatography (10% EtOAc in 
hexanes) to yield as an inseparable mixture 151 and 152 in a 1.47 : 1 ratio as a pale yellow oil (113 mg, 
75% yield). Rf = 0.54 (EtOAc : hexane 10% : 90%). On a mixture IR (ATR): νmax 2914, 2831, 1737 (C=O), 
1439, 1380, 1274, 1128, 1020 cm–1. Integration of the 1H NMR are reported as a 1 : 1 mixture due to 
the presence of overlapping peaks. 1H NMR (400 MHz, CDCl3): 2.49‒2.41 (1H, m), 2.41‒2.34 (1H, m), 
2.33‒2.24 (2H, m), 2.23‒2.11 (6H, m), 2.10‒1.88 (6H, m), 1.84‒1.64 (4H, m), 1.62 (6H, s), 1.59 (3H, s), 
1.56 (3H, s) ppm. 13C NMR (400 MHz, CDCl3):  219.7 (C=O, 151), 218.9 (C=O, 152), 125.6 (C=C, 152), 
124.9 (C=C, 152), 123.9 (C=C, 151), 123.4 (C=C, 151), 51.9 (CH, 152), 47.6 (CH, 151), 39.4 (CH, 152), 
38.8 (CH2, 152), 37.5 (CH2, 152), 34.2 (CH2, 151), 32.8 (CH, 151), 32.7 (CH2, 151), 31.0 (CH2, 152), 27.8 
(CH2, 151), 27.7 (CH2, 152), 26.4 (CH2, 151), 19.3 (CH3, 151), 19.2 (CH3, 152), 19.1 (CH3, 152), 18.7 (CH3, 
151) ppm. On a mixture MS (ESI): m/z 187 (M+Na+); HRMS: found: (M+Na+) 187.1099. C11H16NaO 
159 
 
requires (M+Na+) 187.1093. m/z 165 (M+H+); HRMS: found: (M+H+) 165.1276. C11H17O requires (M+H+) 
165.1274. 
 
(12R*, 7S*)-10-Methyl-11,12,15,6,6a,7-hexahydro-1H-benzo[15]annulen-13(6H)-one, 15477 
 
(12S*, 7S*)-10-Methyl-11,12,15,6,6a,7-hexahydro-1H-benzo[15]annulen-13(6H)-one, 15577 
 
To a solution of cycloheptenone 153 (0.10 mL, 1.0 mmol) in dry CH2Cl2 (5.0 mL), was added a 1.0 M 
solution of EtAlCl2 in hexane (0.20 mL, 0.20 mmol) and the reaction was stirred at room temperature 
for 30 minutes. Isoprene 133 (1.00 mL, 10.0 mmol) was added and the reaction was stirred at room 
temperature for 24 hours. After this time, Rochelle’s salt 10% aqueous solution (20 mL) was added 
and stirred vigorously for 1 hour. The mixture was then diluted with water (10 mL) and the organic 
phase was extracted with CH2Cl2 (3 × 10 mL). The combined organic layers were washed with water (5 
mL) and brine (5 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product (10 : 
1 cis : trans) was purified by silica gel flash column chromatography (2% to 5% EtOAc in hexanes) to 
yield 154 as a pale yellow oil (92.0 mg, 52% yield) and 155 as a pale yellow oil (8.0 mg, 5% yield).  
(12R*, 7S*)-10-Methyl-11,12,15,6,6a,7-hexahydro-1H-benzo[15]annulen-13(6H)-one, 154; Rf = 0.48 
(EtOAc : hexane 10% : 90%). IR (ATR): νmax 2920, 2854, 1693 (C=O), 1436, 1377, 1145, 942 cm–1. 1H 
NMR (400 MHz, CDCl3):  5.39‒5.34 (1H, m, H-10), 2.71‒2.60 (2H, m, H-12 + H-14) 2.50‒2.40 (1H, m, 
H-14), 2.32‒2.23 (3H, m, H-15 + H-6 + H-7), 2.17‒2.06 (1H, m, H-8), 1.97‒1.86 (4H, m, H-8 + H-6a + H-
11), 1.67-1.59 (6, m, H-24 + H-6 + H-6a + H-15) ppm. 13C NMR (400 MHz, CDCl3):  215.7 (C-13), 132.3 
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(C-9), 119.1 (C-10), 49.5 (C-12), 43.8 (C-14), 36.9 (C-8), 34.2 (C-7), 33.1 (C-11), 27.6 (C-6), 26.1 (C-15), 
24.2 (C-6a), 23.7 (C-24) ppm. MS (ESI): m/z 201 (M+Na+); HRMS: found: (M+Na+) 201.1254. C12H18NaO 
requires (M+Na+) 201.1250. m/z 179 (M+H+); HRMS: found: (M+H+) 179.1435. C12H19O requires (M+H+) 
179.1430. (12S*, 7S*)-10-Methyl-11,12,15,6,6a,7-hexahydro-1H-benzo[15]annulen-13(6H)-one, 155; 
Rf = 0.51 (EtOAc : hexane 10% : 90%).  IR (ATR): νmax 2920, 1698 (C=O), 1444, 1340, 1150, 521 cm–1. 1H 
NMR (400 MHz, CDCl3):  5.39‒5.34 (1H, m), 2.72‒2.61 (2H, m), 2.51‒2.40 (1H, m), 2.39‒2.34 (1H, m), 
2.29‒2.17 (2H, m), 2.12‒2.04 (3H, m), 2.02‒1.87 (5H, m), 1.66 (3H, s) ppm. 13C NMR (400 MHz, CDCl3): 
 217.1 (C=O), 134.2 (C=C), 119.3 (CH), 54.9 (CH), 41.1 (CH2), 38.6 (CH2), 36.9 (CH), 35.4 (CH2), 29.7 
(CH2), 29.1 (CH2), 26.4 (CH2), 23.2 (CH3) ppm. MS (ESI): m/z 201 (M+Na+); HRMS: found: (M+Na+) 
201.1253. C12H18NaO requires (M+Na+) 201.1250. m/z 179 (M+H+); HRMS: found: (M+H+) 179.1431. 
C12H19O requires (M+H+) 179.1430. Characterisation of this compound matched the compound 
reported in the literature.77  
 
(12R*, 7S*)-10-Methyl-9-(phenylthio)-15,6,7,8,11,12-hexahydronaphthalen-13(2H)-one, 15672 
 
 
To a solution of cyclohexenone 131 (0.10 mL, 1.0 mmol) in dry CH2Cl2 (2.5 mL), was added a 1.0 M 
solution of EtAlCl2 in hexane (0.20 mL, 0.20 mmol). After 15 minutes, a soluton of sulfur substituted 
diene 116 (704 mg, 4.00 mmol) in dry CH2Cl2 (2.5 mL) was added and the reaction was stirred at room 
temperature for 1.5 hours. After this time, Rochelle’s salt 10% aqueous solution (20 mL) was added 
and stirred vigorously for 16 hours. The mixture was then diluted with water (10 mL) and the organic 
phase was extracted with CH2Cl2 (3 × 10 mL). The combined organic layers were washed with water 
(10 mL) and brine (10 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product 
was purified by silica gel flash column chromatography (2% to 5% EtOAc in hexanes) to yield 156 as a 
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pale yellow solid (242 mg, 90% yield).72 Melting point = 95‒97 °C. Rf = 0.43 (EtOAc : hexane 10% : 
90%). IR (ATR): νmax 2922, 1698 (C=O), 1580, 1475, 1370, 1306, 1138, 1023, 737 cm–1. 1H NMR (500 
MHz, CDCl3):  7.25‒7.21 (3H, m, Ar-H), 7.14‒7.07 (2H, m, Ar-H), 2.81‒2.76 (1H, m, H-12), 2.70 (1H, 
dd, J = 18.7, 2.3 Hz, H-11), 2.48‒2.43 (1H, m, H-7), 2.39 (1H, dddd, J = 9.9, 9.9, 5.1, 1.5 Hz, H-14), 2.33‒
2.25 (1H, m, H-14), 2.19‒2.12 (1H, m, H-11), 2.10‒2.07 (2H, m, H-8), 1.97 (3H, s, H-24), 1.95‒1.80 (3H, 
m, H-15 + H-6), 1.73‒1.65 (1H, m, H-6) ppm. 13C NMR (500 MHz, CDCl3):  211.9 (C-13), 139.9 (C-9), 
136.6 (Ar), 128.9 (Ar-H), 127.7 (Ar-H), 125.3 (Ar-H), 120.8 (C-10), 48.6 (C-12), 40.4 (C-14), 37.4 (C-7), 
33.6 (C-8), 31.3 (C-11), 28.4 (C-6), 23.9 (C-15), 21.4 (C-24) ppm. MS (ESI): m/z 295 (M+Na+); HRMS: 
found: (M+Na+) 295.1119. C17H20NaOS requires (M+Na+) 295.1127. m/z 273 (M+H+); HRMS: found: 
(M+H+) 273.1310. C17H21OS requires (M+H+) 273.1308. Characterisation of this compound matched the 
compound reported in the literature.72  
 
 (12R*, 7S*)-10-Methyl-15,6,7,8,11,12-hexahydronaphthalen-13(2H)-one, 15772 
 
(12R*, 7S*)-10-Methyl-13,14,15,6,7,8,11,12-octahydronaphthalen-13-ol, 158 
 
To a solution of thiophenyl cis-declalin 156 (75.0 mg, 0.280 mmol) in acetone (30.0 mL), was added an 
excess of unwashed Raney Nickel (0.240 mg, 2.80 mmol) and the reaction was stirred at room 
temperature for 45 minutes under H2 atm. After this time, the reaction was filtered through a pad of 
celite with CH2Cl2 (50 mL) and the filtrate was dried with Na2SO4, filtered and concentrated in vacuo. 
The crude product was purified by silica gel flash column chromatography (5% to 10% EtOAc in 
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hexanes) to yield 157 as a pale yellow oil (10.0 mg, 23% yield) and 158 as a white solid (5.0 mg, 11% 
yield).72 (12R*, 7S*)-10-Methyl-15,6,7,8,11,12-hexahydronaphthalen-13(2H)-one, 157; Rf = 0.48 
(EtOAc : hexane 10% : 90%). IR (ATR): νmax 2911, 1709 (C=O), 1444, 1375, 1225, 1135, 1024, 597, 497 
cm–1. 1H NMR (500 MHz, CDCl3):  5.35‒5.31 (1H, m, H-9), 2.74‒2.68 (1H, m, H-12), 2.39 (1H, dddd, J 
= 14.2, 5.8, 5.8, 0.9 Hz, H-14), 2.36‒2.23 (3H, m, H-11 + H-7 + H-14), 2.07‒1.84 (5H, m, H-11 + H-6 + H-
15), 1.81‒1.68 (2H, m, H-8), 1.69 (3H, s, H-24) ppm. 13C NMR (500 MHz, CDCl3):  212.9 (C-13), 131.4 
(C-10), 119.1 (C-9), 48.9 (C-12), 40.0 (C-14), 35.7 (C-7), 28.6 (C-11), 28.5 (C-8), 27.6 (C-15), 24.3 (C-6), 
23.5 (C-24) ppm. MS (ESI): m/z 187 (M+Na+); HRMS: found: (M+Na+) 187.1093. C11H16NaO requires 
(M+Na+) 187.1093. m/z 165 (M+H+); HRMS: found: (M+H+) 165.1257. C11H17O requires (M+H+) 
165.1274. Characterisation of this compound matched the compound reported in the literature.72  
 (12R*, 7S*)-10-Methyl-13,14,15,6,7,8,11,12-octahydronaphthalen-13-ol, 158; Melting point = 74‒77 
°C. Rf = 0.22 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 3338 (C-OH), 2923, 2855, 1377, 1447, 1088, 
1034, 571 cm–1. 1H NMR (400 MHz, CDCl3):  5.37‒5.31 (1H, m), 3.82 (1H, ddd, J = 10.9, 4.6, 4.6 Hz), 
2.31‒2.20 (1H, m), 2.01‒1.90 (2H, m), 1.89‒1.73 (2H, m), 1.67 (3H, s), 1.64‒1.48 (1H, m), 1.47‒1.40 
(2H, m), 1.39‒1.23 (4H, m) ppm. 13C NMR (400 MHz, CDCl3):  131.3 (C=C), 119.3 (CH), 73.3 (CH), 38.7 
(CH), 33.2 (CH2), 31.5 (CH), 30.3 (CH2), 29.1 (CH2), 26.1 (CH2), 23.7 (CH2), 20.3 (CH3) ppm. MS (ESI): m/z 
189 (M+Na+); HRMS: found: (M+Na+) 189.1251. C11H18NaO requires (M+Na+) 189.1250. 
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(12S*, 7S*)-10-Methyl-15,6,7,8,11,12-hexahydronaphthalen13(2H) one, 15972 
 
To a solution of thiophenyl trans-declalin 137 (171 mg; 0.630 mmol) in acetone (66.0 mL), was added 
an excess of unwashed Raney Nickel (540 mg, 6.30 mmol) and the reaction was stirred at room 
temperature for 45 minutes under H2 atm. After this time, the reaction was filtered through a pad of 
celite with CH2Cl2 (50 mL) and the filtrate was dried with Na2SO4, filtered and concentrated in vacuo. 
The crude product was purified by silica gel flash column chromatography (5% to 10% EtOAc in 
hexanes) to yield 159 as a white solid (61.0 mg, 60% yield).72 Melting point = 49‒51 °C. Rf = 0.51 (EtOAc 
: hexane 10% : 90%). IR (ATR): νmax 2902, 2844, 2828, 1701 (C=O), 1428, 1374, 1236, 1182, 845 cm–1. 
1H NMR (400 MHz, CDCl3):  5.36‒5.29 (1H, m, H-9), 2.47‒2.41 (1H, dddd, J = 13.5, 4.6, 2.6, 1.8 Hz,  H-
14), 2.36 (1H, dddd, J = 13.5, 13.5, 5.0, 0.9 Hz, H-14), 2.28‒2.13 (3H, m, H-12 + H-8), 2.12‒2.02 (2H, m, 
H-6 + H-11), 1.96‒1.85 (2H, m, H-15), 1.76‒1.69 (1H, m, H-7), 1.68 (3H, s, H-24), 1.65‒1.56 (1H, m, H-
11), 1.44 (1H, dddd, J = 13.5, 13.5, 11.4, 3.5 Hz, H-6) ppm. 13C NMR (400 MHz, CDCl3):  212.5 (C-13), 
133.1 (C-9), 119.3 (C-10), 50.7 (C-12), 42.0 (C-14), 40.4 (C-7), 33.7 (C-8), 32.2 (C-6), 29.2 (C-11), 26.1 
(C-15), 23.5 (C-24) ppm. MS (ESI): m/z 187 (M+Na+); HRMS: found: (M+Na+) 187.1084. C11H16NaO 
requires (M+Na+) 187.1093. Characterisation of this compound matched the compound reported in 
the literature.72  
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(13S*, 6S*)-6-(((Triisopropylsilyl)oxy)methyl)cyclohexanol, 165 
 
 
(13R*, 6S*)-6-(((Triisopropylsilyl)oxy)methyl)cyclohexanol, 166 
 
 
To a suspension of lithium aluminium hydride (2.07 g, 54.4 mmol) in dry THF (200 mL) at 0 ˚C, ethyl-4-
oxocyclohexane carboxylate 117 (10.0 mL, 54.6 mmol) was added dropwise (10 minutes). The reaction 
was stirred for 45 minutes and then quenched with water (2.10 mL), followed by 15% sodium 
hydroxide aqueous solution (2.10 mL), and then more water (4.20 mL) and stirred for a further 30 
minutes. MgSO4 was added and filtered through celite, which was washed with copious amounts of 
Et2O and concentrated in vacuo to give the title compound as a white sticky residue which was used 
directly in the next reaction without further purification. 
To a solution of the title compound (8.23 g, 63.2 mmol) in dry CH2Cl2 (250 mL), were added imidazole 
(6.46 g, 94.8 mmol), DMAP (772 mg, 6.30 mmol) and triisopropylsilyl chloride (15.0 mL, 70.1 mmol) 
and the reaction was stirred at room temperature for 16 hours. After this time, an aqueous solution 
of 2 M HCl (100 mL) was added and the organic phase was extracted with CH2Cl2 (3 × 50 mL). The 
combined organic layers were washed with water (20 mL) and brine (20 mL), dried with Na2SO4 and 
concentrated in vacuo to give a mixture of diastereoisomers as a colourless oil. The crude product was 
purified by silica gel flash column chromatography (3% to 10% EtOAc in hexanes) to yield 165 as a pale 
yellow oil (8.01 g, 44%) and 166 as a colourless oil (2.50 g, 14%). (13S*, 6S*)-6-
(((Triisopropylsilyl)oxy)methyl)cyclohexanol, 165; Rf = 0.28 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 
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3350 (C-OH), 2924, 2890, 1463, 1254, 881, 679 cm–1. 1H NMR (400 MHz, CDCl3):  3.56 (1H, dddd, J = 
10.5, 10.5, 4.1, 4.1 Hz, H-13), 3.52‒3.49 (2H, m, H-5), 2.04‒1.96 (2H, m, H-12), 1.88‒1.79 (3H, m, H-12 
+ H-7), 1.52‒1.40 (1H, m, H-6), 1.33‒1.19 (3H, m, H-7), 1.15‒0.96 (21H, m, OSiCH(CH3)2) ppm.13C NMR 
(400 MHz, CDCl3):  δ 67.9 (C-13), 67.1 (C-5), 39.4 (C-6), 32.0 (C-12), 23.4 (C-7), 18.0 (OSiCH(CH3)2),  12.0 
(OSiCH(CH3)2) ppm. MS (ESI): m/z 309 (M+Na+); HRMS: Found (M+Na+) 309.2216. C16H34NaO2Si 
requires (M+Na+) 309.2220. m/z 287 (M+H+); Found (M+H+), 287.2392. C16H35O2Si requires (M+H+) 
287.2401. (13R*, 6S*)-6-(((Triisopropylsilyl)oxy)methyl)cyclohexanol, 166; Rf = 0.26 (EtOAc : hexane 
10% : 90%). IR (ATR): νmax 3261 (C-OH), 2924, 2890, 2864, 1463, 1383, 1254, 1111, 1064, 881, 679 
cm−1. 1H NMR (400 MHz, CDCl3):  4.03‒3.97 (1H, m, H-13), 3.56‒3.53 (2H, m, H-5), 1.77‒1.68 (2H, m, 
H-12 + H-7), 1.61‒1.50 (5H, m, H-12 + H-7 + H-6), 1.46‒1.32 (2H, m, H-12 + H-7), 1.13‒1.00 (21H, m, 
OSiCH(CH3)2) ppm. 13C NMR (400 MHz, CDCl3):  δ 68.0 (C-13), 67.1 (C-5), 39.4 (C-6), 32.2 (C-12), 23.4 
(C-7), 18.0 (OSiCH(CH3)2), 12.0 (OSiCH(CH3)2) ppm. MS (ESI): m/z 309 (M+Na+); HRMS: Found (M+Na+), 
309.2216. C16H34NaO2Si requires (M+Na+) 309.2220. m/z 287 (M+H+); Found (M+H+), 287.2392. 
C16H35O2Si requires (M+H+) 287.2401.  
 
(6S*)-6-(((Triisopropylsilyl)oxy)methyl)cyclohexanone, 160 
 
 
Dimethyl sulfoxide (3.30 mL, 46.9 mmol) was added slowly to a stirred solution of oxalyl chloride (3.81 
mL, 45.0 mmol) in dry CH2Cl2 (360 mL) at ‒78 ˚C and stirred for 1 hour. A solution of cyclohexanols 165 
and 166 (10.7 g, 37.5 mmol) in dry CH2Cl2 (40.0 mL) was added slowly and the reaction stirred at ‒78 
˚C for 1 hour. After this time, Et3N (26.0 mL, 188 mmol) was added and the mixture was warmed to 
room temperature and after a further 2.5 hours, water (20 mL) was added, followed by aqueous 
solution of 2 M HCl (100 mL). The aqueous phase was extracted with CH2Cl2 (3 × 100 mL) and the 
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combined organic layers were washed with aqueous solution of 2 M HCl (50 mL) and brine (20 mL), 
dried with Na2SO4 and concentrated in vacuo. The crude product was purified by silica gel flash column 
chromatography (3% to 10% EtOAc in hexanes) to yield 160 as a pale yellow oil (10.6 g, 98% yield). Rf 
= 0.39 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 2942, 2865, 1716 (C=O), 1463, 1120, 1103, 881, 680, 
658 cm−1. 1H NMR (500 MHz, CDCl3): δ 3.66‒3.64 (2H, m, H-5), 2.42 (2H, dddd, J = 14.8, 4.7, 3.3, 1.8 
Hz, H-12), 2.35 (2H, ddd, J = 14.8, 12.9, 6.1 Hz, H-12), 2.11 (2H, dddd, J = 13.2, 6.2, 6.1, 3.3 Hz, H-7), 
1.95 (1H, dddddd, J = 12.9, 12.9, 6.2, 6.2, 3.3, 3.3 Hz, H-6), 1.47 (2H, dddd, J = 13.2, 12.9, 12.9,  4.7 Hz, 
H-7), 1.15‒1.03 (21H, m, OSiCH(CH3)2) ppm. 13C NMR (500 MHz, CDCl3): δ 212.4 (C-13), 67.3 (C-5), 40.6 
(C-12), 39.0 (C-6), 29.2 (C-7), 18.0 (OSiCH(CH3)2), 11.9 (OSiCH(CH3)2) ppm. MS (ESI): m/z 307 (M+Na+); 
HRMS: Found (M+Na+), 307.2070. C16H32NaO2Si requires (M+Na+) 307.2064. m/z 285 (M+H+); Found 
(M+H+), 285.2249. C16H33O2Si requires (M+H+) 285.2244.  
 
(6S*)-6-(((Triisopropylsilyl)oxy)methyl)cyclohex-13-enone, 115 
.  
 
Example procedure for re-addition experiment 
To a solution of cyclohexanone 160 (1.67 g, 5.88 mmol) in chlorobenzene (60.0 mL) were added 
Pd(OAc)2 (66.0 mg, 0.290 mmol) and 4,4ʹ-tBu-2,2ʹ-dipyridyl (79.0 mg, 0.290 mmol) and the reaction 
was stirred at 120 ˚C in an aluminium drysyn® under a O2 balloon. After 72 hours, additional Pd(OAc)2 
(66.0 mg, 0.290 mmol) and 4,4ʹ-di-tert-butyl-2,2ʹ-dipyridyl (79.0 mg, 0.290 mmol) were added and the 
O2 balloon refreshed. After a further 44 hours, additional Pd(OAc)2 (66.0 mg, 0.290 mmol) and 4,4ʹ-di-
tert-butyl-2,2ʹ-dipyridyl (79.0 mg, 0.290 mmol) were added and the O2 balloon refreshed. The reaction 
was stirred for a further 45 hours, then concentrated in vacuo to give a brown oil (2.50 g). The crude 
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product was purified by silica gel flash column chromatography (3% to 10% EtOAc in hexanes) and by 
kugelrohr disitillation to yield 115 as a pale yellow oil (1.17 g, 70% yield). 
Example reaction for nitrate experiment 
To a solution of cyclohexanone 160 (10.6 g, 37.5 mmol) in chlorobenzene (375 mL), were added 
Pd(OAc)2 (420 mg, 1.88 mmol), 4,4ʹ-tBu-2,2ʹ-dipyridyl (510 mg, 1.88 mmol) and KNO3 (1.90 g, 18.8 
mmol) and the reaction was stirred at 120 ˚C in an aluminium drysyn® under a balloon of O2. After 48 
hours, additional Pd(OAc)2 (420 mg, 1.88 mmol), 4,4ʹ-di-tert-butyl-2,2ʹ-dipyridyl (510 mg, 1.88 mmol) 
were added and the O2 balloon refreshed. The O2 balloon was refreshed every 24 hours and after a 
further 5 days, the reaction was cooled to room temperature and concentrated in vacuo. The crude 
product was purified by silica gel flash column chromatography (3% to 10% EtOAc in hexanes) and by 
kugelrohr disitillation to yield 115 as a pale yellow oil (9.0 g, 85% yield, 92% conversion). 
B.P. 147 ˚C @ 0.6 mbar; Rf = 0.38 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 2942, 2891, 2865, 1682 
(C=O), 1462, 1389, 1110, 881, 783, 681 cm−1.1H NMR (400 MHz, CDCl3): δ 7.00 (1H, ddd, J = 10.2, 2.7, 
1.4 Hz, H-7), 6.05 (1H, dd, J = 10.2, 2.5 Hz, H-12), 3.76 (1H, dd, J = 9.6, 6.4 Hz, H-5), 3.68 (1H, dd, J = 
9.6, 6.9 Hz, H-5), 2.63 (1H, dddddd, J = 9.6, 6.9, 6.4, 4.6, 2.7, 2.5 Hz, H-6), 2.54 (1H, ddd, J = 16.5, 4.6, 
4.6 Hz, H-14), 2.39 (1H, ddd, J = 16.5, 12.8, 5.0 Hz, H-14), 2.10 (1H, ddddd, J = 13.3, 5.0, 4.6, 4.6, 1.4 
Hz, H-15), 1.79 (1H, dddd, J = 13.3, 12.8, 9.6, 4.6 Hz, H-15), 1.15‒1.00 (21H, m, OSiCH(CH3)2) ppm. 13C 
NMR (400 MHz, CDCl3): δ 199.9 (C-13), 152.1 (C-7), 129.8 (C-12), 65.8 (C-5), 29.4 (C-14), 36.7 (C-6), 
25.4 (C-15), 17.9 (OSiCH(CH3)2), 11.8 (OSiCH(CH3)2) ppm. MS (ESI): m/z 305 (M+Na+); HRMS: Found 
(M+Na+), 305.1899 C16H30NaO2Si requires (M+Na+) 305.1907. m/z 283 (M+H+); Found (M+H+), 
283.2083. C16H31O2Si requires (M+H+) 283.2088.  
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(12R*, 7R*, 6S*)-9-Methyl-6-(((triisopropylsilyl)oxy)methyl)-15,6,7,8,11,12-hexahydronaphthalen-
13(2H)-one, 191 
 
 
(12S*, 7R*, 6S*)-9-Methyl-6-(((triisopropylsilyl)oxy)methyl)-15,6,7,8,11,12-hexahydronaphthalen-
13(2H)-one, 192 
 
 
 
To solution of enone 115 (282 mg, 1.00 mmol) in dry CH2Cl2 (5.0 mL), was added a 1.0 M solution of 
EtAlCl2 in hexane (0.20 mL, 0.20 mmol) and the reaction was stirred at room temperature for 30 
minutes. After this time, isoprene 133 (1.00 mL, 10.0 mmol) was added and the reaction was stirred 
at 30°C for a further 8 hours. Rochelle’s salt 10% aqueous solution (20 mL) was added and stirred 
vigorously for 16 hours. The mixture was then diluted with water (10 mL) and the organic phase was 
extracted with CH2Cl2 (3 × 10 mL). The combined organic layers were washed with water (10 mL) and 
brine (10mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified 
by silica gel flash column chromatography (2% to 5% EtOAc in hexanes) to yield 191 as a pale yellow 
oil (61.0 mg, 17% yield) and 192 as a pale yellow oil (80.0 mg, 23% yield). (12R*, 7R*, 6S*)-9-Methyl-
6-(((triisopropylsilyl)oxy)methyl)-15,6,7,8,11,12-hexahydronaphthalen-13(2H)-one 191; Rf = 0.34 
(EtOAc : hexane 10% : 90%). IR (ATR): νmax 2866, 1707 (C=O), 1110, 905, 729, 646, 597 cm–1. 1H NMR 
(400 MHz, CDCl3):  5.38‒5.35 (1H, m, H-10), 3.88 (1H, dd, J = 9.3, 5.3 Hz, H-5), 3.84 (1H, dd, J = 9.3, 
3.2 Hz, H-5), 2.77‒2.68 (1H, m, H-12), 2.52‒2.44 (1H, m, H-11), 2.42‒2.32 (3H, m, H-14 + H-6), 2.01‒
1.81 (5H, m, H-8 + H-11 + H-7 + H-15), 1.76‒1.65 (1H, m, H-15), 1.63 (3H, s, H-24), 1.15‒1.11 (21H, m, 
OSiCH(CH3)2) ppm. 13C NMR (400 MHz, CDCl3):  213.5 (C-13), 132.0 (C-9), 118.7 (C-10), 65.5 (C-5), 45.2 
(C-12), 42.6 (C-7), 39.0 (C-14), 37.4 (C-6), 36.5 (C-8), 33.1 (C-11), 25.9 (C-15), 23.7 (C-24), 18.0 
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(OSiCH(CH3)2), 11.9 (OSiCH(CH3)2) ppm. MS (ESI): m/z 373 (M+Na+); HRMS: found: (M+Na+) 373.2540. 
C21H38NaO2Si requires (M+Na+) 373.2533. m/z 351 (M+H+); HRMS: found: (M+H+) 351.2725. C21H39O2Si 
requires (M+H+) 351.2714. (12S*, 7R*, 6S*)-9-Methyl-6-(((triisopropylsilyl)oxy)methyl)-
15,6,7,8,11,12-hexahydronaphthalen-13(2H)-one 192; Rf = 0.38 (EtOAc : hexane 10% : 90%). IR (ATR): 
νmax 2924, 2865, 1714 (C=O), 1462, 1118, 881, 794, 682 cm–1. 1H NMR (500 MHz, CDCl3):  5.41‒5.36 
(1H, m, H-10), 3.82 (1H, dd, J = 9.7, 2.3 Hz, H-5), 3.66 (1H, dd, J = 9.7, 5.1 Hz, H-5), 2.48‒2.36 (2H, m, 
H-14), 2.22‒2.11 (5H, m, H-12 + H-11 + H-15 + H-8), 1.91‒1.82 (1H, m, H-11), 1.71‒1.64 (3H, m, H-6 + 
H-7 + H-15), 1.63 (3H, s, H-24), 1.15‒1.11 (21H, m, OSiCH(CH3)2) ppm. 13C NMR (500 MHz, CDCl3):  
212.5 (C-13), 132.2 (C-9), 119.9 (C-10), 64.7 (C-5), 48.9 (C-12), 45.2 (C-6), 41.3 (C-14), 40.8 (C-7), 36.4 
(C-11), 29.9 (C-8), 25.1 (C-15), 23.5 (C-24), 18.1 (OSiCH(CH3)2), 12.1 (OSiCH(CH3)2) ppm. MS (ESI): m/z 
373 (M+Na+); HRMS: found: (M+Na+) 373.2542. C21H38NaO2Si requires (M+Na+) 373.2533. 
 
15,6,7,8,11,12-hexahydronaphthalen-13(2H)-ylidene)hydrazine, 193 
 
 
To a solution of trans-decalin 192 (15 mg, 0.040 mmol) in dry methanol (2.0 mL) and 3Å molecular 
sieves, were added 2,4-dinitrophenylhydrazine 140 (15 mg, 0.080 mmol) and glacial acetic acid (0.25 
mL). The reaction was stirred at 50 °C for 16 hours. After this time, the reaction was quenched with 
saturated aqueous solution of NaHCO3 (5 mL) and the organic layer was extracted with CH2Cl2 (3 × 10 
mL) dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by silica gel 
flash column chromatography (5% to 20% EtOAc in hexane) to yield 193 as an orange solid (14 mg, 
67% yield). Crystalizaion method attempted: slow evaporation of solvent from a solution of 193 in a 
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minimum amount of CHCl3 and solvent/antisolvent system such as EtOAc/hexane and CH2Cl2/hexane. 
Melting point = 140‒142 °C. Rf = 0.61 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 3323, 2940, 2864, 
1616 (C=N), 1518, 1461, 1116, 871 cm–1. 1H NMR (400 MHz, CDCl3):  11.28 (1H, s, N-H), 9.14 (1H, d, J 
= 2.3 Hz, Ar-H), 8.31 (1H, dd, J = 9.6, 2.3 Hz, Ar-H), 7.98 (1H, d, J = 9.6 Hz, Ar-H), 5.52‒5.48 (1H, m, H-
10), 3.84 (1H, dd, J = 9.6, 3.4 Hz, H-5), 3.66 (1H, dd, J = 9.6, 5.0 Hz, H-5), 2.98 (1H, ddd, J = 14.7, 3.7, 
3.7 Hz, H-14), 2.48‒2.32 (2H, m, H-11), 2.31‒2.19 (3H, m, H-12 + H-8 + H-14), 2.18‒2.08 (2H, m, H-15), 
1.94‒1.82 (1H, m, H-8), 1.70 (3H, s, H-24), 1.65‒1.49 (2H, m, H-6 + H-7), 1.15‒0.99 (21H, m, 
OSiCH(CH3)2) ppm. 13C NMR (400 MHz, CDCl3):  161.9 (C=N), 145.6 (C-9), 137.5 (Ar), 132.1 (Ar), 129.9 
(Ar), 128.9 (Ar-H), 123.6 (Ar-H), 120.0 (C-10), 116.4 (Ar-H), 64.6 (C-5), 45.2 (C-6), 43.6 (C-12), 40.3 (C-
7), 36.4 (C-8), 28.5 (C-15), 26.9 (C-11), 26.5 (C-14), 23.4 (C-24), 18.0 (OSiCH(CH3)2), 11.9 (OSiCH(CH3)2) 
ppm. MS (ESI): m/z 529 (M-H+); HRMS: found: (M-H+) 529.2863. C27H41N4O5Si requires (M-H+) 
529.2852. 
 
(12R*, 7R*, 6S*)-10-Methyl-9-(phenylthio)-6-(((triisopropylsilyl)oxy)methyl)-15,6,7,8,11,12-
hexahydronaphthalen-13(2H)-one, 194 
 
 
To a solution of enone 115 (854 mg, 3.02 mmol) in dry CH2Cl2 (7.5 mL), was added a 1.0 M solution of 
EtAlCl2 in hexane (0.60 mL, 0.60 mmol). After 10 minutes, a solution of sulfur substituted diene 116 
(5.30 g, 30.2 mmol) in dry CH2Cl2 (7.5 mL) was added and the reaction was stirred at room temperature 
for 1 hour. After this time, Rochelle’s salt 10% aqueous solution (20 mL) was added and stirred 
vigorously for 16 hours. The mixture was then diluted with water (10 mL) and the organic phase was 
extracted with CH2Cl2 (3 × 10 mL). The combined organic layers were washed with water (10 mL) and 
brine (10 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified 
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by silica gel flash column chromatography (2% to 5% EtOAc in hexane) to yield 194 as a yellow oil (1.18 
g, 85% yield). Rf = 0.48 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 2925, 2864, 1703 (C=O), 1582, 1476, 
1104, 1068, 882, 739 cm–1. 1H NMR (500 MHz, CDCl3):  7.26‒7.22 (2H, m, Ar-H), 7.17‒7.10 (3H, m, Ar-
H), 3.82 (1H, dd, J = 9.9, 5.9 Hz, H-5), 3.78 (1H, dd, J = 9.9, 6.1 Hz, H-5), 2.90 (1H, ddd, J = 6.1, 5.8, 3.2 
Hz, H-12), 2.71 (1H, dd, J = 17.2, 3.2 Hz, H-11), 2.47 (1H, dddd, J = 9.5, 9.5, 6.1, 4.9 Hz, H-7), 2.40‒2.30 
(2H, m, H-14), 2.21‒2.12 (3H, m, H-8 + H-11), 2.00 (3H, s, H-24), 1.98‒1.87 (2H, m, H-15), 1.78‒1.72 
(1H, m, H-6), 1.11‒0.98 (21H, m, OSiCH(CH3)2) ppm. 13C NMR (500 MHz, CDCl3):  212.4 (C-13), 140.1 
(C-9), 136.4 (Ar), 128.9 (Ar-H), 127.9 (Ar-H), 125.3 (Ar-H), 121.1 (C-10), 65.1 (C-5), 45.4 (C-12), 38.9 (C-
6), 37.4 (C-7), 37.4 (C-14), 35.0 (C-8), 31.2 (C-11), 25.4 (C-15), 21.3 (C-24), 18.0 (OSiCH(CH3)2), 11.9 
(OSiCH(CH3)2) ppm. MS (ESI): m/z 481 (M+Na+); HRMS: found: (M+Na+) 481.2552. C27H42NaO2SSi 
requires (M+Na+) 481.2567. m/z 459 (M+H+); HRMS: found: (M+H+) 459.2750. C27H43O2SSi requires 
(M+H+) 459.2748. 
 
(12S*, 7R*, 6S*)-10-Methyl-9-(phenylthio)-6-(((triisopropylsilyl)oxy)methyl)-15,6,7,8,11,12 
hexahydronaphthalen-13(2H)-one, 195 
 
 
To a solution of thiophenyl cis-decalin 194 (542 mg, 1.18 mmol) in dry CH2Cl2 (6.0 mL), was added a 
1.0 M solution of EtAlCl2 in hexane (0.30 mL, 0.30 mmol) and the reaction was stirred at room 
temperature for 3 days. After this time, Rochelle’s salt 10% aqueous solution (20 mL) was added and 
stirred vigorously for 16 hours. The mixture was then diluted with water (10 mL) and the organic phase 
was extracted with CH2Cl2 (3 × 10 mL). The combined organic layers were washed with water (10 mL) 
and brine (10 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product was 
purified by silica gel flash column chromatography (2% to 5% EtOAc in hexanes) to yield 195 as an 
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orange oil (459 mg, 84% yield). Rf = 0.48 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 2865, 1712 (C=O), 
1476, 1119, 882, 739, 689 cm–1. 1H NMR (400 MHz, CDCl3):  7.27‒7.21 (2H, m, Ar-H) 7.20‒7.11 (3H, 
m, Ar-H), 3.65 (1H, dd, J = 10.1, 3.2 Hz, H-5), 3.61 (1H, dd, J = 10.1, 5.0 Hz, H-5), 2.57‒2.42 (4H, m, H-
14 + H-8 + H-11), 2.41‒2.23 (2H, m, H-12 + H-11), 2.19‒2.08 (2H, m, H-15 + H-8), 2.00 (3H, s, H-24), 
1.87‒1.70 (2H, m, H-15 + H-7), 1.70‒1.60 (1H, m, H-6), 1.01‒0.89 (21H, m, OSiCH(CH3)2) ppm. 13C NMR 
(400 MHz, CDCl3):  211.6 (C-13), 140.5 (C-9), 136.0 (Ar), 128.9 (Ar-H), 128.1 (Ar-H), 125.5 (Ar-H), 121.5 
(C-10), 64.1 (C-5), 48.9 (C-12), 44.6 (C-6), 41.5 (C-7), 41.1 (C-14), 37.9 (C-8), 32.3 (C-11), 29.8 (C-15), 
21.5 (C-24), 17.9 (OSiCH(CH3)2), 11.8 (OSiCH(CH3)2) ppm. MS (ESI): m/z 481 (M+Na+); HRMS: found: 
(M+Na+) 481.2572. C27H42NaO2SSi requires (M+Na+) 481.2567. m/z 459 (M+H+); HRMS: found: (M+H+) 
459.2753. C27H43O2SSi requires (M+H+) 459.2748. 
 
(12S*, 7R*, 6S*)-10-Methyl-6-(((triisopropylsilyl)oxy)methyl)-15,6,7,8,11,12-hexahydronaphthalen-
13(2H)-one, 114 
 
 
To a solution of sulfur trans-decalin 195 (401 mg, 0.880 mmol) in acetone (88.0 mL), was added an 
excess of unwashed Raney Nickel (0.754 mg, 8.80 mmol) and the reaction was stirred at room 
temperature for 40 minutes under H2 atm. After this time, the reaction was filtered through celite 
with CH2Cl2 (50 mL) and the filtrate was dried with Na2SO4, filtered and concentrated in vacuo. The 
crude product was purified by silica gel flash column chromatography (1% to 2% EtOAc in hexane) to 
yield 114 as a white solid (238 mg, 77% yield). Melting point = 51‒53 °C. Rf = 0.58 (EtOAc : hexane 
10% : 90%). IR (ATR): νmax 2924, 2865, 1713 (C=O), 1462, 1118, 882, 682 cm–1. 1H NMR (400 MHz, 
CDCl3):  5.37‒5.26 (1H, m, H-9), 3.83 (1H, dd, J = 9.9, 2.5 Hz, H-5), 3.65 (1H, dd, J = 9.9, 5.5 Hz, H-5), 
2.47‒2.45 (2H, m, H-14), 2.38‒2.14 (5H, m, H-12 + H-11 + H-15 + H-7 + H-8), 2.08‒2.04 (1H, m, H-11), 
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1.94‒1.83 (1H, m, H-8), 1.68 (3H, s, H-24), 1.66‒1.59 (1H, m, H-6 + H-15), 1.10‒1.02 (21H, m, 
OSiCH(CH3)2) ppm. 13C NMR (400 MHz, CDCl3):  212.5 (C-13), 132.9 (C-10), 119.0 (C-9), 64.6 (C-5), 49.3 
(C-12), 45.0 (C-6), 41.2 (C-14), 40.1 (C-7), 31.6 (C-8), 29.9 (C-11), 29.5 (C-15), 23.4 (C-24), 18.0 
(OSiCH(CH3)2), 11.9 (OSiCH(CH3)2) ppm. MS (ESI): m/z 373 (M+Na+); HRMS: found: (M+Na+) 373.2527. 
C21H38NaO2Si requires (M+Na+) 373.2533. 
 
13-(2,4-Dinitrophenyl)-14-((12S*, 7R*, 6S*)-10-methyl-6-(((triisopropylsilyl)oxy)methyl)-
15,6,7,8,11,12-hexahydronaphthalen-13(2H)-ylidene)hydrazine, 196 
 
 
To a solution of trans-decalin 114 (25 mg, 0.070 mmol) in dry methanol (4.0 mL) and 3Å molecular 
sieves, were added 2,4-dinitrophenylhydrazine 140 (28 mg, 0.14 mmol) and glacial acetic acid (0.50 
mL). The reaction was stirred at 50 °C for 16 hours. After this time, the reaction was quenched with 
saturated aqueous solution of NaHCO3 (5 mL) and the organic layer was extracted with CH2Cl2 (3 × 10 
mL) dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by silica gel 
flash column chromatography (5% to 20% EtOAc in hexane) to yield 196 as an orange solid (26 mg, 
70% yield). Crystalizaion method: slow evaporation of solvent from a solution of 196 in a minimum 
amount of CHCl3. Melting point = 71‒73 °C. Rf = 0.61 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 3006, 
2942, 2864, 1617 (C=N), 1518, 1422, 1333, 1119, 1092 cm–1. 1H NMR (400 MHz, CDCl3):  11.29 (1H, 
s, N-H), 9.15 (1H, d, J = 2.8 Hz, Ar-H), 8.34 (1H, dd, J = 9.6, 2.8 Hz, Ar-H), 8.00 (1H, d, J = 9.6 Hz, Ar-H), 
5.41‒5.37 (1H, m, H-9), 3.83 (1H, dd, J = 10.1, 2.8 Hz, H-5), 3.64 (1H, dd, J = 10.1, 5.5 Hz, H-5), 3.01 (1H, 
ddd, J = 14.2, 3.2, 3.2 Hz, H-14), 2.45‒2.30 (4H, m, H-12 + H-11 + H-8), 2.29‒2.20 (1H, m, H-14), 2.18‒
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2.03 (1H, m, H-15), 1.94‒1.82 (1H, m, H-8), 1.78 (3H, s, H-24), 1.57‒1.49 (3H, m, H-6 + H-7 + H-15), 
1.09‒1.02 (21H, m, OSiCH(CH3)2) ppm. 13C NMR (400 MHz, CDCl3):  162.1 (C=N), 145.6 (C-10), 137.5 
(Ar), 132.9 (Ar), 130.0 (Ar), 128.9 (Ar-H), 123.4 (Ar-H), 119.2 (C-9), 116.4 (Ar-H), 64.6 (C-5), 45.2 (C-6), 
44.0 (C-12), 39.8 (C-7), 31.7 (C-8), 31.5 (C-11), 28.6 (C-15), 26.5 (C-14), 23.7 (C-24), 18.0 (OSiCH(CH3)2), 
11.9 (OSiCH(CH3)2) ppm. MS (ESI): m/z 529 (M-H+); HRMS: found: (M-H+) 529.2847. C27H41N4O5Si 
requires (M-H+) 529.2852. 
Triethyl-(((8S*, 7S*)-9-methyl,15,6,7,8,11,12-hexahydronaphthalen-13-yl)oxy)silane, 202 
 
To a solution of freshly distilled diisopropylamine (0.12 mL, 0.83 mmol) in dry THF (0.80 mL) at ‒78 °C, 
was added n-BuLi (0.390 mL, 2.11 M) and the solution was stirred at ‒78 °C for 30 minutes. A solution 
of the model trans-decalin 139 (106 mg, 0.640 mmol) in dry THF (2.41 mL) was added to the LDA 
solution and stirred at ‒78 °C for 1 hour. After this time, freshly distilled TESCl (0.15 mL, 0.89 mmol) 
was added and the reaction was stirred at ‒78 °C for a further 30 minutes and then allowed to warm 
to room temperature for 30 minutes. The reaction was then quenched with water (2 mL), extracted 
with Et2O (20 mL) and the organic layer was dried with Na2SO4, filtered and concentrated in vacuo. 
The crude product was purified by silica gel flash column chromatography (100% hexane) to yield 202 
as a pale yellow oil (138 mg, 78% yield). Rf = 0.88 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 2954, 
2875, 1412, 1243, 1196 cm–1. 1H NMR (400 MHz, CDCl3):  5.45‒5.41 (1H, m, H-10), 4.81‒4.78 (1H, m, 
H-14), 2.38 (1H, ddd, J = 17.4, 4.7, 4.7 Hz, H-11), 2.17‒1.89 (5H, m, H-12 + H-6 + H-15 + H-7), 1.85‒1.73 
(3H, m, H-11 + H-8), 1.68 (3H, s, H-24), 0.68 (9H, t, J = 8.1 Hz, OSiCH2CH3), 0.52 (6H, q, J = 8.1 Hz, 
OSiCH2CH3) ppm. 13C NMR (400 MHz, CDCl3):  152.6 (C-13), 133.9 (C-9), 121.3 (C-10), 102.9 (C-14), 
41.2 (C-12), 38.1 (C-8), 37.5 (C-7), 29.3 (C-11), 29.2 (C-6), 23.7 (C-15), 23.2 (C-24), 6.4 (OSiCH2CH3), 4.4 
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(OSiCH2CH3) ppm. MS (ESI): m/z 279 (M+H+); HRMS: found: (M+H+) 279.2141. C17H31OSi requires 
(M+H+) 279.2139. 
 
(12S*, 7S*)-9-Methyl-7,8,11,12-tetrahydronaphthalen-13(4H)-one, 179 
 
Ito-Saegusa conditions 
To a solution of TES-enol trans-decalin 202 (781 mg, 2.81 mmol) in dry DMSO (14.0 mL), was added 
Pd(OAc)2 (378 mg, 1.69 mmol) and the reaction was stirred at room temperature for 1 day under an 
O2 atm. After this time, the reaction was diluted with water (10 mL) and extracted with hexane (4 × 
50 mL). The reunited organic layers were washed with brine (20 mL), dried with Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by silica gel flash column chromatography (10% 
EtOAc in hexane) to yield 179 as an orange oil (234 mg, 52% yield).  
IBX conditions 
To a solution of TES-enol trans-decalin 202 (122 mg, 0.440 mmol) in dry DMSO (7.0 mL), was added 
IBX (616 mg, 2.20 mmol) and the reaction was stirred at 40 °C for 16 hours. After this time, the reaction 
was cooled to room temperature and quenched with saturated aqueous solution of NaHCO3 (10 mL) 
and extracted with hexane (4 × 10 mL). The reunited organic layers were washed with brine (20 mL), 
dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by silica gel 
flash column chromatography (5% to 10% EtOAc in hexane) to yield 179 as an orange oil (88.0 mg, 
62% yield).  
Direct palladium oxidation conditions 
To a solution of trans-decalin 139 (100 mg, 0.610 mmol) in dry chlorobenzene (6.0 mL), were added 
Pd(OAc)2 (7.0 mg, 3.0 μmol), 4,4ʹ-tBu-2,2ʹ-dipyridyl (8.0 mg, 3.0 μmol) and KNO3 (31 mg, 0.030 mmol) 
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and the reaction was stirred at 120 °C for 7 days under an O2 atm. After this time, the solvent was 
removed in vacuo and the crude product was purified by silica gel flash column chromatography (5% 
to 10% EtOAc in hexane) to yield 179 as an orange oil (23.0 mg, 23% yield). 
Rf = 0.39 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 2923, 1668 (C=O), 1549, 1434, 1386, 1291, 1115, 
772 cm–1. 1H NMR (400 MHz, CDCl3):  6.97 (1H, ddd, J = 10.1, 6.2, 1.6 Hz, H-15), 6.05 (1H, dd, J = 10.1, 
3.2 Hz, H-14), 5.49‒5.38 (1H, m, H-10), 2.56‒2.45 (2H, m, H-6 + H-11), 2.27‒1.91 (6H, m, H-11 + H-12 
+ H-8 + H-7 + H-6), 1.67 (3H, s, H-24) ppm. 13C NMR (400 MHz, CDCl3):  201.2 (C-13), 148.8 (C-15), 
132.0 (C-9), 129.8 (C-14), 120.1 (C-10), 46.3 (C-12), 37.4 (C-8), 35.6 (C-7), 33.0 (C-6), 25.3 (C-11), 23.2 
(C-24) ppm. MS (ESI): m/z 185 (M+Na+); HRMS: found: (M+Na+) 185.0930. C11H14NaO requires (M+Na+) 
185.0937. m/z 163 (M+H+); HRMS: found: (M+H+) 163.1120. C11H15O requires (M+H+) 163.1117. 
 
(13S*, 12S*, 7S*)-9-Methyl-13,6,7,8,11,12-hexahydronaphthalen-13-ol, 224 
 
 
To a solution of enone trans-decalin 179 (47.0 mg, 0.290 mmol) in dry MeOH (3.0 mL) at 0 °C, was 
added CeCl3·7H2O (108 mg, 0.290 mmol) and stirred for 10 minutes. Solid NaBH4 (11.0 mg, 0.290 
mmol) was added and the mixture was stirred for further 10 minutes. After this time, the reaction was 
quenched with saturated aqueous solution of NH4Cl (7 mL) at 0 °C and allowed to warm to room 
temperature for 40 minutes at which time the mixture was diluted further with water (5 mL) and 
extracted with CH2Cl2 (4 × 10 mL). The combined organic layers were washed with brine (10 mL), dried 
with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by silica gel flash 
column chromatography (10% to 30% EtOAc in hexane) to yield 224 as a white solid (30.0 mg, 62% 
yield). Melting point = 73‒75°C. Rf = 0.35 (EtOAc : hexane 20% : 80%). IR (ATR): νmax 3348 (C-OH), 
2922, 1435, 1178, 1089, 1026, 959, 772 cm–1. 1H NMR (400 MHz, C6D6):  5.65 (1H, ddd, J = 10.1, 3.3, 
177 
 
1.5 Hz, H-14), 5.55 (1H, dddd, J = 10.1, 4.8, 2.0, 2.0 Hz, H-15), 5.41‒5.37 (1H, m, H-10), 3.77‒3.71 (1H, 
m, H-13), 2.64‒2.55 (1H, m, H-11), 1.97‒1.89 (1H, m, H-7), 1.81‒1.66 (2H, m, H-8), 1.57 (3H, s, H-24), 
1.52‒1.48 (2H, m, H-6), 1.39‒1.31 (2H, m, H-12 + H-11) ppm. 13C NMR (400 MHz, C6D6):  132.9 (C-9), 
132.5 (C-14), 127.7 (C-15), 121.2 (C-10), 74.7 (C-13), 42.8 (C-12), 38.3 (C-8), 33.4 (C-6), 33.2 (C-7), 31.4 
(C-11), 24.2 (C-24) ppm. MS (ESI): m/z 187 (M+Na+); HRMS: found: (M+Na+) 187.1095. C11H16NaO 
requires (M+Na+) 187.1093. 
 
(13S*, 12S*, 7S*)-9-Methyl-13,6,7,8,11,12-hexahydronaphthalen-13-yl propionate, 227 
 
To a solution of hydroxyl trans-decalin 224 (24.0 mg, 0.150 mmol) in pyridine (1.50 mL), were added 
DMAP (4.0 mg, 0.030 mmol) and propionyl chloride 216 (0.13 mL, 1.5 mmol) and the reaction was 
stirred at room temperature for 5 hours. After this time, the reaction was diluted with EtOAc (10 mL) 
and the pyridine was removed by washing with saturated aqueous solution of Cu2SO4 (3 × 10 mL). The 
organic layer was washed with water (4 × 10 mL) and brine (10 mL), dried with Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by silica gel flash column chromatography (10% 
to 30% EtOAc in hexane) to yield 227 as a pale yellow oil (20.0 mg, 61% yield). Rf = 0.82 (EtOAc : hexane 
10% : 90%). IR (ATR): νmax 2913, 2849, 1735 (C=O), 1179, 597 cm–1. 1H NMR (400 MHz, CDCl3):  5.82 
(1H, dddd, J = 10.1, 5.0, 2.0, 2.0 Hz, H-14), 5.56 (1H, dddd, J = 10.1, 3.2, 1.5, 1.5 Hz, H-15), 5.42‒5.32 
(1H, m, H-10), 5.21‒5.16 (1H, m, H-13), 2.36 (2H, q, J = 7.4 Hz, H-16), 2.31‒2.20 (2H, m, H-6), 2.09‒
2.05 (1H, m,  H-11), 1.93‒1.84 (5H, m, H-11 + H-7 + H-8 + H-12), 1.65 (3H, s, H-24), 1.16 (3H, t, J = 7.4 
Hz, H-25) ppm. 13C NMR (400 MHz, CDCl3):  174.6 (C-17), 132.7 (C-9), 129.4 (C-15), 126.8 (C-14), 119.6 
(C-10), 76.1 (C-13), 34.1 (C-12), 30.1 (C-11), 29.5 (C-6), 29.4 (C-7), 27.9 (C-8), 23.4 (C-16), 22.7 (C-25), 
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9.3 (C-24) ppm. MS (ESI): m/z 243 (M+Na+); HRMS: found: (M+Na+) 243.1365. C14H20NaO2 requires 
(M+Na+) 243.1356. 
 
(13S*, 12S*, 7S*)-9-Methyl-13,6,7,8,11,12-hexahydronaphthalen-13-yl acetate, 226 
 
To a solution of hydroxyl trans-decalin 224 (17.0 mg, 0.110 mmol) in pyridine (1.0 mL), were added 
DMAP (3.0 mg, 0.020 mmol) and acetyl chloride 225 (0.10 mL, 1.0 mmol) and the reaction was stirred 
at room temperature for 5 hours. After this time, the reaction was diluted with EtOAc (10 mL) and the 
pyridine was removed by washing with saturated aqueous solution of Cu2SO4 (3 × 10 mL). The organic 
layer was washed with water (4 × 10 mL) and brine (10 mL), dried with Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by silica gel flash column chromatography (10% 
to 30% EtOAc in hexane) to yield 226 as a pale yellow oil (17.0 mg, 76% yield). Rf = 0.80 (EtOAc : hexane 
10% : 90%). IR (ATR): νmax 2962, 2907, 2830, 1731 (C=O), 1435, 1370, 1235, 1020 cm–1. 1H NMR (400 
MHz, C6D6):  5.73 (1H, dddd, J = 10.1, 3.5, 2.0, 1.3 Hz, H-14), 5.59 (1H, dddd, J = 10.1, 5.0, 2.0, 2.0 Hz, 
H-15), 5.39‒5.33 (1H, m, H-13), 5.32‒5.29 (1H, m, H-10), 2.40‒2.33 (1H, m, H-11), 1.87 (1H, ddddd, J 
= 17.6, 5.0, 5.0, 1.7, 1.7 Hz, H-7), 1.80‒1.75 (2H, m, H-12 + H-6), 1.77 (3H, s, H-16), 1.73‒1.67 (2H, m, 
H-11 + H-8), 1.53 (3H, s, H-24), 1.51‒1.41 (2H, m, H-8 + H-6) ppm. 13C NMR (400 MHz, C6D6):  170.3 
(C-17), 132.4 (C-9), 129.2 (C-15), 127.5 (C-14), 120.0 (C-10), 76.3 (C-13), 38.8 (C-12), 37.4 (C-8), 32.9 
(C-6), 32.5 (C-7), 30.5 (C-11), 23.4 (C-24), 20.8 (C-16) ppm. MS (ESI): m/z 229 (M+Na+); HRMS: found: 
(M+Na+) 229.1204. C13H18NaO2 requires (M+Na+) 229.1199. 
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Triethyl(((12S*,7R*, 6S*)-10-methyl-6-(((triisopropylsilyl)oxy)methyl)-15,6,7,8,11,12-
hexahydronaphthalen-13-yl)oxy)silane, 203 
 
 
To a solution of freshly distilled diisopropylamine (0.200 mL, 1.42 mmol) in dry THF (1.42 mL) at ‒
78 °C, was added n-BuLi (0.72 mL, 1.97 M) and the solution was stirred at ‒78 °C for 30 minutes. A 
solution of trans-decalin 114 (414 mg, 1.18 mmol) in dry THF (4.48 mL) was added and the mixture 
was stirred at ‒78 °C for 1 hour. After this time, distilled TESCl (0.260 mL, 1.53 mmoL) was added and 
the reaction was stirred at ‒78 °C for a further 30 minutes and then allowed to warm to room 
temperature for 30 minutes. The reaction was then quenched with water (2 mL) and extracted with 
of Et2O (20 mL). The organic layer was dried with Na2SO4, filtered and concentrated in vacuo. The 
crude product was purified by silica gel flash column chromatography (100% hexane) to yield 203 as a 
colourless oil (401 mg, 79% yield). Rf = 0.91 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 2957, 1462, 
1378, 1199, 1092, 904, 649 cm–1. 1H NMR (400 MHz, CDCl3):  5.41‒5.33 (1H, m, H-9), 4.84 (1H, ddd, J 
= 5.6, 1.6, 1.6 Hz, H-14), 3.77 (1H, dd, J = 9.6, 3.4 Hz, H-5), 3.59 (1H, dd, J = 9.6, 6.1 Hz, H-5), 2.31‒2.27 
(1H, m, H-11), 2.24‒1.97 (4H, m, H-8 + H-15 + H-12), 1.80‒1.71 (2H, m, H-15 + H-11), 1.68 (3H, s, H-
24), 1.53‒1.40 (2H, m, H-7 + H-6), 1.11‒1.03 (21H, m, OSiCH(CH3)2), 0.99 (9H, t, J = 8.1 Hz, OSiCH2CH3), 
0.69 (6H, q, J = 8.1 Hz, OSiCH2CH3) ppm. 13C NMR (400 MHz, CDCl3):  151.9 (C-13), 134.1 (C-10), 120.3 
(C-9), 102.2 (C-14), 65.1 (C-5), 41.4 (C-12), 41.1 (C-6), 38.2 (C-7), 34.1 (C-11), 30.2 (C-8), 27.7 (C-15), 
23.7 (C-24), 18.1 (OSiCH(CH3)2), 11.9 (OSiCH(CH3)2), 6.8 (OSiCH2CH3), 5.1 (OSiCH2CH3) ppm. MS (ESI): 
m/z 487 (M+Na+); HRMS: found: (M+Na+) 487.3375. C27H52NaO2Si2 requires (M+Na+) 487.3398. m/z 
465 (M+H+); HRMS: found: (M+H+) 465.3579. C27H53O2Si2 requires (M+H+) 465.3578. 
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(12S*, 7R*, 6S*)-10-Methyl-6-(((triisopropylsilyl)oxy)methyl)-7,8,11,12-
tetrahydronaphthalen-13(4H)-one, 113 
 
Ito-Saegusa oxidation 
To a solution of TES-enol trans-decalin 203 (234 mg, 0.500 mmol) in dry DMSO (2.5 mL), was added 
Pd(OAc)2 (67 mg, 0.30 mmol) and the reaction was stirred at room temperature for 2 days under O2 
atm. After this time, the reaction was diluted with water (10 mL) and extracted with MTBE (3 × 30 mL). 
The combined organic layers were washed with water (2 × 20 mL) and brine (2 × 20 mL), dried with 
Na2SO4, filtered and concentrated in vacuo. The crude product was purified by silica gel flash column 
chromatography (2% to 5% EtOAc in hexane) to yield 113 as a yellow solid (82.0 mg, 47% yield). 
Direct oxidation  
To a solution of trans-decalin 114 (100 mg, 0.290 mmol) in dry chlorobenzene (3.0 mL), were added 
Pd(OAc)2 (3 mg, 0.02 mmol), 4,4ʹ-tBu-2,2ʹ-dipyridyl (4 mg, 0.02 mmol) and KNO3 (12 mg, 0.15 mmol) 
and the reaction was stirred at 120 °C for 7 days under O2 atm. After this time, the solvent was 
removed in vacuo and the crude product was purified by silica gel flash column chromatography (5% 
to 10% EtOAc in hexane) to yield 113 as a yellow solid (20 mg, 20% yield). 
IBX oxidation 
To a solution of TES-enol trans-decalin 203 (401 mg, 0.860 mmol) in dry DMSO (7.2 mL), was added 
IBX (605 mg, 2.16 mmol) and the reaction was stirred at 40 °C for 2 days. After this time, the reaction 
was cooled to room temperature and quenched with saturated aqueous solution of NaHCO3 (5 mL) 
and extracted with MTBE (5 × 30 mL). The combined organic layers were washed with water (2 × 20 
mL) and brine (2 × 20 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product 
was purified by silica gel flash column chromatography (2% to 5% EtOAc in hexane) to yield 113 as a 
yellow solid (188 mg, 63% yield). Melting point = 48‒50 °C. Rf = 0.56 (EtOAc : hexane 10% : 90%). IR 
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(ATR): νmax 2942, 2891, 2865, 1671 (C=O), 1462, 1112, 1068, 731 cm–1. 1H NMR (400 MHz, CDCl3):  
7.09 (1H, dd, J = 10.2, 1.8 Hz, H-15), 6.09 (1H, dd, J = 10.2, 2.8 Hz, H-14), 5.37‒5.34 (1H, m, H-9), 3.98 
(1H, dd, J = 9.8, 4.1 Hz, H-5), 3.66 (1H, dd, J = 9.8, 7.1 Hz, H-5), 2.47‒2.30 (4H, m, H-11 + H-6 + H-12), 
2.09‒1.84 (3H, m, H-7 + H-8), 1.71 (3H, s, H-24), 1.13‒1.01 (21H, m, OSiCH(CH3)2) ppm. 13C NMR (400 
MHz, CDCl3):  201.2 (C-13), 152.1 (C-15), 133.2 (C-10), 129.1 (C-14), 118.7 (C-9), 63.7 (C-5), 45.9 (C-
12), 45.8 (C-6), 36.1 (C-7), 31.0 (C-8), 30.1 (C-11), 23.4 (C-24), 17.9 (OSiCH(CH3)2), 11.9 (OSiCH(CH3)2) 
pm. MS (ESI): m/z 371 (M+Na+); HRMS: found: (M+Na+) 371.2356. C21H36NaO2Si requires (M+Na+) 
371.2377. m/z 349 (M+H+); HRMS: found: (M+H+) 349.2538. C21H37O2Si requires (M+H+) 349.2557. 
Tsuji Trost conditions 
To a solution of Pd(OAc)2 (1.0 mg, 2.0 μmol) and PPh3 (1.0 mg, 3.0 μmol) in dry THF (0.20 mL), was 
added a solution of acetate trans-decalin 236 (11 mg, 0.030 mmol) in dry THF (0.20 mL) and the 
reaction was stirred at room temperature for 10 minutes. After this time, a pre-cooled solution at 0 
°C of dimethylmalonate (4 μL, 0.04 mmoL) and NaH (60% dispersion in mineral oil, 6.0 mg, 0.10 mmoL) 
in dry THF (0.20 mL) was added and the reaction was stirred at 60 °C for 16 hours. The reaction was 
cooled to room temperature and diluted with Et2O (10 mL), washed with water (2 × 10 mL) and brine 
(10 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by 
silica gel flash column chromatography (3% to 20% EtOAc in hexanes) to yield 113 as a yellow solid 
(4.0 mg, 38% yield) and 232 as a pale yellow oil (3.0 mg, 29% yield). 
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(13S*, 12S*, 7R*, 6S*)-10-Methyl-6-(((triisopropylsilyl)oxy)methyl)-13,6,7,8,11,12- 
hexahydronaphthalen-13-ol, 232 
 
(13R*, 12S*, 6S*, 7R*)-10-Methyl-6-(((triisopropylsilyl)oxy)methyl)-13,6,7,8,11,12-
hexahydronaphthalen-13-ol, 215 
 
 
 
To a solution of enone trans-decalin 113 (30 mg, 0.090 mmol) in dry THF (0.90 mL) at ‒78 °C, was 
added a 1.0 M solution of Dibal-H in toluene (0.09 mL, 0.09 mmol) and the reaction was stirred at ‒78 
°C for 30 minutes. After this time, the reaction was quenched with acetone (1.20 mL) at ‒78 °C, 
warmed to room temperature and then Rochelle’s salt 10% aqueous solution (10 mL) was added and 
stirred for 16 hours. The mixture was diluted with water (5 mL), extracted with EtOAc (4 × 10 mL) and 
the combined organic layers were washed with brine (10 mL), dried with Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by silica gel flash column chromatography (10% 
to 30% EtOAc in hexane) to yield 232 as a pale yellow oil (25.0 mg, 79% yield) and 215 as a pale yellow 
oil (5.0 mg, 16% yield). (13S*, 12S*, 7R*, 6S*)-10-Methyl-6-(((triisopropylsilyl)oxy)methyl)-
13,6,7,8,11,12-hexahydronaphthalen-13-ol, 232; Rf = 0.41 (EtOAc : hexane 20% : 80%). IR (ATR): νmax 
3318 (C-OH), 2941, 2863, 1462, 1390, 1114, 1091, 881 cm–1. 1H NMR (400 MHz, CDCl3):  5.84 (1H, 
ddd, J = 10.1, 2.3, 2.3 Hz, H-14), 5.72 (1H, ddd, J = 10.1, 2.3, 2.3 Hz, H-15), 5.39‒5.34 (1H, m, H-9), 
3.91‒3.87 (1H, m, H-13), 3.81 (1H, dd, J = 9.6, 4.1 Hz, H-5), 3.51 (1H, dd, J = 9.6, 7.3 Hz, H-5), 2.45 (1H, 
dd, J = 15.1, 5.5 Hz, H-11), 2.40‒2.31 (1H, m, H-8), 2.08‒1.99 (1H, m, H-6), 1.86‒1.75 (2H, m, H-11 + H-
8), 1.68 (3H, s, H-24), 1.52‒1.45 (1H, m, H-12), 1.43‒1.37 (1H, m, H-7), 1.14‒0.99 (21H, m, OSiCH(CH3)2) 
ppm. 13C NMR (400 MHz, CDCl3):  132.7 (C-10), 130.8 (C-14), 130.6 (C-15), 119.8 (C-9), 73.9 (C-13), 
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65.6 (C-5), 45.9 (C-6), 42.3 (C-12), 34.9 (C-11), 33.3 (C-7), 31.3 (C-8), 23.4 (C-24), 18.0 (OSiCH(CH3)2), 
11.9 (OSiCH(CH3)2) ppm. MS (ESI): m/z 373 (M+Na+); HRMS: found: (M+Na+) 373.2517. C21H38NaO2Si 
requires (M+Na+) 373.2533. m/z 351 (M+H+); HRMS: found: (M+H+) 351.2677. C21H39O2Si requires 
(M+H+) 351.2714.  (13R*, 12S*, 6S*, 7R*)-10-Methyl-6-(((triisopropylsilyl)oxy)methyl)-13,6,7,8,11,12-
hexahydronaphthalen-13-ol, 215; Rf = 0.38 (EtOAc : hexane 20% : 80%). IR (ATR): νmax 3386 (C-OH), 
2922, 2864, 1462, 1379, 1093, 1013, 930 cm–1. 1H NMR (500 MHz, C6D6):  6.04 (1H, ddd, J = 9.7, 5.6, 
2.4 Hz, H-14), 5.94 (1H, dd, J = 9.7, 2.4 Hz, H-15), 5.43‒5.37 (1H, m, H-9), 3.78‒3.72 (1H, m, H-13), 3.68 
(1H, dd, J = 9.4, 3.9 Hz, H-5), 3.49 (1H, dd, J = 9.4, 6.7 Hz, H-5), 2.62‒2.53 (1H, m, H-11), 2.41‒2.32 (1H, 
m, H-8), 1.89‒1.82 (1H, m, H-6), 1.72‒1.69 (3H, m, H-11 + H-7 + H-8), 1.68 (3H, s, H-24), 1.62‒1.58 (1H, 
m, H-12), 1.12‒1.02 (21H, m, OSiCH(CH3)2) ppm. 13C NMR (500 MHz, C6D6):  133.8 (C-10), 132.9 (C-
14), 130.1 (C-15), 119.3 (C-9), 65.8 (C-13), 64.9 (C-5), 46.9 (C-6), 38.9 (C-12), 32.4 (C-8), 32.1 (C-11), 
28.6 (C-7), 23.8 (C-24), 18.2 (OSiCH(CH3)2), 12.3 (OSiCH(CH3)2) ppm. MS (ESI): m/z 373 (M+Na+); HRMS: 
(ESI): m/z (M+Na+) 373.2518, C21H38NaO2Si requires (M+Na+) 373.2533. 
 
(13S*, 12S*, 7R*, 6S*)-10-Methyl-6-(((triisopropylsilyl)oxy)methyl)-13,6,7,8,11,12-
hexahydronaphthalen-13-yl acetate, 238 
 
 
To a solution of hydroxyl trans-decalin 232 (25 mg, 0.080 mmol) in pyridine (1.0 mL), were added 
DMAP (2 mg, 0.01 mmol) and acetyl chloride 225 (0.050 mL, 0.80 mmol) and the reaction was stirred 
at room temperature for 5 hours. After this time, the mixture was diluted with EtOAc (20 mL), washed 
with saturated aqueous solution of Cu2SO4 (3 × 10 mL), water (2 × 10 mL) and brine (2 × 10 mL), dried 
with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by silica gel flash 
column chromatography (10% to 30% EtOAc in hexanes) to yield 238 as a pale yellow oil (18.0 mg, 
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58% yield). Rf = 0.83 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 2942, 2922, 2865, 1728 (C=O), 1462, 
1368, 1238, 732 cm–1. 1H NMR (400 MHz, CDCl3):  5.91 (1H, ddd, J = 10.1, 2.3, 2.3 Hz, H-14), 5.62 (1H, 
ddd, J = 10.1, 2.3, 2.3 Hz, H-15), 5.43‒5.37 (1H, m, H-9), 5.19‒5.11 (1H, m, H-13), 3.81 (1H, dd, J = 9.6, 
4.6 Hz, H-5), 3.52 (1H, dd, J = 9.6, 7.3 Hz, H-5), 2.39 (1H, ddd, J = 16.9, 6.0, 6.0 Hz, H-8), 2.20‒2.13 (1H, 
m, H-11), 2.11 (3H, s, H-16), 2.05 (1H, ddddd, J = 9.6, 7.3, 4.6, 2.3, 2.3 Hz, H-6), 1.80‒1.78 (3H, m, H-11 
+ H-8 + H-12), 1.65 (3H, s, H-24), 1.55 (1H, dddd, J = 12.4, 9.6, 9.6, 6.0 Hz, H-7), 1.13‒0.99 (21H, m, 
OSiCH(CH3)2) ppm. 13C NMR (400 MHz, CDCl3):  171.2 (C-17), 132.4 (C-10), 132.2 (C-14), 126.6 (C-15), 
119.3 (C-9), 76.1 (C-13), 65.5 (C-5), 45.7 (C-6), 38.6 (C-12), 34.6 (C-11), 33.3 (C-7), 31.2 (C-8), 23.3 (C-
24), 21.3 (C-16), 18.0 (OSiCH(CH3)2), 11.9 (OSiCH(CH3)2) ppm. MS (ESI): m/z 415 (M+Na+); HRMS: found: 
(M+Na+) 415.2642. C23H40NaO3Si requires (M+Na+) 415.2639. m/z 393 (M+H+); HRMS: found: (M+H+) 
393.2884. C23H41O3Si requires (M+H+) 393.2819. 
 
(13R*, 12S*, 7R*, 6S*)-10-Methyl-6-(((triisopropylsilyl)oxy)methyl)-13,6,7,8,11,12-
hexahydronaphthalen-13-yl propionate, 112 
 
 
To a solution of hydroxyl trans-decalin 215 (8.0 mg, 0.023 mmol) in pyridine (1.0 mL), were added 
DMAP (1.0 mg, 0.050 mmol) and propionyl chloride 216 (0.05 mL, 0.23 mmol) and the reaction was 
stirred at room temperature for 5 hours. After this time, the mixture was diluted with EtOAc (20 mL), 
washed with saturated aqueous solution of Cu2SO4 (3 × 10 mL), water (2 × 10 mL) and brine (2 × 10 
mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by silica 
gel flash column chromatography (10% to 30% EtOAc in hexanes) to yield 112 as a pale yellow oil (5.0 
mg, 62% yield).  Rf = 0.83 (EtOAc : hexane 10 % : 90%). IR (ATR): νmax 2941, 2865, 1724 (C=O), 1462, 
1189, 1066, 907, 731 cm–1. 1H NMR (400 MHz, CDCl3):  6.08 (1H, dd, J = 10.1, 2.4 Hz, H-14), 5.95 (1H, 
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ddd, J = 10.1, 5.0, 2.4 Hz, H-15), 5.39‒5.33 (1H, m, H-9), 5.17‒5.13 (1H, m, H-13), 3.85 (1H, dd, J = 9.5, 
4.4 Hz, H-5), 3.58 (1H, dd, J = 9.5, 7.4 Hz, H-5), 2.46‒2.39 (1H, m, H-8), 2.31 (2H, q, J = 7.6 Hz, H-16), 
1.99‒1.97 (2H, m, H-8 + H-11), 1.83‒1.80 (3H, m, H-11 + H-12 + H-6), 1.79‒1.70 (1H, m, H-7), 1.67 (3H, 
s, H-24), 1.14 (3H, t, J = 7.6 Hz, H-25), 1.08‒1.05 (21H, m, OSiCH(CH3)2) ppm. 13C NMR (400 MHz, CDCl3): 
 174.3 (C-17), 135.3 (C-10), 132.9 (C-14), 124.5 (C-15), 119.3 (C-9), 67.9 (C-13), 65.5 (C-5), 46.8 (C-6), 
36.7 (C-12), 31.9 (C-8), 31.3 (C-11), 29.0 (C-7), 27.8 (C-16), 23.5 (C-24), 18.0 (OSiCH(CH3)2), 11.9 
(OSiCH(CH3)2), 9.2 (C-25) ppm. MS (ESI): m/z 429 (M+Na+); HRMS: found: (M+Na+) 429.2788. 
C24H42NaO3Si requires (M+Na+) 429.2795. 
 
(15S*, 6R*)-15-Allyl-6-(((triisopropylsilyl)oxy)methyl)cyclohexanone, 183 
 
To a solution of enone 115 (50 mg, 0.18 mmol) in dry CH2Cl2 (1.8 mL) at ‒78 °C, was added TiCl4 (0.030 
mL, 0.25 mmol) and the orange solution was stirred for 5 minutes. Allyltrimethylsilane 250 (0.030 mL, 
0.24 mmol) was added and the reaction was stirred at ‒78 °C for a further 30 minutes. After this time, 
saturated aqueous solution of NaHCO3 (8 mL) was added at ‒78 °C and then allowed to warm to room 
temperature for 30 minutes. The aqueous phase was then extracted with CH2Cl2 (3 × 10 mL) and the 
combined organic layers were washed with saturated aqueous solution of NaHCO3 (10 mL) and brine 
(10 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by 
silica gel flash column chromatography (3% to 10% EtOAc in hexanes) to yield 183 as a pale yellow oil 
(34.0 mg, 59% yield). Rf = 0.52 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 2941, 2864, 1714 (C=O), 
1462, 1382, 1246, 1109, 1066 cm–1. 1H NMR (400 MHz, CDCl3):  5.72 (1H, dddd, J = 16.5, 10.6, 8.2, 5.5 
Hz, H-17), 5.08‒5.05 (1H, m, H-18), 5.04‒5.01 (1H, m,H-18),  3.86‒3.74 (2H, m, H-5), 2.48‒2.39 (2H, 
m, H-14), 2.37‒2.30 (3H, m, H-12 + H-7), 2.19‒2.16 (2H, m, H-6 + H-16), 1.88‒1.78 (3H, m, H-16 + H-
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15 + H-7), 1.09‒1.03 (21H, m, OSiCH(CH3)2) ppm. 13C NMR (400 MHz, CDCl3):  212.2 (C-13), 136.2 (C-
17), 116.9 (C-18), 63.3 (C-5), 44.7 (C-14), 40.6 (C-6), 39.6 (C-12), 37.9 (C-15), 33.6 (C-16), 25.4 (C-7), 
18.0 (OSiCH(CH3)2), 11.9 (OSiCH(CH3)2) ppm. MS (ESI): m/z 347 (M+Na+); HRMS: found: (M+Na+) 
347.2380. C19H36NaO2Si requires (M+Na+) 347.2377. m/z 325 (M+H+); HRMS: found: (M+H+) 325.2560. 
C19H37O2Si requires (M+H+) 325.2557. 
 
(15S*, 6R*)-15-Allyl-6-hydroxymethyl-cyclohexanone, 263 
 
 
In a plastic vial, to a solution of allyl-cyclohexanone 183 (30 mg, 0.090 mmol) in dry pyridine (0.90 mL), 
was added hydrogen fluoride 70% in pyridine (0.070 mL, 3.6 mmol) and the reaction was stirred at 
room temperature for 24 hours. After this time, the reaction was quenched with saturated aqueous 
solution of NaHCO3 and extracted with EtOAc (4 × 20 mL). The combined organic layers were washed 
with 2 M HCl (2 × 10 mL) and brine (10 mL), dried with Na2SO4, filtered and concentrated in vacuo. The 
crude product was purified by silica gel flash column chromatography (20% to 50% EtOAc in hexanes) 
to yield 263 as a pale yellow oil (13.0 mg, 98% yield). Rf = 0.25 (EtOAc : hexane 20% : 80%). IR (ATR): 
νmax 3405 (C-OH), 2923, 1702 (C=O), 1035, 913, 597 cm–1. 1H NMR (400 MHz, CDCl3):  5.73 (1H, dddd, 
J = 16.5, 10.6, 8.2, 5.5 Hz, H-17), 5.11‒5.06 (1H, m, H-18), 5.06‒5.02 (1H, m, H-18), 3.76 (1H, dd, J = 
10.6, 6.9 Hz, H-5), 3.71 (1H, dd, J = 10.6, 7.1 Hz, H-5), 2.47‒2.35 (3H, m, H-14 + H-12), 2.34‒2.23 (2H, 
m, H-12 + H-15), 2.23‒2.13 (2H, m, H-16 + H-6), 1.94‒1.78 (3H, m, H-7 + H-16) ppm. 13C NMR (400 
MHz, CDCl3):  211.9 (C-13), 136.2 (C-17), 117.3 (C-18), 62.9 (C-5), 44.9 (C-14), 40.6 (C-6), 39.6 (C-12), 
30.1 (C-15), 33.8 (C-16), 25.4 (C-7) ppm. MS (APCI): m/z 169 (M+H+); HRMS: found: (M+H+) 169.1226. 
C10H17O2 requires (M+H+) 169.1223. 
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(17R*, 15S*,6R*)-15-Iodomethyl-octahydro-isochromen-13-one, 264 
 
(17S*, 15S*,6R*)-15-Iodomethyl-octahydro-isochromen-13-one, 265 
 
 
To a solution of allyl-hydroxyl-cyclohexanone 263 (13 mg, 0.090 mmol) in dry CH3CN (0.90 mL) at 0 °C, 
were added iodine (28 mg, 0.11 mmol) and solid NaHCO3 (15 mg, 0.18 mmol) and the reaction was 
stirred at room temperature for 16 hours. After this time, the reaction was quenched with saturated 
aqueous solution of Na2SO3 (2 mL) and extracted with EtOAc (5 × 20 mL). The combined organic layers 
were washed with 2 M HCl (10 mL) and brine (10 mL), dried with Na2SO4, filtered and concentrated in 
vacuo. The crude product was purified by silica gel flash column chromatography (20% to 40% EtOAc 
in hexanes) to yield 264 as a white solid (14.0 mg, 54% yield) and 265 as a pale yellow oil (8.0 mg, 31% 
yield).120 (17R*, 15S*,6R*)-15-Iodomethyl-octahydro-isochromen-13-one, 264; Crystallized using a 
solvent/antisolvent system: EtOAc/hexane. Rf = 0.44 (EtOAc : hexane 20% : 80%). Melting point = 57‒
59 °C. IR (ATR): νmax 2925, 2853, 1709 (C=O), 1463, 1376, 1108, 1095, 904 cm–1. 1H NMR (500 MHz, 
CDCl3):  3.92 (1H, dd, J = 11.4, 0.6 Hz, H-5), 3.72 (1H, dd, J = 11.4, 2.6 Hz, H-5), 3.30 (1H, dddd, J = 
11.2, 6.3, 4.4, 2.1 Hz, H-17), 3.22 (1H, dd, J = 10.6, 4.4 Hz, H-18), 3.17 (1H, dd, J = 10.6, 6.3 Hz, H-18), 
2.66 (1H, dd, J = 14.3, 6.3 Hz, H-14), 2.46‒2.38 (3H, m, H-16 + H-12), 2.35‒2.21 (3H, m, H-16 + H-15 + 
H-7), 2.18 (1H, ddd, J = 14.3, 1.6, 1.6 Hz, H-14), 2.03‒1.96 (2H, m, H-6 + H-7) ppm. 13C NMR (500 MHz, 
CDCl3):  210.7 (C-13), 76.9 (C-17), 71.6 (C-5), 46.6 (C-14), 40.5 (C-12), 36.4 (C-6), 34.5 (C-15), 32.8 (C-
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16), 25.1 (C-7), 9.1 (C-18) ppm. MS (APCI): m/z 295 (M+H+); HRMS: found: (M+H+) 295.0188. C10H16IO2 
requires (M+H+) 295.0189. (17S*, 15S*,6R*)-15-Iodomethyl-octahydro-isochromen-13-one, 265; Rf = 
0.41 (EtOAc : hexane 20% : 80%). IR (ATR): νmax 2922, 2852, 1711 (C=O), 1459, 1081 cm–1. 1H NMR (500 
MHz, CDCl3):  4.06 (1H, dd, J = 11.6, 3.7 Hz, H-5), 3.75 (1H, dd, J = 11.6, 4.7 Hz, H-5), 3.65‒2.59 (1H, 
m, H-17), 3.25‒3.19 (2H, m, H-18), 2.52‒2.37 (5H, m, H-14 + H-6 + H-12), 2.29‒2.25 (3H, m, H-16 + H-
15), 1.94‒1.88 (2H, m, H-7) ppm. 13C NMR (500 MHz, CDCl3):  209.6 (C-13), 76.1 (C-17), 66.3 (C-5), 
48.6 (C-14), 42.3 (C-6), 40.8 (C-12), 38.6 (C-15), 31.9 (C-16), 26.5 (C-7), 8.9 (C-18) ppm. MS (APCI): m/z 
295 (M+H+); HRMS: found: (M+H+) 295.0186. C10H16IO2 requires (M+H+) 295.0189. 
 
(15S*, 12S*, 7R*, 6S*)-15-Allyl-10-methyl-6-(((triisopropylsilyl)oxy)methyl)-15,6,7,8,11,12- 
hexahydronaphthalen-13(2H)-one, 266 
 
(15R*, 12S*, 7R*, 6S*)-15-Allyl-10-methyl-6-(((triisopropylsilyl)oxy)methyl)-15,6,7,8,11,12-
hexahydronaphthalen-13(2H)-one, 267 
 
 
To a solution of enone trans-decalin 113 (40 mg, 0.12 mmol) in dry CH2Cl2 (1.2 mL) at ‒78 °C, was 
added TiCl4 (0.020 mL, 0.14 mmol). After 5 minutes allyltrimethylsilane 250 (0.020 mL, 0.13 mmol) 
was also added and the reaction was stirred at ‒78 °C for 30 minutes. After this time, saturated 
aqueous solution of NaHCO3 (4.5 mL) was added at ‒78 °C, stirred for 45 minutes and then allowed to 
warm to room temperature for 30 minutes. The aqueous phase was then extracted with CH2Cl2 (3 × 
10 mL) and the combined organic layers were washed with saturated aqueous solution of NaHCO3 (10 
mL) and brine (10 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product was 
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purified by silica gel flash column chromatography (3% to 10% EtOAc in hexanes) to yield 266 as a pale 
yellow oil (25.0 mg, 61% yield) and 267 as a pale yellow oil (3.0 mg, 7% yield).  (15S*, 12S*, 7R*, 6S*)-
15-Allyl-10-methyl-6-(((triisopropylsilyl)oxy)methyl)-15,6,7,8,11,12-hexahydronaphthalen-13(2H)-
one, 266; Rf = 0.52 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 2921, 2864, 1710 (C=O), 1462, 1331, 
1118, 1097, 881 cm–1. 1H NMR (400 MHz, CDCl3):  5.72 (1H, dddd, J = 16.5, 10.6, 8.2, 5.5 Hz, H-17), 
5.14‒5.12 (1H, m, H-9), 5.07‒5.01 (2H, m, H-18), 3.76 (1H, dd, J = 9.9, 1.4 Hz, H-5), 3.62 (1H, dd, J = 
9.9, 9.9 Hz, H-5), 2.60‒2.51 (2H, m, H-15 + H-14), 2.45‒2.40 (1H, m, H-14), 2.32‒2.23 (2H, m, H-12 + 
H-16), 2.18‒2.12 (2H, m, H-8 + H-11), 2.10‒1.99 (2H, m, H-6 + H-11), 1.94‒1.84 (1H, m, H-8), 1.68 (3H, 
s, H-24), 1.65‒1.56 (2H, m, H-16 + H-7), 1.10‒1.02 (21H, m, OSiCH(CH3)2) ppm. 13C NMR (400 MHz, 
CDCl3):  212.2 (C-13), 136.5 (C-17), 133.2 (C-10), 119.1 (C-9), 116.9 (C-18), 62.6 (C-5), 49.7 (C-12), 47.3 
(C-6), 44.7 (C-14), 36.9 (C-15), 36.8 (C-7), 31.8 (C-16), 31.9 (C-8), 29.4 (C-11), 23.4 (C-24), 18.1 
(OSiCH(CH3)2), 11.9 (OSiCH(CH3)2) ppm. MS (ESI): m/z 413 (M+Na+); HRMS: found: (M+Na+) 413.2830. 
C24H42NaO2Si requires (M+Na+) 413.2846. m/z 391 (M+H+); HRMS: found: (M+H+) 391.3033. C24H43O2Si 
requires (M+H+) 391.3027. (15R*, 12S*, 7R*, 6S*)-15-Allyl-10-methyl-6-
(((triisopropylsilyl)oxy)methyl)-15,6,7,8,11,12-hexahydronaphthalen-13(2H)-one, 267; Rf = 0.54 
(EtOAc : hexane 10% : 90%). IR (ATR): νmax 2923, 2865, 1712 (C=O), 1462, 1247, 1097, 873, 685 cm–1. 
1H NMR (500 MHz, CDCl3):  5.77 (1H, dddd, J = 16.5, 10.6, 8.2, 5.5 Hz, H-17), 5.34‒5.32 (1H, m, H-9), 
4.99‒4.97 (2H, m, H-18), 3.85 (1H, dd, J = 9.2, 4.9 Hz, H-5), 3.60 (1H, dd, J = 9.2, 9.2 Hz, H-5), 2.65‒2.60 
(1H, m, H-15), 2.53 (1H, dd, J = 13.2, 3.2 Hz, H-14), 2.45 (1H, dd, J = 13.2, 5.8 Hz, H-14), 2.28‒2.15 (3H, 
m, H-16 + H-12 + H-8), 2.12‒2.05 (2H, m, H-11), 1.93‒1.81 (1H, m, H-6), 1.86‒1.80 (1H, m, H-8), 1.75‒
1.70 (1H, m, H-16), 1.68 (3H, s, H-24), 1.66‒1.58 (1H, m, H-7), 1.10‒1.05 (21H, m, OSiCH(CH3)2) ppm. 
13C NMR (500 MHz, CDCl3):  212.2 (C-13), 137.0 (C-17), 133.2 (C-10), 119.3 (C-9), 116.1 (C-18), 62.6 
(C-5), 49.7 (C-12), 48.1 (C-6), 45.1 (C-14), 39.8 (C-16), 37.2 (C-7), 34.2 (C-15), 33.7 (C-8), 32.1 (C-11), 
29.7 (C-24), 18.1 (OSiCH(CH3)2), 11.9 (OSiCH(CH3)2) ppm. MS (ESI): m/z 413 (M+Na+); HRMS: found: 
(M+Na+) 413.2842. C24H42NaO2Si requires (M+Na+) 413.2846.  
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13-((15S*, 12S*, 7S*, 6S*)-15-Allyl-10-methyl-6-(((triisopropylsilyl)oxy)methyl)-15,6,7,8,11,12-
hexahydronaphthalen-13(2H)-ylidene)-14-(2,4-dinitrophenyl)hydrazine, 268 
 
 
To a solution of allyl-trans-decalin 266 (10 mg, 0.030 mmol) in dry MeOH (1.0 mL) and 3Å molecular 
sieves, were added 2,4-dinitrophenyl hydrazine 140 (12 mg, 0.060 mmol) and glacial acetic (0.50 mL) 
and the reaction was stirred at 50 °C with for 16 hours. After this time, the reaction was cooled to 
room temperature and quenched with saturated aqueous solution of NaHCO3 (20 mL) and extracted 
with CH2Cl2 (3 × 20 mL). The combined organic layers were washed with brine (10 mL), dried with 
Na2SO4, filtered and concentrated in vacuo. The crude product was purified by silica gel flash column 
chromatography (3% to 10% EtOAc in hexanes) to yield 268 as an orange solid (4.0 mg, 24% yield). 
Crystallization method: slow evaporation of CH2Cl2 from a solution of 268 in CH2Cl2. Melting point = 
135‒137 °C. Rf = 0.58 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 2923, 1617 (C=N), 1334, 1099 cm–1. 
1H NMR (500 MHz, CDCl3):  11.23 (1H, s, N-H), 9.15 (1H, d, J = 2.6 Hz, Ar-H), 8.33 (1H, d, J = 9.6, 2.6 
Hz, Ar-H), 8.00 (1H, d, J = 9.6 Hz, Ar-H), 5.82‒5.72 (1H, m, H-17), 5.41‒5.38 (1H, m , H-9), 5.07‒4.87 
(2H, m, H-18), 3.91 (1H, dd, J = 9.7, 5.5 Hz, H-5), 3.61 (1H, dd, J = 9.7, 9.7 Hz, H-5), 3.01 (1H, dd, J = 
14.8, 3.8 Hz, H-14), 2.61‒2.52 (1H, m, H-15), 2.46‒2.41 (1H, m, H-12), 2.39‒2.33 (3H, m, H-16 + H-14 
+ H-11), 2.27‒2.26 (2H, m, H-8), 1.91‒1.88 (2H, m, H-6 + H-11), 1.77 (3H, s, H-24), 1.71‒1.58 (2H, m, 
H-16 + H-7), 1.13‒1.02 (21H, m, OSiCH(CH3)2) ppm. 13C NMR (500 MHz, CDCl3):  160.9 (C=N), 145.4 
(Ar), 137.5 (C-17), 137.3 (C-10), 133.3 (Ar), 129.9 (Ar), 128.8 (Ar-H), 123.7 (C-9), 119.2 (Ar-H), 117.3 
(Ar-H), 116.3 (C-18), 62.7 (C-5), 47.5 (C-6), 44.2 (C-12), 37.1 (C-8), 35.9 (C-15), 32.2 (C-7), 31.6 (C-16), 
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30.7 (C-11), 29.7(C-14), 23.6 (C-24), 18.1 (OSiCH(CH3)2), 11.9 (OSiCH(CH3)2) ppm. MS (ESI): m/z 569 (M-
H+); HRMS: found: (M-H+) 569.3209. C30H45N4O5Si requires (M-H+) 569.3165.  
 
(15S*, 12S*, 7R*, 6S*)-15-Allyl-6-(hydroxymethyl)-10-methyl-15,6,7,8,11,12-hexahydronaphthalen-
13(2H)-one, 269 
 
 
In a plastic vial, to a solution of allyl-trans-decalin 266 (20 mg, 0.050 mmol) in pyridine (1.0 mL), was 
added hydrogen fluoride 70% in pyridine (0.200 mL, 1.47 mmol) and the reaction was stirred at room 
temperature for 16 hours. After this time, the reaction was quenched with saturated aqueous solution 
of NaHCO3 (10 mL) and extracted with EtOAc (3 × 20 mL). The combined organic layers were washed 
with 2 M HCl (20 mL) and brine (10 mL), dried with Na2SO4, filtered and concentrated in vacuo. The 
crude product was purified by silica gel flash column chromatography (10% to 40% EtOAc in hexanes) 
to yield 269 as a pale yellow oil (10.0 mg, 85% yield). Rf = 0.28 (EtOAc : hexane 20% : 80%). IR (ATR): 
νmax 3417 (C-OH), 2919, 2852, 1704 (C=O), 1436, 1376, 1027, 911 cm–1. 1H NMR (500 MHz, CDCl3):  
5.80‒5.71 (1H, m, H-17), 5.36‒5.31 (1H, m, H-9), 5.10‒5.01 (2H, m, H-18), 3.90 (1H, dd, J = 10.8, 4.9 
Hz, H-5), 3.65 (1H, dd, J = 10.8, 9.2 Hz, H-5), 2.56 (1H, dd, J = 12.8, 2.7 Hz, H-14), 2.53‒2.43 (3H, m, H-
15 + H-14 + H-16), 2.39‒2.13 (5H, m, H-12 + H-6 + H-8 + H-11 + H-16), 2.12‒2.04 (2H, m, H-7 + H-11), 
2.00‒1.87 (1H, m, H-8), 1.71‒1.65 (3H, s, H-24) ppm. 13C NMR (500 MHz, CDCl3):  211.7 (C-13), 136.4 
(C-17), 133.2 (C-10), 119.1 (C-9), 117.2 (C-18), 62.3 (C-5), 49.8 (C-12), 47.1 (C-6), 45.0 (C-14), 37.1 (C-
15), 37.1 (C-7), 31.8 (C-11), 29.7 (C-16), 29.4 (C-8), 23.4 (C-24) ppm. MS (ESI): m/z 257 (M+Na+); HRMS: 
found: (M+Na+) 257.1503. C15H22NaO2 requires (M+Na+) 257.1512. m/z 235 (M+H+); HRMS: found: 
(M+H+) 235.1672. C15H23O2 requires (M+H+) 235.1693.  
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But-2-yn-1-yltrimethylsilane, 271123 
 
To a suspension of magnesium (290 mg, 11.9 mmol) in dry Et2O (2.71 mL), was added 
mercurydichloride (40 mg, 0.15 mmol) and stirred for 30 minutes. The grey mixture was cooled to 0 
°C and a solution of 1-bromo-2-butyne 273 (0.50 mL, 5.9 mmol) in dry Et2O (5.50 mL) was added over 
10 minutes. The resulting mixture was stirred at room temperature for 30 minutes and then re-cooled 
to 0 °C before the addition of TMSCl (0.75 mL, 5.9 mmol). The resulting reaction was stirred vigorously 
at room temperature for 16 hours. The reaction was then filtrated through celite with Et2O (10 mL) 
and the filtrate was distilled at atmospheric pressure (80‒90 °C) to yield the desired compound 271 
as a colourless liquid (50.0 mg, 6% yield). 123 1H NMR (400 MHz, CDCl3):  1.78 (3H, t, J = 2.8 Hz), 1.40 
(2H, q, J = 2.8 Hz), 0.08 (9H, s, Si(CH3)3) ppm. 13C NMR (400 MHz, CDCl3):  76.7 (CH), 74.1 (CH), 7.2 
(CH3), 3.9 (CH2), 1.8 (Si(CH3)3) ppm. This compound was characterized only by 1H NMR due to its 
volatilty and instability, and the data matched the literature.123 
 
9-methyl-15,6-dihydronaphthalen-13(2H)-one, 20794 
 
To a solution of freshly distilled diisopropylamine (0.150 mL, 1.09 mmol) in dry THF (1.09 mL) at ‒78 
°C, was added n-BuLi (0.510 mL, 2.15 M) and the resulting solution was stirred at ‒78 °C for 30 minutes. 
At this time, a solution of model trans-decalin 139 (89 mg, 0.54 mmol) in dry THF (1.61 mL) was 
introduced and the resulting solution was stirred for 1 hour at ‒78 °C. Freshly distilled TMSCl (0.210 
mL, 1.62 mmol) was added and the reaction was stirred at ‒78 °C for a further 30 minutes and then 
allowed to warm to room temperature for 1 hour. The reaction was cooled to 0 °C and NBS 
(recriystallised, 125 mg, 0.710 mmol) was added as a solid, and the resulting reaction was stirred at 0 
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°C for 3 hours. The reaction was allowed to warm to room temperature and DBU (0.81 mL, 5.40 mmol) 
was added and the reaction was stirred at 50 °C for 16 hours. A solution of 2 M HCl (10 mL) was added 
and stirred for 2 hours and then the mixture was washed with saturated aqueous solution of NaHCO3 
(3 × 10 mL) and brine (20 mL) dried with Na2SO4, filtered and concentrated in vacuo. The crude product 
was purified by silica gel flash column chromatography (5% to 10% EtOAc in hexanes) to yield 207 as 
a pale yellow oil (11.0 mg, 14% yield).91  
IBX oxidations 
To a solution of IBX (207 mg, 0.740 mmol) in dry DMSO (2.0 mL) at 40 °C, was added a solution of 
model trans-decalin 139 (61 mg, 0.37 mmol) in dry DMSO (0.47 mL) and the reaction was stirred at 95 
°C for 16 hours. After this time, the reaction was cooled to room temperature and quenched with 
saturated aqueous solution of NaHCO3 (10 mL) and extracted with MTBE (4 × 10 mL). The combined 
organic layers were washed with brine (10 mL), dried with Na2SO4, filtered and concentrated in vacuo. 
The crude product was purified by silica gel flash column chromatography (3% to 10% EtOAc in 
hexanes) to yield 207 as a pale yellow oil (12.0 mg, 20% yield).93 Rf = 0.38 (EtOAc : hexane 10% : 90%). 
IR (ATR): νmax 2923, 2854, 1680 (C=O), 1435, 1347, 1284, 1184, 817 cm–1. 1H NMR (400 MHz, CDCl3):  
7.94 (1H, d, J = 8.0 Hz, Ar-H), 7.12 (1H, d, J = 8.0 Hz, Ar-H), 7.07 (1H, s, Ar-H), 2.93 (2H, t, J = 6.2 Hz, H-
14), 2.64 (2H, t, J = 6.4 Hz, H-6), 2.40 (3H, s, H-24), 2.19‒2.08 (2H, m, H-15) ppm. 13C NMR (500 MHz, 
CDCl3):  198.2 (C-13), 144.6 (Ar), 144.2 (Ar), 130.3 (Ar), 129.2 (Ar-H), 127.6 (Ar-H), 127.3 (Ar-H), 39.1 
(C-14), 29.7 (C-6), 23.3 (C-15), 21.7 (C-24) ppm.  MS (ESI): m/z 161 (M+H+); HRMS: found: (M+H+) 
161.0968. C11H13O requires (M+H+) 161.0961. Characterisation of this compound matched the 
compound reported in the literature.94  
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(12S*, 7S*)-9-Methyl-15,6,7,8,11,12-hexahydronaphthalen-13-yl trifluoromethanesulfonate, 244 
 
To a solution of freshly distilled diisopropylamine (0.13 mL, 0.92 mmol) in dry THF (0.92 mL) at ‒78 °C, 
was added n-BuLi (0.390 mL, 2.38 M) and the solution was stirred at ‒78 °C for 30 minutes. A solution 
of trans-decalin 139 (100 mg, 0.610 mmol) in dry THF (1.33 mL) was added and stirred for a further 1 
hour at ‒78 °C. After this time, a solution of N-phenylbistrifluoromethanesulfonimide 243 (327 mg, 
0.920 mmol) in dry THF (1.33 mL) was added at ‒78 °C and the reaction was allowed to warm to room 
temperature for 2 hours. After this time, the reaction was quenched with water (5 mL) and the 
aqueous phase was extracted with Et2O (2 × 20 mL). The combined organic layers were dried with 
Na2SO4, filtered and concentrated in vacuo. The crude product was purified by silica gel flash column 
chromatography (2% to 5% EtOAc in hexanes) to yield 244 as a pale yellow oil (66.0 mg, 36% yield). Rf 
= 0.75 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 2918, 1414, 1247, 1203, 1141, 1033, 877 cm–1. 1H 
NMR (400 MHz, CDCl3):  5.80‒5.70 (1H, m, H-14), 5.46‒5.38 (1H, m, H-10), 2.40‒2.29 (2H, m, H-12 + 
H-11), 2.27‒2.22 (2H, m, H-15), 2.01 (1H, dd, J = 15.1, 5.0 Hz, H-8), 1.95‒1.80 (3H, m, H-7 + H-6 + H-
11), 1.80‒1.72 (1H, m, H-8), 1.70 (3H, s, H-24), 1.46‒1.24 (1H, m, H-6) ppm. 13C NMR (400 MHz, CDCl3): 
 151.8 (C-13), 134.1 (C-9), 119.7 (C-10), 118.4 (C-14), 39.7 (C-12), 37.7 (C-7), 37.2 (C-8), 28.3 (C-11), 
27.8 (C-6), 23.8 (C-15), 23.3 (C-24) ppm. 19F NMR (376 MHz, CDCl3):  -70.5, -73.9, -75.8 ppm. MS 
(APCI): m/z 297 (M+H+); HRMS: found: (M+H+) 297.0755. C12H16F3O3S requires (M+H+) 297.0767. 
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(12S*, 7S*)-9-Methyl-13,14,7,8,11,12-hexahydronaphthalene, 245 
 
To a solution of triflate-enol trans-decalin 244 (66 mg, 0.20 mmol) in dry DMF (12.5 mL), were added 
Bu3N (0.17 mL, 0.70 mmol), bis(acetato)bis(triphenylphosphine)palladium (II) (14 mg, 0.020 mmol) 
and formic acid (0.020 mL, 0.47 mmol) and the reaction was heated at 50 °C for 3 hours. After this 
time, the reaction was cooled to room temperature and Et2O (10 mL) was added and it was filtrated 
through a celite pad. The filtrate was washed with water (5 × 20 mL), brine (20 mL), dried with Na2SO4, 
filtered and concentrated in vacuo. The crude product was purified by silica gel flash column 
chromatography (2% to 5% EtOAc in hexanes) to yield 245 as a pale yellow oil (13.0 mg, 45% yield). Rf 
= 0.89 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 2911, 2852, 1449, 1376, 1047, 915, 873, 800, 735 
cm–1. 1H NMR (400 MHz, CDCl3):  5.69‒5.64 (1H, m, H-14), 5.55‒5.49 (1H, m, H-13), 5.42‒5.38 (1H, 
m, H-10), 2.14‒2.04 (3H, m, H-12 + H-11), 1.97‒1.86 (2H, m, H-8), 1.82‒1.70 (3H, m, H-15 + H-7), 1.67 
(3H, s, H-24), 1.50‒1.36 (2H, m, H-6) ppm. 13C NMR (400 MHz, CDCl3):  134.4 (C-10), 131.3 (C-13), 
126.6 (C-14), 121.1 (C-9), 38.0 (C-8), 37.5 (C-12), 36.5 (C-7), 32.5 (C-15), 29.3 (C-6), 25.7 (C-11), 23.6 
(C-24) ppm. MS (EI): m/z 148 (M+H+); HRMS: found: (M+H+) 148.1256. C11H16 requires (M+H+) 
148.1252.  
 
(E)-But-2-en-1-yltrimethylsilane, 272122 
 
 
To a suspension of CuCl (980 mg, 10.0 mmol) and Et3N (4.60 mL, 33.0 mmol) in dry Et2O (7.0 mL) at 0 
°C, a solution of trans-crotyl chloride 274 (3.0 mL, 33.0 mmol) and Cl3SiH (3.30 mL, 33.0 mmol) in dry 
Et2O (3.0 mL) was transferred over 10 minutes. The reaction was stirred at room temperature for 3 
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hours and was then diluted with Et2O (50 mL) and filtered under nitrogen. The resulting ethereal 
solution was transferred into a solution of MeMgI (63.5 mL, 140 mmoL) in dry Et2O (60 mL) at 0 °C, 
and the reaction was stirred at 50 °C for 16 hours. After this time, the reaction was cooled to 0 °C and 
quenched with a pre-cooled saturated aqueous solution of NH4Cl (30 mL) and the aqueous phase was 
extracted with Et2O (3 × 20 mL). The combined organic layers were dried with Na2SO4, filtered and the 
ether was evaporated at 45 °C and the orange liquid was distilled at ambient pressure (112‒115 °C) to 
yield 272 as a colourless liquid (1.44 g, 34% yield).122 IR (ATR): νmax 2953, 2891, 1452, 1398, 1244, 1038, 
962, 834 cm–1. 1H NMR (400 MHz, CDCl3):  5.44‒5.34 (1H, m), 5.31‒5.21 (1H, m), 1.65 (3H, dtd, J = 
7.0, 1.3, 1.2 Hz), 1.39 (2H, dqd, J = 7.8, 1.3, 1.0 Hz), 0.04 (9H, s, Si(CH3)3) ppm. 13C NMR (400 MHz, 
CDCl3):  127.0 (CH), 123.1 (CH), 22.6 (CH2), 18.0 (CH3), 2.0 (Si(CH3)3) ppm. MS (EI): m/z 128 (M+H+); 
HRMS: found: (M+H+) 128.1024. C7H16Si requires (M+H+) 128.1021.  
Characterisation of this compound matched the compound reported in the literature122 
 
(15R*, 12S*, 7R*, 6S*)-15-((R*)-But-17-en-16-yl)-10-methyl-6-(((triisopropylsilyl)oxy)methyl)-
15,6,7,8,11,12-hexahydronaphthalen-13(2H)-one, 276 
 
(12S*, 7R*, 6S*)-15-(-But-17-en-16-yl)-10-methyl-6-(((triisopropylsilyl)oxy)methyl)-15,6,7,8,11,12-
hexahydronaphthalen-13(2H)-one, 277 
 
 
 
To a solution of enone trans-decalin 113 (100 mg, 0.290 mmol) in dry CH2Cl2 (2.90 mL) at ‒40 °C, was 
added TiCl4 (0.040 mL, 0.37 mmol). After 5 minutes, E-crotyltrimethylsilane 272 (0.060 mL, 0.13 mmol) 
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was added and the reaction was stirred at ‒40 °C for 1.5 hours. After this time, saturated aqueous 
solution of NaHCO3 (4.5 mL) was added at ‒40 °C, stirred for 45 minutes and then allowed to warm to 
room temperature and stirred for an additional 30 minutes. The aqueous phase was extracted with 
CH2Cl2 (3 × 10 mL) and the combined organic layers were washed with saturated aqueous solution of 
NaHCO3 (10 mL) and brine (10 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude 
product was purified by silica gel flash column chromatography (3% to 10% EtOAc in hexanes) to yield 
276 and 277 as an inseparable mixture in a 2 : 1 ratio as a pale yellow oil (50.0 mg, 43% yield). Rf = 
0.58 (EtOAc : hexane 10% : 90%). On a mixture IR (ATR): νmax 2922, 2865, 1711 (C=O), 1461, 1379, 
1247, 1067, 911 cm–1. Integration of the 1H NMR are reported as a 1 : 1 mixture due to the presence 
of overlapping peaks. 1H NMR (400 MHz, CDCl3):  5.82‒5.72 (2H, m, 276 + 277), 5.37‒5.31 (2H, m, 
276 + 277), 5.06‒4.92 (4H, m, 276 + 277), 3.95‒3.89 (2H, m, 277), 3.77 (1H, dd, J = 9.8, 6.1 Hz, 276), 
3.74 (1H, dd, J = 9.8, 4.9 Hz, 276), 2.77‒2.70 (1H, m, 276), 2.49‒2.40 (3H, m, 276 + 277), 2.39‒2.32 (2H, 
m, 276 + 277), 2.30‒2.04 (11H, m, 276 + 277), 1.99‒1.80 (5H, m, 276 + 277), 1.69 (6H, 276 + 277), 
1.10‒1.03 (42H, m, OSiCH(CH3)2, 276 + 277), 0.99 (3H, d, J = 6.3 Hz, 276), 0.94 (3H, d, J = 6.9 Hz, 277) 
ppm. Major (15R*, 12S*, 7R*, 6S*)-15-((R*)-But-17-en-16-yl)-10-methyl-6-
(((triisopropylsilyl)oxy)methyl)-15,6,7,8,11,12-hexahydronaphthalen-13(2H)-one, 276; 13C NMR (400 
MHz, CDCl3):  213.5 (C=O), 143.8 (CH), 133.4 (C=C), 120.0 (CH), 113.5 (CH2), 65.9 (CH2), 48.5 (CH), 
45.5 (CH), 42.6 (CH2), 40.1 (CH), 38.7 (CH), 38.5 (CH), 37.2 (CH2), 33.9 (CH2), 23.4 (CH3), 19.4 (CH3), 18.1 
(OSiCH(CH3)2), 11.9 (OSiCH(CH3)2);  Minor (12S*, 7R*, 6S*)-15-(-But-17-en-16-yl)-10-methyl-6-
(((triisopropylsilyl)oxy)methyl)-15,6,7,8,11,12- hexahydronaphthalen-13(2H)-one, 277; 13C NMR (400 
MHz, CDCl3):   212.9 (C=O), 142.7 (CH), 132.9 (C=C), 119.2(CH), 113.8 (CH2), 59.3 (CH2), 49.6 (CH), 
46.4 (CH), 41.7 (CH), 40.5 (CH2), 38.5 (CH), 35.9 (CH), 32.0 (CH2), 31.9 (CH2), 23.4 (CH3), 18.1 
(OSiCH(CH3)2), 11.9 (OSiCH(CH3)2), 11.0 (CH3) ppm. On a mixture MS (ESI): m/z 427 (M+Na+); HRMS: 
found: (M+Na+) 427.3012. C25H44NaO2Si requires (M+Na+) 427.3003. 
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(12S*,7R*, 6S*)-15-(But-17-en-16-yl)-10-methyl-6-(((triisopropylsilyl)oxy)methyl)-15,6,7,8,11,12-
hexahydronaphthalen-13(2H)-one, 277 
 
 
 
Exclusively the minor diasteroisomer 277 was recovered unreacted in the deprotection reaction using 
HF 70% in pyridine and was characterized as single a compound. Pale yellow oil (15.0 mg, 41% yield). 
Rf = 0.58 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 2923, 1713 (C=O), 1507, 1102 cm–1. 1H NMR (400 
MHz, CDCl3):  5.82‒5.72 (1H, m), 5.37‒5.31 (1H, m), 5.06‒4.92 (2H, m), 3.95‒3.89 (2H, m), 2.77‒2.70 
(1H, m), 2.49‒2.40 (1H, m), 2.39‒2.32 (1H, m), 2.30‒2.04 (6H, m), 1.99‒1.80 (2H, m), 1.69 (3H, s), 
1.10‒1.03 (21H, m, OSiCH(CH3)2), 0.94 (3H, d, J = 6.9 Hz, CH3) ppm. 13C NMR (400 MHz, CDCl3):  212.9 
(C=O), 142.7 (CH), 132.9 (C=C), 119.2(CH), 113.8 (CH2), 59.3 (CH2), 49.6 (CH), 46.4 (CH), 41.7 (CH), 40.5 
(CH2), 38.5 (CH), 35.9 (CH), 32.0 (CH2), 31.9 (CH2), 23.4 (CH3), 18.1 (OSiCH(CH3)2), 11.9 (OSiCH(CH3)2), 
11.0 (CH3) ppm. MS (ESI): m/z 427 (M+Na+); HRMS: found: (M+Na+) 427.3007. C25H44NaO2Si requires 
(M+Na+) 427.3003. 
 
(12S*, 7R*, 6S*)-3-(But-17-en-16-yl)-6-(hydroxymethyl)-10-methyl-15,6,7,8,11,12- 
hexahydronaphthalen-13(2H)-one, 280 
 
 
 
In a plastic vessel, to a solution of minor crotyl-trans-decalin 277 (15 mg, 0.040 mmol) in pyridine (0.10 
mL), was added hydrogen fluoride 70% in pyridine (0.030 mL, 1.6 mmol) and the reaction was stirred 
at room temperature for 2 days. After this time, the reaction was quenched with saturated aqueous 
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solution of NaHCO3 (5 mL) and the aqueous phase was extracted with EtOAc (3 × 10 mL). The combined 
organic layers were washed with aqueous solution of 2 M HCl (10 mL) and brine (10 mL), dried with 
Na2SO4, filtered and concentrated in vacuo. The crude product was purified by silica gel flash column 
chromatography (20% to 30% EtOAc in hexanes) to yield 280 as a pale yellow oil (7.0 mg, 78% yield). 
Rf = 0.35 (EtOAc : hexane 20% : 80%). IR (ATR): νmax 3402 (C-OH), 2915, 1704 (C=O), 911 cm–1. 1H NMR 
(500 MHz, CDCl3):  5.80 (1H, ddd, J = 17.5, 10.6, 5.6 Hz, H-17), 5.37‒5.35 (1H, m, H-9), 5.06 (1H, ddd, 
J = 10.6, 1.5, 1.5 Hz, H-18), 5.02 (1H, ddd, J = 17.5, 1.5, 1.5 Hz, H-18), 3.99‒3.86 (2H, m, H-5), 2.72‒
2.66 (1H, m, H-16), 2.51‒2.42 (1H, m, H-11), 2.37 (1H, dd, J = 12.9, 3.4 Hz, H-14), 2.32‒2.24 (1H, m, H-
12), 2.23‒2.15 (2H, m, H-8), 2.14‒2.06 (2H, m, H-14 + H-15), 1.93‒1.85 (1H, m, H-11), 1.82 (1H, dddd, 
J = 12.1, 12.1, 10.5, 4.1 Hz, H-7), 1.69 (3H, s, H-24), 1.50 (1H, dddd, J = 10.5, 10.5, 2.3, 2.3 Hz, H-6), 0.94 
(3H, d, J = 5.9 Hz, H-25) ppm. 13C NMR (500 MHz, CDCl3): 212.2 (C-13), 142.4 (C-17), 133.1 (C-10), 
119.1 (C-9),  114.1 (C-18),  58.7 (C-5), 49.6 (C-12), 45.8 (C-6), 41.6 (C-16), 40.8 (C-14), 38.4 (C-7), 36.3 
(C-15), 31.8 (C-8), 30.0 (C-11), 23.3 (C-24), 11.3 (C-25) ppm. MS (ESI): m/z 271 (M+Na+); HRMS: found: 
(M+Na+) 271.1678. C16H24NaO2 requires (M+Na+) 271.1669. 
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(15R*, 12S*, 7R*, 6S*)-15-((R*)-But-17-en-16-yl)-6-(hydroxymethyl)-10-methyl-15,6,7,8,11,12- 
hexahydronaphthalen-13(2H)-one, 278 
 
 
(15R*, 12R*, 7R*, 6S*)-15-((R*)-But-17-en-16-yl)-6-(hydroxymethyl)-10-methyl-15,6,7,8,11,12- 
hexahydronaphthalen-13(2H)-one, 279 
 
 
 
 
 
In a plastic vessel, to a solution of a 2 : 1 inseparable mixture of crotyl-trans-decalin 276 and 277 (52 
mg, 0.13 mmol) in pyridine (0.31 mL), was added hydrogen fluoride 70% in pyridine (0.10 mL, 5.2 
mmol) and the reaction was stirred at room temperature for 16 hours. After this time, the reaction 
was quenched with saturated aqueous solution of NaHCO3 (10 mL) and the aqueous phase was 
extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with aqueous solution 
of 2 M HCl (10 mL) and brine (10 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude 
product was purified by silica gel flash column chromatography (20% to 30% EtOAc in hexanes) to 
yield 278 and 279 as an inseparable mixture in a 1 : 1 ratio as a pale yellow oil (13.0 mg, 62% yield). 
Due to the 1 : 1 ratio and the presence of many overlapping peaks in the 1H NMR, it was impossible to 
determine which resolved proton peaks belonged to the trans-isomer and which was instead 
generated from the cis-compound. Rf = 0.32 (EtOAc : hexane 20% : 80%). IR (ATR): νmax 3417 (C-OH), 
2910, 1703 (C=O), 1436, 1376, 1039, 912, 786 cm–1. 1H NMR (500 MHz, CDCl3):  5.79 (1H, ddd, J = 
17.5, 10.2, 9.0 Hz), 5.68 (1H, ddd, J = 17.5, 10.2, 9.0 Hz), 5.38‒5.33 (1H, m), 5.33‒5.28 (1H, m), 5.11‒
4.98 (4H, m), 4.05 (1H, dd, J=10.7, 4.4 Hz), 3.93 (1H, dd, J = 10.7, 9.5 Hz), 3.75 (1H, dd, J = 10.7, 6.7 Hz), 
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3.66 (1H, dd, J = 10.7, 6.5 Hz), 2.98 (1H, dd, J = 5.8, 5.8 Hz), 2.67 (1H, dddd, J = 11.6, 5.6, 5.6, 2.0 Hz), 
2.52‒2.33 (5H, m), 2.30‒2.14 (5H, m), 2.11‒1.75 (10H, m), 1.69 (6H, s), 1.01 (3H, d, J = 6.4 Hz), 0.98 
(3H, d, J = 6.4 Hz) ppm.13C NMR (500 MHz, CDCl3):  213.1 (C=O), 211.2 (C=O), 149.9 (CH), 142.7 (CH), 
133.5 (C=C), 132.0 (C=C), 119.9 (CH), 118.9 (CH), 114.3 (CH2), 113.9 (CH2), 62.5 (CH2), 59.9 (CH2), 48.8 
(CH), 45.6 (CH), 43.7 (CH), 43.1 (CH2), 42.4 (CH2), 42.1 (CH), 41.7 (CH), 40.7 (CH), 40.7 (CH), 38.7 (CH), 
37.7 (CH), 35.7 (CH), 33.6 (CH2), 29.9 (CH2), 27.9 (CH2), 27.5 (CH2), 23.4 (CH3), 23.4 (CH3), 19.6 (CH3), 
19.6 (CH3) ppm. MS (ESI): m/z 271 (M+Na+); HRMS: found: (M+Na+) 271.1671. C16H24NaO2 requires 
(M+Na+) 271.1669. m/z 249 (M+H+); HRMS: found: (M+H+) 249.1851. C16H25O2 requires (M+H+) 
249.1849. 
 
(17S*, 16R*, 15R*, 12S*, 7R*, 6S*)-17-(Iodomethyl)-16,10-dimethyl-17,16,15,14,12,11,8,7-
octahydro-1H-benzo[h]isochromen-13(6H)-one, 281 
 
 
(17S*,1 6R*, 15R*, 12R*, 10R*, 9R*, 7R*, 6S*)-10-Hydroxy-9-iodo-17-(iodomethyl)-4,10-
dimethyldecahydro-1H-benzo[h]isochromen-13(6H)-one, 282 
 
 
 
 
To a solution of crotyl-hydroxyl-trans-decalin 278 and 279 (12 mg, 0.060 mmol) in dry CH3CN (0.60 ml) 
at 0 °C, were added iodine (15 mg, 0.060 mmol) and solid NaHCO3 (8.0 mg, 0.12 mmol) and the 
reaction was allowed to stir at room temperature for 24 hours. After this time, the reaction was 
quenched with saturated aqueous solution of Na2SO3 (1 mL) and the aqueous phase was extracted 
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with EtOAc (3 × 10 mL). The combined organic layers were washed with aqueous solution 2 M HCl (10 
mL) and brine (10 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product was 
purified by silica gel flash column chromatography (10% to 30% EtOAc in hexanes) to yield 281 as a 
white solid (6.0 mg, 27% yield) and 282 as a white solid (9.0 mg, 29% yield).   
(17S*, 16R*, 15R*, 12S*, 7R*, 6S*)-17-(Iodomethyl)-16,10-dimethyl-17,16,15,14,12,11,8,7-
octahydro-1H-benzo[h]isochromen-13(6H)-one, 281; Crystallization method solvent/antisolvent 
system: EtAOc/hexane. Melting point = 110‒113 °C. Rf = 0.65 (EtOAc : hexane 30% : 70%). IR (ATR): 
νmax 2923, 2854, 1706 (C=O), 1465, 1357, 1161, 817 cm–1. 1H NMR (500 MHz, CDCl3):  5.38‒5.35 (1H, 
m, H-9), 3.85 (1H, ddd, J = 10.7, 4.5, 4.5 Hz, H-17), 3.76‒3.66 (2H, m, H-5), 3.46 (1H, dd, J = 10.7, 10.7 
Hz, H-18), 3.23 (1H, dd, J = 10.7, 4.5 Hz, H-18), 2.58 (1H, dd, J = 14.6, 7.7 Hz, H-14), 2.48 (1H, dd, J = 
14.6, 4.9 Hz, H-14), 2.37‒2.35 (2H, m, H-12 + H-8), 2.28‒2.22 (1H, m, H-15), 2.19‒2.13 (1H, m, H-11), 
2.11‒2.04 (1H, m, H-8), 1.97‒1.86 (3H, m, H-16 + H-11 + H-7), 1.86‒1.82 (1H, m, H-6), 1.68 (3H, s, H-
24), 0.96 (3H, d, J = 7.1 Hz, H-25) ppm. 13C NMR (500 MHz, CDCl3):  211.7 (C-13), 133.1 (C-10), 119.3 
(C-9), 76.9 (C-17), 62.8 (C-5), 48.2 (C-12), 42.2 (C-14), 39.5 (C-6), 38.1 (C-15), 35.1 (C-7), 33.4 (C-16), 
32.9 (C-11), 29.6 (C-8), 23.3 (C-24), 14.2 (C-25), 3.7 (C-18) ppm. MS (ESI): m/z 397 (M+Na+); HRMS: 
found: (M+Na+) 397.0633. C16H23INaO2 requires (M+Na+) 397.0635. (17S*,1 6R*, 15R*, 12R*, 10R*, 
9R*, 7R*, 6S*)-10-Hydroxy-9-iodo-17-(iodomethyl)-4,10-dimethyldecahydro-1H-
benzo[h]isochromen-13(6H)-one, 282; Crystallization method solvent/antisolvent system: 
EtAOc/hexane. Melting point = 104‒107 °C. Rf = 0.62 (EtOAc : hexane 30% : 70%). IR (ATR): νmax 3417 
(C-OH), 2922, 2852, 1659 (C=O), 1430, 1374, 1141, 1081, 597 cm–1. 1H NMR (500 MHz, CDCl3):  4.40 
(1H, dd, J = 5.5, 2.6 Hz, H-9), 3.96‒3.91 (2H, m, H-5), 3.88 (1H, ddd, J = 7.8, 6.8, 2.3 Hz, H-17), 3.23 (1H, 
dd, J = 10.0, 7.8 Hz, H-18), 3.05 (1H, dd, J = 10.0, 6.8 Hz, H-18), 2.90 (1H, dd, J = 13.2, 13.2 Hz, H-14), 
2.73‒2.71 (1H, m, H-12), 2.62‒2.58 (1H, m, H-7), 2.37‒2.25 (3H, m, H-14 + H-8 + H-15), 2.14‒2.02 (3H, 
m, H-11 + H-6), 1.97‒1.92 (1H, m, H-8), 1.76 (1H, dqd, J = 13.7, 7.6, 2.3 Hz, H-16), 1.69 (3H, s, H-24), 
1.02 (3H, d, J = 7.6 Hz, H-25) ppm. 13C NMR (500 MHz, CDCl3):  216.4 (C-13), 81.8 (C-10), 75.3 (C-17), 
67.7 (C-5), 46.0 (C-12), 42.0 (C-14), 41.7 (C-9), 41.6 (C-15), 37.2 (C-7), 35.8 (C-16), 35.2 (C-11), 34.4 (C-
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6), 31.2 (C-8), 22.7 (C-24), 12.6 (C-25), 5.5 (C-18) ppm. MS (ESI): m/z 540 (M+Na+); HRMS: found: 
(M+Na+) 540.9707. C16H24I2NaO3 requires (M+Na+) 540.9707.  
 
(E)-((1-Ethoxyprop-1-en-1-yl)oxy)trimethylsilane, 240113 
 
 
To a solution of freshly distilled diisopropylamine (1.47 mL, 10.4 mmol) in dry THF (10.4 mL) at ‒78 °C, 
was added n-BuLi (4.42 mL, 2.36 M) and the solution was stirred at ‒78 °C for 30 minutes. A solution 
of ethyl-propionate (1.0 mL, 8.7 mmol) in dry THF (11.3 mL) was added to the LDA solution and stirred 
for 1 hour at ‒78 °C. After this time, freshly distilled TMSCl (1.32 mL, 10.4 mmol) was added and the 
reaction was stirred at ‒78 °C for a further 30 minutes and then allowed to stir at room temperature 
for 2 hours. The solvent was concentrated in vacuo and the residue was dissolved with pentane (10 
mL) and filtered through a sinter funnel and the pentane was concentrated in vacuo. The crude was 
purified by kugelrohr distillation pressure 0.2 mmbar at room temperature to yield 240 as a colourless 
liquid (767 mg, 51% yield).113 1H NMR (400 MHz, C6D6): 3.90 (1H, q, J = 6.5 Hz, CH), 3.79 (2H, q, J = 
7.0 Hz), 1.74 (3H, d, J = 6.5 Hz), 1.10 (1H, t, J = 7.0 Hz), 0.17‒0.13 (9H, m, OSi(CH3)3). This compound 
was characterized only by 1H NMR due to its volatilty and instability and the data matched the 
literature.113  
 
 
 
 
 
 
204 
 
(R*)-Ethyl-15-((15R*, 12S*, 7R*, 6R*)-10-methyl-13-oxo-6-(((triisopropylsilyl)oxy)methyl)-
6,15,14,13,12,11,8,7-octahydronaphthalen-15-yl)propanoate, 241 
 
 
 
Method A 
To a solution of enone trans-decalin 113 (25 mg, 0.072 mmol) in dry CH2Cl2 (0.72 mL) at ‒78 °C was 
added TiCl4 (0.010 mL, 0.10 mmol). After 5 minutes, TMS-silyl keten acetal 240 (0.020 mL, 0.14 mmol) 
was added and the reaction was stirred at ‒78 °C for 30 minutes. After this time, the reaction was 
quenched with saturated aqueous solution of NaHCO3 (1.5 mL) at ‒78 °C, stirred for 45 minutes and 
then warmed to room temperature for a further 30 minutes. The aqueous phase was extracted with 
CH2Cl2 (3 × 10 mL) and the combined organic layers were washed with saturated aqueous solution of 
NaHCO3 (10 mL) and brine (10 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude 
product was purified by silica gel flash column chromatography (3% to 10% EtOAc in hexanes) to yield 
241 as a pale yellow oil (15.0 mg, 48% yield).  
Method B 
A solution of TMS-enol trans-decalin 242 (20 mg, 0.048 mmol) in THF (0.48 mL) and aqueous solution 
of 2 M HCl (0.48 mL) was stirred at room temperature for 30 minutes. After this time, the reaction 
was diluted with water (5 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers 
were dried with Na2SO4, filtered and concentrated in vacuo. The crude product 241 was used in the 
next step without further purification as a pale yellow oil (18.0 mg, 99% crude yield). Rf = 0.45 (EtOAc 
: hexane 10% : 90%). IR (ATR): νmax 2924, 2865, 1725 (C=O ester), 1713 (C=O ketone), 1462, 1380, 
1146, 881 cm–1. 1H NMR (500 MHz, C6D6):  5.36‒5.31 (1H, m, H-9), 4.15 (1H, dd, J = 10.8, 2.5 Hz, H-
5), 3.98‒3.87 (2H, m, H-18), 3.85 (1H, dd, J = 10.8, 2.1 Hz, H-5), 3.07 (1H, qd, J = 7.4, 3.7 Hz, H-16), 2.77 
(1H, dd, J = 13.5, 3.9 Hz, H-14), 2.54 (1H, dd, J = 13.5, 13.5 Hz, H-14), 2.46‒2.34 (2H, m, H-8 + H-11), 
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2.21‒2.09 (2H, m, H-15 + H-11), 1.96‒1.82 (2H, m, H-12 + H-7), 1.71‒1.63 (1H, m, H-8), 1.61‒1.58 (1H, 
m, H-6), 1.57 (3H, s, H-24), 1.08 (3H, d, J = 7.4 Hz, H-25), 1.04‒0.99 (21H, m, OSiCH(CH3)2), 0.93 (3H, t, 
J = 7.2 Hz, H-19) ppm. 13C NMR (500 MHz, C6D6): 208.7 (C-13), 173.6 (C-17),133.0 (C-10), 118.9 (C-
9), 59.6 (C-18), 59.4 (C-5), 49.2 (C-12), 47.2 (C-6), 41.8 (C-15), 41.1 (C-14), 39.2 (C-16), 38.3 (C-7), 31.9 
(C-8), 30.2 (C-11), 23.1 (C-24), 17.8 (OSiCH(CH3)2), 15.3 (C-25), 13.9 (C-19), 11.9 (OSiCH(CH3)2) ppm.MS 
(ESI): m/z 473 (M+Na+); HRMS: found: (M+Na+) 473.3070. C26H46NaO4Si requires (M+Na+) 473.3058. 
m/z 451 (M+H+); HRMS: found: (M+H+) 451.3250. C26H47O4Si requires (M+H+) 451.3238. 
 
(R*)-Ethyl-15-((15S*, 12S*, 7R* 6R*)-10-methyl-6-(((triisopropylsilyl)oxy)methyl)-13-
((trimethylsilyl)oxy)-6,15,12,11,8,7-hexahydronaphthalen-15-yl)propanoate, 242 
 
 
 
 
To a solution of enone trans-decalin 113 (25 mg, 0.072 mmol) in dry CH2Cl2 (0.72 mL) at ‒78 °C, was 
added Yb(OTf)3 (56 mg, 0.072 mmol). After 5 minutes, TMS-silyl keten acetal 240 (0.020 mL, 0.14 
mmol) was added and the reaction was stirred at ‒78 °C for 2 hours. After this time, the reaction was 
quenched with saturated aqueous solution of NaHCO3 (1.5 mL) at ‒78 °C, stirred for 45 minutes and 
then the mixture was warmed to room temperature and stirred for an additional 30 minutes. The 
aqueous phase was extracted with CH2Cl2 (3 × 10 mL) and the combined organic layers were washed 
with saturated aqueous solution of NaHCO3 (10 mL) and brine (10 mL), dried with Na2SO4, filtered and 
concentrated in vacuo. The crude product 242 was used in the next step without further purification 
as a pale yellow oil (36.0 mg, 99% crude yield). Rf = 0.58 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 
2866, 1725 (C=O ester), 1462, 1379, 1264, 1191, 876, 704 cm–1. 1H NMR (500 MHz, C6D6):  5.41‒5.36 
(1H, m, H-9), 4.86 (1H, dd, J = 2.7, 2.7 Hz, H-14), 4.16‒4.00 (2H, m, H-18), 3.97 (1H, dd, J = 10.5, 2.3 Hz, 
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H-5), 3.87 (1H, dd, J = 10.5, 2.8 Hz, H-5), 2.87 (1H, qd, J = 6.9, 5.6 Hz, H-16), 2.49 (1H, ddd, J = 10.6, 5.6, 
2.7 Hz, H-15), 2.38‒2.29 (1H, m, H-11), 2.27‒2.17 (1H, m, H-8), 2.09‒1.94 (1H, m, H-12), 1.78‒1.71 
(3H, m, H-8 + H-11 + H-7), 1.69 (3H, s, H-24), 1.52 (1H, dddd, J = 10.6, 10.6, 2.8, 2.3 Hz,  H-6), 1.21 (3H, 
t, J = 7.3 Hz, H-19), 1.19 (3H, d, J = 6.9 Hz, H-25), 1.10‒1.03 (21H, m, OSiCH(CH3)2), 0.20 (9H, s, OSi(CH3)3) 
ppm. 13C NMR (500 MHz, C6D6): 174.7 (C-17), 152.9 (C-13),133.7 (C-10), 120.4 (C-9), 102.7 (C-14), 
60.0 (C-18), 59.9 (C-5), 43.5 (C-6), 40.7 (C-12), 40.0 (C-16), 39.9 (C-15), 36.6 (C-7), 33.9 (C-8), 30.6 (C-
11), 23.6 (C-24), 18.1 (OSiCH(CH3)2), 15.7 (C-25), 14.4 (C-19), 12.0 (OSiCH(CH3)2), 0.17 (OSi(CH3)3) 
ppm.MS (ESI): m/z 545 (M+Na+); HRMS: found: (M+Na+) 545.3476. C29H54NaO4Si2 requires (M+Na+) 
545.3453. 
 
(16R*, 15S*, 12S*, 7R*, 6R*)-16,10-Dimethyl-17-oxo-17,16,15,12,11,8,7,6-octahydro-1H-
benzo[h]isochromen-13-yl trifluoromethanesulfonate, 246 
 
 
To a solution of freshly distilled diisopropylamine (0.020 mL, 0.12 mmol) in dry THF (0.12 mL) at ‒78 
°C, was added n-BuLi (0.0510 mL, 2.36 M) and the solution was stirred at ‒78 °C for 30 minutes. A 
solution of ethylester-trans-decalin 241 (47 mg, 0.10 mmol) in dry THF (0.4 mL) was added and stirred 
at ‒78 °C for 1 hour. After this time, N-phenyl-bis-(trifluoromethanesulfonimide) 243 (43 mg, 0.12 
mmol) in dry THF (1 mL) was added and the reaction was stirred at ‒78 °C for a further 30 minutes 
and then allowed to warm to room temperature for 1 hour. The reaction was then quenched with 
water (2 mL) and extracted with Et2O (20 mL) and the organic layer was dried with Na2SO4, filtered 
and concentrated in vacuo. The crude product (48 mg, 83% crude yield) was carried into the next step 
without further purification. 
To a solution of this crude (40 mg, 0.071 mmol) in dry THF (0.71 mL), was added a 1.0 M solution of 
TBAF in THF (0.20 mL, 0.70 mmol) and the reaction was stirred at room temperature for 16 hours. 
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After this time, the reaction was diluted with EtOAc (10 mL), and washed with water (2 × 10 mL) and 
brine (10 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified 
by silica gel flash column chromatography (10% to 30% EtOAc in hexanes) to yield 246 as a pale yellow 
oil (14.0 mg, 54% yield). Rf = 0.25 (EtOAc : hexane 30% : 70%). IR (ATR): νmax 2919, 1735 (C=O), 1416, 
1209, 1141, 1057, 825, 624 cm–1. 1H NMR (500 MHz, C6D6): 5.07‒5.02 (1H, m, H-9), 4.92‒4.89 (1H, 
m, H-14), 3.73 (1H, dd, J = 10.7, 5.0 Hz, H-5), 3.15 (1H, dd, J = 11.8, 10.7 Hz, H-5), 2.31 (1H, qd, J = 7.5, 
5.5 Hz, H-16), 2.12‒2.04 (3H, m, H-12 + H-7 + H-11), 1.71‒1.65 (1H, m, H-15), 1.61‒1.49 (3H, m, H-8 + 
H-11), 1.43 (3H, s, H-24), 1.15‒1.05 (1H, m, H-6), 0.94 (3H, d, J = 7.5 Hz, H-25) ppm. 13C NMR (500 
MHz, C6D6): 171.4 (C-17), 151.6 (C-13),132.7 (C-10), 120.0 (C-9), 118.4 (C-14), 71.5 (C-5), 39.6 (C-12), 
38.6 (C-7), 38.5 (C-15), 38.1 (C-16), 32.7 (C-11), 32.5 (C-6), 28.3 (C-8), 23.4 (C-24), 13.8 (C-25) ppm. 19F 
NMR (376 MHz, CDCl3):  -73.9 ppm.MS (APCI): m/z 381 (M+H+); HRMS: found: (M+H+) 381.0968. 
C16H20F3O5S requires (M+H+) 381.0978.  
 
(16R*, 15R*, 12R*, 7S*, 6R*)-16,10-Dimethyl-16,15,12,11,8,7-hexahydro-1H-benzo[h]isochromen-
17(6H)-one, 247 
 
 
 
To a solution of triflate enol -trans-decalin 246 (14 mg, 0.040 mmol) in dry DMF (2.50 mL), were added 
Bu3N (0.030 mL, 0.14 mmol), bis(acetate)bis(triphenylphosphine)palladium (II) (3.0 mg, 3.8 μmol) and 
formic acid (3.39 μL, 0.090 mmol) and the reaction was heated at 50 °C for 3 hours. After this time, 
the reaction was cooled to room temperature and diluted with Et2O (10 mL), washed with water (5 × 
10 mL) and brine (10 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product 
was purified by silica gel flash column chromatography (10% EtOAc in hexanes) to yield 247 as a pale 
yellow solid (5.0 mg, 51% yield). Melting point = 89‒91 °C. Rf = 0.31 (EtOAc : hexane 10% : 90%). IR 
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(ATR): νmax 2923, 1736 (C=O), 1459, 1217, 1057, 790, 597 cm–1. 1H NMR (500 MHz, CDCl3): 5.69 (1H, 
ddd, J = 9.9, 2.2, 2.2 Hz, H-13), 5.41 (1H, ddd, J = 9.9, 2.2, 2.2 Hz, H-14), 5.39‒5.36 (1H, m, H-9), 4.50 
(1H, dd, J = 10.9, 5.0 Hz, H-5), 4.01 (1H, dd, J = 11.8, 10.9 Hz, H-5), 2.86 (1H, qd, J = 7.5, 5.6 Hz, H-16), 
2.64‒2.58 (1H, m, H-15), 2.21‒2.12 (1H, m, H-12), 2.09‒2.00 (2H, m, H-8 + H-11), 1.95‒1.74 (3H, m, H-
6 + H-8 + H-11), 1.68 (3H, s, H-24), 1.40‒1.32 (1H, m, H-7), 1.20 (3H, d, J = 7.5 Hz, H-25) ppm. 13C NMR 
(500 MHz, CDCl3): 174.4 (C-17), 134.4 (C-10),133.2 (C-13), 125.6 (C-9), 119.9 (C-14), 73.4 (C-5), 39.6 
(C-15), 38.7 (C-16), 37.6 (C-12), 37.6 (C-7), 36.7 (C-11), 33.7 (C-6), 29.2 (C-8), 23.4 (C-24), 13.6 (C-25) 
ppm.MS (APCI): m/z 233 (M+H+); HRMS: found: (M+H+) 233.1531. C15H21O2 requires (M+H+) 233.1536. 
 
p-methoxybenzyl 2,2,2-trichloroacetimidate, 300127 
 
 
To a solution of p-methoxybenzylalcohol (3.30 g, 12.0 mmol) in dry Et2O (9 mL) at room temperature, 
was added NaH (60% dispersion in mineral oil, 241 mg, 6.06 mmol) and the mixture was stirred at 
room temperature for 30 minutes. After this time, the mixture was cooled to 0 °C and 
Trichloroacetonitrile (2.40 mL, 12.02 mmol) was added, and the reaction was stirred for 2 hours at 
room temperature. The reaction was then quenched with saturated solution of NaHCO3 (10 mL) and 
extracted with Et2O (4 × 20 mL). The combined organic layers were dried with Na2SO4, filtered and 
concentrated in vacuo. The crude product 300 was used into the next step without further purification 
as a pale yellow oil (3.39 g, >99% crude yield).127 IR (ATR): νmax 2955, 2836, 1661, 1612, 1514, 1175, 
1033, 819 cm–1. 1H NMR (400 MHz, CDCl3):  8.37 (1H, br. s.), 7.38 (2H, d, J = 8.70 Hz), 6.92 (2H, d, J = 
8.70 Hz), 5.28 (2H, s), 3.82 (3H, s) ppm. 13C NMR (400 MHz, CDCl3):  162.8 (C), 159.8 (C), 129.8 (CH), 
114.0 (CH), 70.8 (CH2), 55.47 (CH3) ppm. MS (ESI): m/z 303 (M+Na+), m/z 305 (M+Na+); HRMS: found: 
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(M+Na+) 303.9652 C10H1035Cl3NNaO2 requires (M+Na+) 303.9669. Characterisation of this compound 
matched the compound reported in the literature127  
 
(R*)-Methyl-21-((methoxybenzyl)oxy)propanoate, 301 
 
 
To a solution of (+)-methyl-D-lactate 299 (1.15 mL, 12.0 mmol) in dry CH2Cl2 (60.0 mL), were added 4-
methoxybenzyl-2,2,2-trichloroacetimidate 300 (6.76 g, 12.0 mmol) in dry CH2Cl2 (60.0 mL) followed by 
CSA (279 mg, 1.20 mmol). The reaction was stirred at room temperature for 24 hours. After this time, 
the reaction was diluted with CH2Cl2 (50 mL) and quenched with saturated aqueous solution of NaHCO3 
(10 mL). The aqueous phase was extracted with CH2Cl2 (3 × 20 mL) and the combined organic layers 
were washed with water (20 mL) and brine (20 mL), dried with Na2SO4, filtered and concentrated in 
vacuo. The crude product was purified by silica gel flash column chromatography (10% to 20% EtOAc 
in hexanes) to yield 301 as a pale yellow oil (2.45 g, 91% yield). [α]20D +76.45 (c 0.50, CHCl3). Rf = 0.25 
(EtOAc : hexane 20% : 80%). IR (ATR): νmax 2952, 1747 (C=O), 1586, 1444, 1205, 1174, 755 cm–1. 1H 
NMR (500 MHz, CDCl3):  7.30 (2H, d, J = 8.7 Hz, Ar-H), 6.89 (2H, d, J = 8.7 Hz, Ar-H), 4.62 (1H, d, J = 
11.5 Hz, H-26), 4.40 (1H, d, J = 11.5 Hz, H-26), 4.06 (1H, q, J = 6.8 Hz, H-21), 3.81 (3H, s, H-28), 3.76 (3H, 
s, H-27), 1.43 (3H, d, J = 6.8 Hz, H-22) ppm. 13C NMR (500 MHz, CDCl3):  173.9 (C-20), 159.5 (Ar), 129.8 
(Ar-H), 129.7 (Ar), 113.9 (Ar-H), 73.7 (C-21), 71.8 (C-26), 55.4 (C-28), 52.1 (C-27), 18.9 (C-22) ppm. MS 
(ESI): m/z 247 (M+Na+); HRMS: found: (M+Na+) 247.0944. C12H16NaO4 requires (M+Na+) 247.0941. 
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(R*)-Methyl 21-((methoxybenzyl)oxy)propanal, 30244 
 
To a solution of PMB-ester 301 (270 mg, 1.20 mmol) in dry CH2Cl2 (12.0 mL) at ‒78 °C, was added a 1.0 
M solution of Dibal-H in toluene (1.20 mL, 1.20 mmol) and the reaction was stirred at ‒78 °C for 1 
hour. After this time, the reaction was quenched with dry acetone (1.2 mL) at ‒78 °C and allowed to 
warm to room temperature and then Rochelle’s salt 10% aqueous solution (20 mL) was added and 
stirred for 16 hours. The aqueous phase was then extracted with CH2Cl2 (3 × 10 mL) and the combined 
organic layers were washed with water (10 mL) and brine (10 mL), dried with Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by silica gel flash column chromatography (10% 
to 20% EtOAc in hexanes) to yield 302 as a pale yellow oil (232 mg, 99% yield). [α]20D +39.89 (c 0.50, 
CHCl3); Rf = 0.25 (EtOAc : hexane 20% : 80%). IR (ATR): νmax 2951, 1730 (C=O), 1612, 1513, 1450, 
1371, 1175, 821 cm–1. 1H NMR (500 MHz, CDCl3):  9.64 (1H, d, J = 1.9 Hz, H-20), 7.30 (2H, d, J = 8.7 
Hz, Ar-H), 6.89 (2H, d, J = 8.7 Hz, Ar-H), 4.58 (1H, d, J = 11.5 Hz, H-26), 4.55 (1H, d, J = 11.5 Hz, H-26), 
3.88 (1H, qd, J = 6.9, 1.9 Hz, H-21), 3.82 (3H, s, H-28), 1.32 (3H, d, J = 6.9 Hz, H-22) ppm. 13C NMR (500 
MHz, CDCl3):  203.6 (C-20), 159.6 (Ar), 129.7 (Ar-H), 129.4 (Ar), 114.0 (Ar-H), 79.1 (C-21), 71.7 (C-26), 
55.3 (C-28), 15.3 (C-22) ppm. MS (ESI): m/z 217 (M+Na+); HRMS: found: (M+Na+) 217.0840. C11H14NaO3 
requires (M+Na+) 217.0835. Characterisation of this compound matched the compound reported in 
the literature44  
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(R*)-19-((But-20-en-21-yloxy)methyl)-methoxybenzene, 30344 
 
To a suspension of methylphenylphosphonium bromide (405 mg, 1.13 mmol) in dry THF (4.0 mL) at 0 
°C, was added n-BuLi (0.50 mL, 2.25 M) and the yellow solution was stirred for 1 hour. A solution of 
PMB-aldehyde 302 (182 mg, 0.930 mmol) in dry THF (2.0 mL) was added and the reaction was stirred 
at 0 °C for 2 hours. After this time, the reaction was filtered through a pad of silica with MTBE (10 mL) 
and the solvent was evaporated under nitrogen flow. The crude product 303 was used in the next 
reaction without further purification as a pale yellow oil (178 mg, >99% crude yield). [α]20D +1.21 (c 
0.50, CHCl3); Rf = 0.62 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 2923, 2853, 1588, 1611, 1462, 1246, 
1071, 997 cm–1. 1H NMR (500 MHz, CDCl3):  7.28 (2H, d, J = 8.5 Hz, Ar-H), 6.88 (2H, d, J = 8.5 Hz, Ar-
H), 5.80 (1H, ddd, J = 17.3, 10.2, 7.4 Hz, H-20), 5.21 (1H, ddd, J = 17.3, 1.5, 1.5 Hz, H-19), 5.18 (1H, ddd, 
J = 10.2, 1.5, 1.5 Hz, H-19), 4.51 (1H, d, J = 11.5 Hz, H-26), 4.33 (1H, d, J = 11.5 Hz, H-26), 3.93‒3.89 
(1H, m, H-21), 3.81 (3H, s, H-28), 1.28 (3H, d, J = 6.4 Hz, H-22) ppm. 13C NMR (500 MHz, CDCl3):  159.1 
(Ar), 140.9 (C-20), 130.9 (Ar), 129.3 (Ar-H), 115.9 (C-19), 113.8 (Ar-H), 75.7 (C-21), 69.6 (C-26), 55.3 (C-
28), 21.4 (C-22) ppm. MS (ESI): m/z 215 (M+Na+); HRMS: found: (M+Na+) 215.1045. C12H16NaO2 
requires (M+Na+) 215.1043. Characterisation of this compound matched the compound reported in 
the literature.44 
 
Allyl phosphonate, 30444 
 
A mixture of TBAI (81 mg, 0.22 mmol), tris(2,2,2 trifluoroethyl)phosphite (0.810 mL, 3.62 mmol) and 
allylbromide (0.50 mL, 5.96 mmol) was stirred in a microwave at 180 °C for 3 hours. After this time, 
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the crude product was purified by silica gel flash column chromatography (10% to 30% EtOAc in 
hexanes) to yield 304 as a pale yellow oil (620 mg, 60% yield). Rf=0.25 (EtOAc : hexane 30% : 70%). IR 
(ATR): νmax 2659, 1506, 1439, 1210, 1126, 1094, 1004, 943 cm–1. 1H NMR (400 MHz, CDCl3):  5.85‒
5.69 (1H, m), 5.41‒5.27 (2H, m), 4.47‒4.30 (4H, m), 2.80 (2H, dd, J = 22.9) ppm. 13C NMR (400 MHz, 
CDCl3):  124.8 (d, J = 11.9 Hz), 122.5 (qd, J = 277.6, 7.3 Hz), 122.1 (d, J = 15.1 Hz), 62.3 (qd, J = 37.8, 
5.8 Hz), 31.9 (d, J = 141.1 Hz) ppm. 19F NMR (376 MHz, CDCl3):  -75.3 (t, J = 7.9 Hz), -75.2 (t, J = 7.9 
Hz), -75.1 (t, J = 7.9 Hz) ppm. MS (ESI): m/z 309 (M+Na+); HRMS: found: (M+Na+) 309.0084. 
C7H9F6NaO3P requires (M+Na+) 309.0086. Characterisation of this compound matched the compound 
reported in the literature.44  
 
(R*, E)-Bis(2,2,2,-trifluoroethyl)-(((21methoxybenzyl)oxy)pent-19en-18-yl)phosphonate, 9244 
 
 
To a solution of PMB-alkene 303 (30.7 mg, 0.160 mmol) and allyl phosphonate 304 (45.8 mg, 0.160 
mmol) in dry CH2Cl2 (2.5 mL), was added Grubbs II generation catalyst (7.0 mg, 8.0 μmol) and the 
reaction was stirred under reflux for 36 hours. After this time, the solvent was concentrated in vacuo. 
The crude product was purified by silica gel flash column chromatography (10% to 40% EtOAc in 
hexanes) to yield 92 as a brown oil (17.0 mg, 34% yield). [α]20D  +19.32 (c 0.50, CHCl3). Rf = 0.32 (EtOAc 
: hexane 30% : 70%). IR (ATR): νmax 2928, 1613, 1586, 1513, 1296, 1249, 1102 cm–1. 1H NMR (400 MHz, 
CDCl3):  7.25 (2H, d, J = 8.9 Hz), 6.88 (2H, d, J = 8.9 Hz), 5.76‒5.66 (1H, m), 5.64 (1H, m), 4.48 (1H, d, J 
= 11.5 Hz), 4.45‒4.34 (4H, m), 4.31 (1H, d, J = 11.5 Hz), 3.97‒3.89 (1H, m), 3.81 (3H, s), 2.83 (2H, dd, J 
= 22.0, 7.3 Hz), 1.26 (3H, d, J = 6.6 Hz) ppm. 13C NMR (400 MHz, CDCl3):  159.1 (C=C), 139.7 (d, J = 15.0 
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Hz, CH), 130.5 (C=C), 129.2 (CH), 121.2 (qd,  J = 27.7, 6.9 Hz), 118.2 (d, J = 12.5 Hz, CH), 113.8 (CH), 
74.5 (d, J = 2.3 Hz, CH), 69.4 (CH2), 62.2 (qdd, J = 37.9, 6.2, 4.2 Hz, CH2), 55.2 (CH), 29.6 (d, J = 141.1 Hz, 
CH2), 21.2 (d,  J = 3.1 Hz, CH2)  ppm. 9F NMR (376 MHz, CDCl3):  -75.3 (q, J = 7.8 Hz) ppm. MS (ESI): 
m/z 473 (M+Na+); HRMS: found: (M+Na+) 473.0924. C17H21F6NaO5P requires (M+Na+) 473.0923.  
Characterisation of this compound matched the compound reported in the literature.44  
 
R*-15-((15S*, 12S*, 7R*, 6S*)-10-Methyl-13-oxo-6(((triisopropylsilyl)oxy)methyl)-
6,15,14,13,12,11,8,7-octahydronaphtalen-15yl)propanal, 290 
 
 
15-((12S*, 7R*, 6S*)-10-Methyl-13-oxo-6(((triisopropylsilyl)oxy)methyl)-6,15,14,13,12,11,8,7-
octahydronaphtalen-15yl)propanal, 291 
 
 
To a solution of crotyl-substituted trans-decalins 276 and 277 (227 mg, 0.560 mmol) in dry THF (0.56 
mL), were added B2pin2 (156 mg, 0.620 mmol), trans-cyclohexanediol 287 (64.9 mg, 0.560 mmol) and 
Cs2CO3 (26.9 mg, 0.080 mmol). The reaction was stirred at 60 °C for 5 days and then cooled to 0 °C and 
an aqueous solution of 3 M NaOH (2.20 mL) was added, followed by addition of an 30% aqueous 
solution of H2O2 (1.10 mL) and the resultant mixture was stirred for 4 hours. Saturated aqueous 
solution of Na2SO3 (4.40 mL) was then added and the aqueous phase was extracted with EtOAc (4 × 
20 mL). The combined organic layers were washed with brine (10 mL), dried with Na2SO4, filtered and 
concentrated in vacuo. The crude product mixture of diols 288 and 289 was directly used in the next 
step without further purification. 
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To a solution of the mixture of diol intermediates 288 and 289 (53 mg, 0.12 mmol) in CH2Cl2 : H2O (1 : 
1, 1.20 mL) at 0 °C, was added NaIO4 (25.7 mg, 0.120 mmol) and the reaction was allowed to stir at 
room temperature for 24 hours. After this time, the mixture was extracted with CH2Cl2 (3 × 10 mL) and 
the combined organic layers were washed with brine (10 mL), dried with Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by silica gel flash column chromatography (5% 
EtOAc in hexanes) to yield 290 as a pale yellow oil (14.0 mg, 30% yield) and 291 as a pale yellow oil 
(8.0 mg, 16% yield).  R*-15-((15S*, 12S*, 7R*, 6S*)-10-Methyl-13-oxo-6(((triisopropylsilyl)oxy)methyl)-
6,15,14,13,12,11,8,7-octahydronaphtalen-15yl)propanal, 290; Rf = 0.38 (EtOAc : hexane 20% : 80%). 
IR (ATR): νmax 2922, 2864, 1714 (C=O, aldehyde + ketone), 1461, 1379, 1094, 1066, 917 cm–1. 1H NMR 
(500 MHz, CDCl3): 9.62 (1H, d, J = 2.7 Hz, H-17), 5.33‒5.29 (1H, m, H-9), 4.07 (1H, dd, J = 10.4, 5.4 Hz, 
H-5), 4.00 (1H, dd, J = 10.4, 6.5 Hz, H-5), 3.05‒3.01 (1H, m, H-15), 2.64 (1H, dqd, J = 8.3, 5.2, 2.7 Hz, H-
16), 2.61‒2.56 (1H, m, H-12), 2.55‒2.50 (1H, m, H-7), 2.49‒2.43 (2H, m, H-11), 2.39 (1H, dd, J = 14.3, 
4.6 Hz, H-14), 2.35‒2.25 (1H, m, H-14), 1.95‒1.83 (3H, m H-8 + H-6), 1.70 (3H, s, H-24), 1.11 (3H, d, J = 
5.2 Hz, H-25), 1.08‒1.02 (21H, m, OSiCH(CH3)2) ppm . 13C NMR (500 MHz, CDCl3):  210.3 (C-17), 203.3 
(C-13), 132.0 (C-10), 118.9 (C-9), 63.2 (C-5), 48.2 (C-16), 44.7 (C-15), 41.6 (C-6), 41.5 (C-14), 38.0 (C-
12), 37.5 (C-7), 27.9 (C-11), 27.7 (C-8), 23.4 (C-24), 18.1 (OSiCH(CH3)2), 12.6 (C-25), 11.9 (OSiCH(CH3)2) 
ppm. MS (ESI): m/z 429 (M+Na+); HRMS: found: (M+Na+) 429.2811. C24H42NaO3Si requires (M+Na+) 
429.2795. m/z 407 (M+H+); HRMS: found: (M+H+) 407.2979. C24H43O3Si requires (M+H+) 407.2976. 15-
((12S*, 7R*, 6S*)-10-Methyl-13-oxo-6(((triisopropylsilyl)oxy)methyl)-6,15,14,13,12,11,8,7-
octahydronaphtalen-15yl)propanal, 291; Rf = 0.41 (EtOAc : hexane 20% : 80%). IR (ATR): νmax 2864, 
1714 (C=O, aldehyde + ketone), 1462, 1094, 788, 680 cm–1. 1H NMR (400 MHz, CDCl3): 9.57 (1H, d, J 
= 2.9 Hz, H-17), 5.35‒5.29 (1H, m, H-9), 3.88 (1H, dd, J = 10.7, 5.1 Hz, H-5), 3.58 (1H, dd, J = 10.7, 9.4 
Hz, H-5), 3.00‒2.94 (1H, m, H-15), 2.57‒2.52 (1H, m, H-16), 2.51‒2.44 (2H, m, H-14), 2.32 (1H, ddd, J = 
11.8, 7.9, 7.5 Hz, H-12), 2.20‒2.14 (1H, m, H-8), 2.14‒2.10 (2H, m, H-11), 2.10‒2.03 (1H, m, H-6), 1.94‒
1.86 (1H, m, H-8), 1.76 (1H, dddd, J = 12.1, 11.8, 10.3, 3.9, H-7), 1.68 (3H, s, H-24), 1.09 (3H, d, J = 5.3 
Hz, H-25), 1.09‒1.02 (21H, m, OSiCH(CH3)2) ppm. 13C NMR (400 MHz, CDCl3):  211.9 (C-17), 204.3 (C-
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13), 133.3 (C-10), 119.1 (C-9), 62.4 (C-5), 49.1 (C-12), 46.5 (C-16), 45.9 (C-6), 42.7 (C-14), 37.1 (C-7), 
35.5 (C-15), 32.5 (C-8), 29.6 (C-11), 23.4 (C-24), 18.0 (OSiCH(CH3)2), 12.6 (C-25), 11.9 (OSiCH(CH3)2) 
ppm.  MS (ESI): m/z 429 (M+Na+); HRMS: found: 429.2805 (M+Na+). C24H42NaO3Si requires (M+Na+) 
429.2795. 
 
(((15R*, 12R*, 7S*, 6R*)-15-((S*)But-14-en-15yl)-10-methyl,-6,15,12,11,8,7-hexahydronaphthalen-6-
yl)methoxy)triisoprpylsilane, 294 
 
 
(((12R*, 7S*, 6R*)-15-(But-14-en-15yl)-10-methyl,-6,15,12,11,8,7-hexahydronaphthalen-6-
yl)methoxy)triisoprpylsilane, 295 
 
 
To a solution of freshly distilled diisopropylamine (0.10 mL, 0.65 mmol) in dry THF (0.65 mL) at ‒78 °C, 
was added n-BuLi (0.31 mL, 2.15 M) and the solution was stirred at ‒78 °C for 30 minutes. A solution 
of trans-decalin 276 and 277 (220 mg, 0.54 mmol) in dry THF (1 mL) was added and stirred for 1 hour. 
After this time, N-phenyl-bis-(trifluoromethanesulfonimide) 243 (232 mg, 0.650 mmol) in dry THF (1 
mL) was added and the reaction was stirred at ‒78 °C for a further 30 minutes and then allowed to 
warm to room temperature for 1 houd. The reaction was then quenched with water (2 mL) and 
extracted with Et2O (20 mL). The organic layer was dried with Na2SO4, filtered and concentrated in 
vacuo. The crude product (401 mg, 79% yield) was carried out into the next step, without further 
purification. 
To a solution of model enol triflate trans-decalin 292 and 293 (286 mg, 0.530 mmol) in dry DMF (33.1 
mL), were added Bu3N (0.440 mL, 1.86 mmol), bis(acetato)bis(triphenylphosphine)palladium (II) (38 
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mg, 0.050 mmol) and formic acid (0.050 mL, 1.86 mmol) and the reaction was heated at 50 °C for 2 
hours. After this time, the reaction was cooled to room temperature and MTBE (10 mL) was added 
and washed with water (5 × 20 mL) and brine (20 mL), dried with Na2SO4, filtered and concentrated in 
vacuo. The crude product was purified by silica gel flash column chromatography (2% to 5% EtOAc in 
hexanes) to yield 294 and 295 as an inseparable mixture in a 2 : 1 ratio as a pale yellow oil (115 mg, 
56% yield over 3 steps). Rf = 0.95 (EtOAc : hexane 10% : 90%). On a mixture IR (ATR): νmax 2923, 2865, 
1461, 1097, 907, 881, 791, 680 cm–1. Integration of the 1H NMR are reported as a 1 : 1 mixture due to 
the presence of overlapping peaks.1H NMR (400 MHz, CDCl3) Major 294 + Minor 295:  6.01‒5.90 (1H, 
m, 294), 5.85‒5.44 (5H, m, 294 + 295), 5.43‒5.29 (2H, m, 295), 5.02‒4.94 (4H, m, 294 + 295), 3.94 (1H, 
dd, J = 10.1, 4.6 Hz, 294),  3.87‒3.82 (2H, m, 295), 3.72 (1H, dd, J = 10.1, 10.1 Hz, 294), 2.79‒2.72 (1H, 
m, 294), 2.64‒2.56 (2H, m, 294 + 295), 2.13‒1.93 (8H, m, 294 + 295), 1.92‒1.82 (2H, m, 294 + 295), 
1.79‒1.73 (2H, m, 294 + 295), 1.67 (6H, s, 294 + 295), 1.53‒1.35 (3H, m, 294 + 295), 1.13‒1.01 (42H, 
OSiCH(CH3)2), 0.95 (6H, d, J = 6.9 Hz, 294 + 295) ppm. (((15R*, 12R*, 7S*, 6R*)-15-((S*)But-14-en-15yl)-
10-methyl,-6,15,12,11,8,7-hexahydronaphthalen-6-yl)methoxy)triisoprpylsilane, 294; 13C NMR (400 
MHz, CDCl3):  145.3 (CH), 134.2 (C=C), 132.3 (CH), 126.9 (CH), 120.7 (CH), 112.0 (CH2), 62.6 (CH2), 45.0 
(CH), 40.1 (CH), 38.7 (CH), 35.6 (CH), 34.6 (CH), 31.9 (CH2), 30.8 (CH2), 23.4 (CH3), 18.1 (OSiCH(CH3)2), 
16.2 (CH3), 11.9 (OSiCH(CH3)2) ppm. (((12R*, 7S*, 6R*)-15-(But-14-en-15yl)-10-methyl,-6,15,12,11,8,7-
hexahydronaphthalen-6-yl)methoxy)triisoprpylsilane,  295; 13C NMR (400 MHz, CDCl3):  143.9 (CH), 
133.8 (C=C), 131.0 (CH), 128.7 (CH), 120.9 (CH), 112.0 (CH2), 60.4 (CH2), 45.2 (CH), 43.4 (CH), 41.3 (CH), 
38.9 (CH), 37.9 (CH), 31.6 (CH2), 29.4 (CH2), 23.5 (CH3), 18.1 (OSiCH(CH3)2), 14.1 (CH3), 12.0 
(OSiCH(CH3)2) ppm. On a mixture MS (APCI): m/z 389 (M+H+); HRMS: found: (M+H+) 389.3228. 
C25H45OSi requires (M+H+) 389.3234. 
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R*-15-((15S*, 12R*, 7S*, 6R*)-10-Methyl-6-(((triisopropylsilyl)oxy)methyl)-6,15,12,11,8,7- 
hexahydronaphthalen-15-yl)propanal, 162 
 
 
15-((12R*, 7S*, 6R*)-10-Methyl-6-(((triisopropylsilyl)oxy)methyl)-6,15,12,11,8,7- 
hexahydronaphthalen-15-yl)propanal, 298 
 
 
 
 
To a solution of crotyl-substituted trans-decalin 294 and 295 (115 mg, 0.280 mmol) in dry THF (0.31 
mL), were added B2pin2 (76 mg, 0.31 mmol), trans-cyclohexanediol 287 (35 mg, 0.31 mmol) and Cs2CO3 
(17 mg, 0.040 mmol). The reaction was stirred at 60 °C for 5 days and then cooled to 0 °C and an 
aqueous solution of 3 M NaOH (1.20 mL) was added, followed by addition of an 30% aqueous solution 
of H2O2 (0.60 mL) and the resultant mixture was stirred for 4 hours. Saturated aqueous solution of 
Na2SO3 (2.40 mL) was added and the aqueous phase was extracted with EtOAc (4 × 20 mL). The 
combined organic layers were washed with brine (10 mL), dried with Na2SO4, filtered and 
concentrated in vacuo. The crude product mixture of diols 296 and 297 was directly used in the next 
step without further purification. 
To a solution of the mixture of diol intermediates 296 and 297 (162 mg, 0.280 mmol) in CH2Cl2 : H2O 
(1 : 1, 3.0 mL) at 0 °C, was added NaIO4 (128 mg, 0.560 mmol) and the reaction was allowed to stir at 
room temperature for 24 hours. After this time, the mixture was extracted with CH2Cl2 (3 × 10 mL) and 
the combined organic layers were washed with brine (10 mL), dried with Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by silica gel flash column chromatography (5% 
EtOAc in hexanes) to yield 162 and 298 as an inseparable mixture in a 2 : 1 ratio as a pale yellow oil 
(49.0 mg, 60% yield b.r.s.m.). Rf = 0.57 (EtOAc : hexane 10% : 90%). On a mixture IR (ATR): νmax 2924, 
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2865, 1725 (C=O), 1462, 1096, 882, 796 cm–1. Integration of the 1H NMR are reported as a 1 : 1 mixture 
due to the presence of overlapping peaks. 1H NMR (500 MHz, CDCl3) Major 162 + Minor 298: 9.76 
(1H, d, J = 5.8 Hz, 298), 9.70 (1H, d, J = 0.9 Hz, 162), 5.68 (1H, ddd, J = 10.4, 1.2, 1.2 Hz, 162), 5.60 (1H, 
ddd, J = 10.2, 1.2, 1.2 Hz, 298), 5.43‒5.40 (1H, m, 298), 5.39‒5.34 (2H, m, 162), 5.16 (1H, ddd, J = 10.2, 
2.3, 2.3 Hz, 298), 3.97 (1H, dd, J = 10.5, 4.8 Hz, 162), 3.87‒3.81 (2H, m, 298), 3.60 (1H, dd, J = 10.5, 
10.5 Hz, 298), 3.21‒3.18 (2H, m, 162 + 298), 2.85‒2.76 (3H, m, 162 + 298), 2.37‒2.27 (3H, m, 162 + 
298), 2.09‒1.95 (7H, m, 162 + 298), 1.79‒1.70 (3H, m, 162 + 298), 1.67 (6H, s, 162 + 298), 1.14-1.00 
(42H, OSiCH(CH3)2, 162 + 298), 0.98‒0.96 (6H, d, J = 6.7 Hz, 162 + 298) ppm. R*-15-((15S*, 12R*, 7S*, 
6R*)-10-Methyl-6-(((triisopropylsilyl)oxy)methyl)-6,15,12,11,8,7-hexahydronaphthalen-15-
yl)propanal, 162; 13C NMR (500 MHz, CDCl3):  205.5 (C=O), 134.3 (C=C), 133.5 (CH), 125.8 (CH), 120.5 
(CH), 62.4 (CH2), 46.2 (CH), 44.1 (CH), 38.4 (CH), 37.2 (CH2), 34.5 (CH), 34.5 (CH2), 30.4 (CH), 23.4 (CH3), 
18.1(OSiCH(CH3)2), 14.1 (CH3), 11.9 (OSiCH(CH3)2) ppm; 15-((12R*, 7S*, 6R*)-10-Methyl-6-
(((triisopropylsilyl)oxy)methyl)-6,15,12,11,8,7-hexahydronaphthalen-15-yl)propanal, 298; 13C NMR 
(500 MHz, CDCl3):   205.3 (C=O), 133.7 (C=C), 133.6 (CH), 125.9 (CH), 120.8 (CH), 60.9 (CH2), 47.6 (CH), 
42.9 (CH), 37.4 (CH2), 37.2 (CH), 36.4 (CH), 36.3 (CH2), 30.3 (CH), 23.4 (CH3), 18.1(OSiCH(CH3)2), 14.2 
(CH3), 11.9 (OSiCH(CH3)2) ppm On a mixture MS (ESI): m/z 413 (M+Na+); HRMS: found: (M+Na+) 
413.2829. C24H42NaO2Si requires (M+Na+) 413.2846. m/z 391 (M+H+); HRMS: found: (M+H+) 391.3020. 
C24H43O2Si requires (M+H+) 391.3027. 
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(15S*, 6S*)-15-Allyl-6-(((triisopropylsilyl)oxymethyl)cyclohex-13-enone, 184 
 
 
 
In a microwave tube, to a solution of allyl-cyclohexanone 183 (75.7 mg, 0.230 mmol) in chlorobenzene 
(2.3 mL), were added Pd(OAc)2 (2.25 mg, 0.010 mmol), 4-4’ditertbutyl-2-2’bypiridyl (2.68 mg, 0.010 
mmol) and KNO3 (12.1 mg, 0.121 mmol). The reaction was stirred at 120 °C for 5 days under O2 atm. 
After this time, the reaction was cooled to room temperature and the solvent was evaporated in 
vacuo. The crude product was purified by silica gel flash column chromatography (3% to 10% EtOAc in 
hexanes) to yield 184 as a pale yellow oil (23.0 mg, 31% yield, starting material recovered 28.0 mg, 
37% yield, 68% yield b.r.s.m.). Rf = 0.48 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 2941, 2865, 1680 
(C=O), 1462, 1382, 1247, 1067, 995 cm–1. 1H NMR (400 MHz, CDCl3):  6.95 (1H, dd, J = 10.5, 4.6 Hz, H-
7), 6.10 (1H, dd, J = 10.5, 1.8 Hz, H-12), 5.75 (1H, dddd, J = 15.6, 12.5, 7.3, 5.5 Hz, H-17), 5.10‒5.03 (2H, 
m, H-18), 3.94 (1H, dd, J = 9.8, 6.4 Hz, H-5), 3.87 (1H, dd, J = 9.8, 5.5 Hz, H-5), 2.71‒2.65 (1H, m, H-15), 
2.58 (1H, dd, J = 17.4, 11.3 Hz, H-14), 2.39 (1H, dd, J = 17.4, 4.1 Hz, H-14), 2.36‒2.32 (1H, m, H-6), 2.26 
(1H, ddddd, J = 13.7, 6.4, 5.5, 1.4, 1.4 Hz, H-16), 2.10 (1H, ddddd, J = 13.7, 7.3, 7.3, 0.9, 0.9 Hz, H-16), 
1.14‒1.04 (21H, m, OSiCH(CH3)2) ppm. 13C NMR (400 MHz, CDCl3):  199.9 (C-13), 151.4 (C-7), 135.9 
(C-17), 130.2 (C-12), 117.1 (C-18), 62.5 (C-5), 41.5 (C-6), 41.4 (C-14), 35.9 (C-15), 35.3 (C-16), 18.0 
(OSiCH(CH3)2), 11.8 (OSiCH(CH3)2) ppm.  MS (ESI): m/z 345 (M+Na+); HRMS: found: (M+Na+) 345.2224. 
C19H34NaO2Si requires (M+Na+) 345.2220. m/z 323 (M+H+); HRMS: found: (M+H+) 323.2402. C19H35O2Si 
requires (M+H+) 323.2401. 
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 (S, S, R, R, S, R)-Dimethyl-((R)-methylheptan-yl)dodecahydrocyclopenta[a]phenanthren-one, 181 
 
(S, S, R, R, S, R)-Dimethyl-((R)-methylheptan-yl)-decahydro-cyclopenta[a]phenanthrene-dione, 182 
 
 
In a microwave tube, to a solution of cholesterone 180 (115 mg, 0.300 mmol) in chlorobenzene (3.0 
mL), were added Pd(OAc)2 (4.49 mg, 0.020 mmol), 4-4’ditertbutyl-2-2’bypiridyl (5.37 mg, 0.020 mmol) 
and KNO3 (15.2 mg, 0.150 mmol). The reaction was stirred at 120 °C for 3 days under O2 atm. After 
this time, the reaction was cooled to room temperature and the solvent was evaporated in vacuo. The 
crude product was purified by silica gel flash column chromatography (3% to 10% EtOAc in hexanes) 
to yield 181 as a pale yellow oil (21.0 mg, 18% yield) and 182 as a pale yellow solid (28.0 mg, 24% 
yield).   (S, S, R, R, S, R)-Dimethyl-((R)-methylheptan-yl)dodecahydrocyclopenta[a]phenanthren-one, 
181; [α] 20D  -19.2 (c 1.00, CHCl3).  Rf = 0.31 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 2944, 2866, 1663 
(C=O), 1585, 1465, 1417, 1325, 967, 924 cm–1. 1H NMR (400 MHz, CDCl3):   6.18‒6.06 (2H, m), 5.69‒
5.65 (1H, m, CH), 2.71‒2.52 (1H, m), 2.49‒2.39 (1H, m), 2.23‒2.15 (1H, m), 2.07 (1H, ddd, J = 12.5, 2.9, 
2.9 Hz), 2.00 (1H, ddd, J = 13.2, 5.4, 2.1 Hz), 1.96‒1.85 (2H, m), 1.84‒1.76 (1H, m), 1.71 (1H, ddd, J = 
13.7, 13.7, 5.0 Hz), 1.58‒1.47 (3H, m), 1.46‒1.29 (5H, m), 1.28‒1.13 (7H, m), 1.11 (3H, s), 0.92 (3H, d, 
J = 6.4 Hz), 0.88 (3H, d, J = 1.8 Hz), 0.86 (3H, d, J = 1.8 Hz), 0.76 (3H, s) ppm. 13C NMR (400 MHz, CDCl3): 
 199.8 (C=O), 164.2 (C-C), 141.7 (CH), 127.7 (CH), 123.4 (CH), 56.0 (CH), 53.4 (CH), 50.6 (CH), 43.4 (C-
C), 39.5 (CH2), 39.4 (CH2), 37.7 (CH), 36.1 (C-C), 36.0 (CH2), 35.8 (CH), 33.9 (CH2), 33.8 (CH2), 28.1 (CH2), 
27.9 (CH), 23.8 (CH2), 23.7(CH2), 22.8 (CH3), 22.5 (CH3) , 20.6 (CH2), 18.6 (CH3), 16.3 (CH3), 11.9 (CH3) 
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ppm.  MS (ESI): m/z 405 (M+Na+); HRMS: found: (M+Na+) 405.3111. C27H42NaO requires (M+Na+) 
405.3128. m/z 383 (M+H+); HRMS: found: (M+H+) 383.3302. C27H43O requires (M+H+) 383.3308. (S, S, 
R, R, S, R)-Dimethyl-((R)-methylheptan-yl)-decahydro-cyclopenta[a]phenanthrene-dione, 182; [α] 20D  -
13.9 (c 1.00, CHCl3). Melting point = 81‒83 °C. Rf = 0.28 (EtOAc : hexane 10% : 90%). IR (ATR): νmax 
2946, 2867, 1683 (C=O), 1465, 1415, 1381, 1327, 1219, 1082, 915 cm–1. 1H NMR (400 MHz, CDCl3):  
6.16 (1H, s), 2.68 (1H, dd, J = 15.8, 3.9 Hz), 2.61‒2.41 (2H, m), 2.18‒2.06 (2H, m), 2.05‒2.02 (1H, m), 
1.95‒1.82 (4H, m), 1.68‒1.58 (2H, m), 1.57‒1.44 (3H, m), 1.41‒1.19 (6H, m), 1.16 (3H, s), 1.13‒1.08 
(5H, m), 0.92 (3H, d, J=6.4 Hz), 0.87 (3H, d, J=1.5 Hz), 0.85 (3H, d, J = 1.5 Hz), 0.72 (3H, s) ppm. 13C NMR 
(400 MHz, CDCl3):  202.4 9 (C=O), 199.5 (C=O), 161.1 (C-C), 125.4 (CH), 56.5 (CH), 55.9 (CH), 50.9 (CH), 
46.8 (CH2), 42.5 (C-C), 39.8 (C-C), 39.4 (CH2), 39.1 (CH2), 36.0 (CH2), 35.6 (CH), 35.5 (CH2), 34.1 (CH), 
33.9 (CH2), 27.6 (CH + CH2), 23.9 (CH2), 23.7 (CH2), 22.8 (CH3), 22.5 (CH3), 20.8 (CH2) , 18.6 (CH3), 17.5 
(CH3), 11.8 (CH3) ppm. MS (ESI): m/z 421 (M+Na+); HRMS: found: (M+Na+) 421.3080. C27H42NaO2 
requires (M+Na+) 421.3077. 
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13. Abbreviations 
 
Å                         Ångstrom 
ACP                    acyl carrier protein 
AcOH                 acetic acid  
APCI             atmospheric pressure chemical ionization  
Br2                     bromine 
BF3·Et2O           borane trifluoride-diethyl etherate 
brsm                 based on recovered starting material 
n-BuLi               butyl lithium 
s-BuLi                sec-butyl lithium 
t-BuOH             tert-butanol  
CA                     california 
CBr4                            carbon tetrabromide  
C-C                   carbon-carbon  
CH2Cl2                      dichloromethane 
CHCl3                        chloroform 
CH3CN              acetonitrile 
CH2N2                       diazomethane 
ClPh                 chlorobenzene 
CSA                  camphorsulfonic acid  
d                       day  
D-Ala                D-alanine 
DBU                  1,8-diazabicyclo[5.4.0]undec-7-ene 
DIBAL-H           diisobutylaluminum hydride  
DIPEA               N,N-diisopropylethylamine 
DMAP              4-dimethylaminopyridine  
DME                 dimethyl ether  
DMF                 dimethylformamide  
DMP                 Dess-Martin periodinane  
DMPU              1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
 
DMSO              dimethysulfoxide 
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DNA                 deoxyribonucleic acid 
dr           diastereomeric ratio 
ESI                    electrospray ionisation 
EI            electron ionisation  
Et2O                 diethyl ether 
EtOAc              ethylacetate 
EtOH                ethanol 
Et3N                 triethylamine 
FAD                  flavin adenine dinucleotide 
FGI                    functional group interconversion 
g                        gram   
h                        hour  
H2                                   hydrogen 
HCC                   hepatocellular carcinoma 
HCl                    hydrochloric acid 
HG II                 hoveyda-Grubbs 2nd generation catalyst  
HFIP                 1,1,1,3,3,3-Hexafluoro-2-propanol  
 
HF                     hydrogen fluoride 
H2O2                           hydrogen peroxide 
Hg                     mercury                
HOMO              highest occupied molecular orbital  
HRMS               high resolution mass spectrometry  
Hz                     hertz 
I2                       iodine 
IBX                    2-iodoxy benzoic acid 
IC50                               half maximal inhibitory concentration 
IR                      infrared spectroscopy 
J                          coupling constant (Hz)  
KHMDS              potassium hexamethyldisilazide 
KNO3                  potassium nitrate 
KOH                   potassium hydroxide  
kJ                        kilojoule 
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LDA                    lithium diisopropylamide 
LED                    light emitting diodie 
Li                        lithium 
LiAlH4                          lithiumaluminium hydride 
LiCl                     lithium chloride 
LovBPKS            lovastatin B polyketide synthase 
LUMO                lowest unoccupied molecular orbital  
M                        molar  
m-CPBA             meta-chloroperoxybenzoic acid  
Me                     methyl 
MeLi                  methylithium 
MeMgI              methylmagnesium 
MeOH               methanol 
MIC                   minimum inhibitory concentration  
Min.                  minutes 
Ms                     mesyl (methanesulfonyl)  
MsCl                 mesylchloride 
mg                    milligram  
MHz                  megahertz 
MRSA               methicillin resistant bacteria 
MS                    mass spectrometry  
M.S.                  molecular sieves 
MW                  microwaves 
mTOR               mammalian target of rapamycin 
NaHCO3           sodium bicarbonate 
NBS                  N-bromosuccinimide 
NCS                  N-chlorosuccinimide 
NMR                nuclear magnetic resonance spectroscopy  
NOE                 nuclear overhauser effect 
O2                                 oxygen 
Pd(OAc)2              palladium acetate 
Pd/C                 palladium on carbon 
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Pd(PPh3)4              palladium tetrakis(triphenylphosphine) 
Ph                      phenyl 
PhI(OAc)2              diacetoxyiodo benzene 
PhSH                 thiophenyl 
PKS                    polyketide synthase 
PPh3                  triphenylphosphine 
PMB                  p-methoxybenzyl  
Py                      pyridine 
RNA                   ribonucleic acid 
rt                        room temperature 
SmI2                   samarium diodide  
SiO2                               silica 
TBAF                  tetra-n-butylammonium fluoride 
TBS                     t-butyldimethylsilyl 
TES                     triethylsilyl  
Tf                        triflate  
TFA                     trifluoroacetic acid  
THF                    tetrahydrofuran 
TIPS                    triisopropylsilyl 
TLC                     thin layer chromatography  
TMS                   trimethylsilyl 
TS                       transition state 
 ν                         vibration frequency (cm-1) 
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